Sin nombre virus full-length m segment-based dna vaccines

ABSTRACT

The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 16/553,556, filed 28 Aug. 2019, which is a divisional of U.S. application Ser. No. 15/081,218, filed 25 Mar. 2016, issued as U.S. Pat. No. 10,443,073 on 15 Oct. 2019, which is a continuation of U.S. application Ser. No. 13/982,606, filed 30 Jul. 2013, issued as U.S. Pat. No. 9,315,826 on 19 Apr. 2016, which is a national stage entry of PCT Application No. PCT/US11/23098, filed 31 Jan. 2011, the contents of which are hereby incorporated in their entirety by reference.

REFERENCE TO SEQUENCE LISTING SUBMITTED AS A COMPLIANT ASCII TEXT FILE (.txt)

Pursuant to the EFS-Web legal framework and 37 C.F.R. § 1.821-825 (see M.P.E.P. § 2442.03(a)), a Sequence Listing in the form of an ASCII-compliant text file (entitled “Sequence_Listing_3000050-007001_ST25.txt” created on 30 Sep. 2021, and 152,769 bytes in size) is submitted concurrently with the instant application, and the entire contents of the Sequence Listing are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Hantaviruses are considered Category A Priority Pathogens by the National Institute of Allergies and Infectious Disease. These viruses cause a spectrum of vascular-leak syndromes including hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Many HPS and HFRS hantaviruses pose a natural threat to persons working, living or traveling in endemic regions, including military personnel. There is one hantavirus (Andes virus) that has unique properties that make amenable to use as a biological weapon.

Andes virus (ANDV) and Sin Nombre virus (SNV) are the predominant causes of HPS in South and North America, respectively. These rodent-borne viruses were discovered in the early 1990's and have caused severe disease in several hundred persons.

Since the discovery of SNV in 1993, it has caused severe disease in ˜500 persons in the United States and Canada, resulting in ˜200 deaths (35% case-fatality rate). SNV is carried by the deer mouse and transmitted via inhalation or ingestion of contaminated secreta/excreta, or by rodent bite. Most of the fatalities occurred in previously healthy working-age males. HPS is a disease with rapid onset, and rapid progression from mild to severe disease (i.e., can occur over the weekend). The disease begins as an influenza-like illness including fever, headache, nausea, cough, and can progress rapidly to respiratory failure and cardiogenic shock. There is no specific therapeutic or vaccine to treat or prevent HPS. Hammerbeck, C. D., Wahl-Jensen, V., Hooper, J. W. Hantavirus. In: Vaccines for Biodefense and Emerging and Neglected Diseases (A. D. T. Barrett and L. R. Stanberry, Eds.), pp. 379-411. London: Academic Press, 2009; Jonsson C. B, J. Hooper, and G. Mertz (2008). Treatment of hantavirus pulmonary syndrome. Antiviral Res. Antiviral Res. 78:162-169.

There is no population with pre-existing immunity to SNV or ANDV and this virus is lethal in 35-40% of the people it infects. Note that this 35-40% case-fatality rate occurs despite treatment in modern intensive care units. All ages and both sexes are susceptible to ANDV and SNV. Most cases occur in previously healthy working-age males. The incubation period is approximately two weeks. Disease onset-to-death is rapid (over the weekend). In an animal model of HPS (Syrian hamsters), ANDV is highly lethal by all routes tested including the oral route. SNV is highly infectious (infectious dose 50% is 2 plaque forming units in Syrian hamsters but does cause lethal disease (Hooper et al., 2001). Thus, an infection model, rather than a lethal disease model, is used to evaluate medical countermeasures to prevent SNV infection.

New-World hantaviruses have been associated with outbreaks of a highly lethal disease, hantavirus pulmonary syndrome (HPS), in the Americas (reviewed in Schmaljohn and Hjelle, 1997, Emerg. Infect Dis. 3, 95-104). The disease is characterized by fever and vascular leakage resulting in non-cardiogenic pulmonary edema followed by shock. Case-fatality for HPS caused by the most prevalent North American and South American hantaviruses, Sin Nombre virus (SNV) and Andes virus (ANDV), respectively is 30-50%.

Currently, there are four known hantaviruses associated with hemorrhagic fever with renal syndrome (HFRS): Hantaan virus (HTNV), Dobrava-Belgrade virus (DOBV), Puumala virus (PUUV), and Seoul virus (SEOV). Because distinct hantaviruses are usually carried by only one principal rodent host species, their distribution is generally limited to the range of that host (reviewed in Schmaljohn and Hjelle, 1997, Emerg. Infect. Dis. 3, 95-104). HTNV, carried by Apodemus agrarius, is found in Asia; DOBV, carried by Apodemus flavicollis, and PUUV, carried by Clethrionomys glareolus, are found in Europe. SEOV is more widely disseminated than any other recognized hantaviruses because its host, the common urban rat (Rattus norvegicus), is found throughout the world.

There is an alarming paucity of existing medical countermeasures to prevent or treat HPS. There is no vaccine against SNV, ANDV or any other HPS-associated hantavirus. Moreover, aside from basic research, there are no funded HPS vaccine development efforts. There is no specific drug to prevent or treat HPS. The treatment for HPS is extracorporeal membrane oxygenation therapy (ECMO) with costs as much as $500,000 per patient. Expertise at performing adult ECMO resides at only a few hospitals in the world. Thus, we are poorly prepared to deal with naturally occurring HPS cases (there have been ˜2500 cases including ˜500 in the US since 1993), or the use of hantaviruses as biological weapons.

Viruses in the Hantavirus genus (family Bunyaviridae) are enveloped and contain a genome comprised of three single-stranded RNA segments designated large (L), medium (M), and small (S) based on size (reviewed in Schmaljohn, 1996, In The Bunyaviridae Ed. R. M. Elliott. New York, Plenum Press p. 63-90). The hantavirus L segment encodes the RNA dependent RNA polymerase, M encodes two envelope glycoproteins (G1 and G2, also known as G_(n), and G_(c)), and S encodes the nucleocapsid protein (N).

A number of inactivated HFRS vaccines derived from cell culture or rodent brain were developed and tested in Asia (Lee et al., 1990, Arch. Virol., Suppl. 1, 35-47; Song et al., 1992, Vaccine 10, 214-216; Lu et al., 1996, J. Med. Virol. 49, 333-335). Drawbacks of these traditional killed-virus vaccines include a requirement for appropriate containment for the growth and manipulation of virus, and the necessity to ensure complete inactivation of infectivity without destroying epitopes on the virion important for protective immunity. In order to overcome these drawbacks, vaccine approaches involving recombinant DNA technology were developed including: vaccinia-vectored vaccines (Schmaljohn et al. 1990, J. Virol. 64, 3162-3170; Schmaljohn et al. 1992, Vaccine 10, 10-13; Xu et al. 1992, Am. J. Trop. Med. Hyg. 47, 397-404), protein subunit vaccines expressed in bacteria or insect cells (Schmaljohn et al. 1990, supra; Yoshimatsu et al., 1993, Arch. Virol. 130, 365-376; Lundkvist et al., 1996, Virology 216, 397-406), and a hepatitis core antigen-based recombinant vaccine (Ulrich et al., 1998, Vaccine 16, 272-280). For a review of hantavirus vaccine efforts see the review by Hooper and Li (Hooper and Li, 2001).; Hammerbeck, C. D., Wahl-Jensen, V., Hooper, J. W. Hantavirus. In: Vaccines for Biodefense and Emerging and Neglected Diseases (A. D. T. Barrett and L. R. Stanberry, Eds.), pp. 379-411).

Vaccination with vaccinia recombinants expressing the M segment of either HTNV or SEOV elicited neutralizing antibodies and protected rodents against infection with both HTNV and SEOV, suggesting that an immune response to Gn-Gc alone can confer protection (Schmaljohn et al. 1990, supra; Xu et al. 1992, supra; Chu et al. 1995, J. Virol. 69, 6417-6423). Similarly, vaccination with Gn-Gc protein expressed in insect cells (baculovirus recombinant virus system) elicited neutralizing antibodies and protected hamsters from infection with HTNV (Schmaljohn et al. 1990, supra). In both the vaccinia and baculovirus systems, vaccination with Gn-Gc provided more complete protection than Gn or Gc alone (Schmaljohn et al. 1990, supra). There are reports that candidate DNA vaccines comprised of around 500 nucleotide stretches of the Sin Nombre virus (SNV) M gene, or the full-length S gene, are immunogenic in mice (Bharadwaj, et al., 1999, Vaccine 17, 2836, 43) and conferred some protection against infection with SNV in a deer mouse infection model (Bharadwaj, et al., 2002, J. Gen. Virol. 83, 1745-1751). The protection was surmised to be cell-mediated because there was no convincing evidence that these constructs elicited a neutralizing, or otherwise protective, antibody response.

There have been several publications reporting the successful use of plasmid DNA vaccines containing the full-length M gene of SEOV, HTNV, ANDV, including the following reports:

-   1. Hooper, J. W., K. I. Kamrud, F. Elgh, D. Custer, and C. S.     Schmaljohn (1999). DNA vaccination with hantavirus M segment elicits     neutralizing antibodies and protects against Seoul virus infection.     Virology, 255:269-278. -   2. Hooper, J. W., D. Custer, E. Thompson, and C. S. Schmaljohn     (2001). DNA Vaccination with the Hantaan virus M gene protects     hamsters against three of four HFRS hantaviruses and elicits a     high-titer neutralizing antibody response in rhesus monkeys. Journal     of Virology 75:8469-8477. -   3. Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek,     and J. W. Hooper (2003). Active and passive vaccination against     hantavirus pulmonary syndrome using Andes virus M genome     segment-based DNA vaccine. Journal of Virology 79:9894:9905. -   4. Hooper, J. W., D. M. Custer, J. Smith, and Victoria Wahl-Jensen.     Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive     neutralizing antibody response in nonhuman primates (2006). Virology     347:208-216.

In all cases high titer neutralizing antibodies were detected in animals (including nonhuman primates) vaccinated with the full-length M gene DNA vaccines, and protection from infection was achieved in rodent models. Neutralizing antibody responses to Gn-Gc in the aforementioned vaccine studies correlated with protection, suggesting that neutralizing antibodies not only play an important role in preventing hantavirus infection, but also might be sufficient to confer protection. Passive transfer of neutralizing monoclonal antibodies (MAbs) specific to either Gn or Gc protected hamsters against HTNV infection (Schmaljohn et al., 1990, supra; Arikawa et al., 1992, J. Gen. Virol. 70, 615-624), supporting the idea that neutralizing antibodies alone can confer protection. This is further supported by the finding that serum from nonhuman primates vaccinated using a gene gun with DNA vaccines containing the HTNV or ANDV full-length M genes protected hamsters from infection with HTNV or lethal disease caused by ANDV Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J. W. Hooper (2003). Active and passive vaccination against hantavirus pulmonary syndrome using Andes virus M genome segment-based DNA vaccine. Journal of Virology 79:9894:9905). Similarly, sera from rabbits vaccinated with the ANDV M gene-based DNA vaccine using electroporation protected hamsters from a lethal challenge with ANDV (Hooper J. W., A. M. Ferro, and V. Wahl-Jensen Immune Serum Produced by DNA Vaccination Protects Hamsters Against Lethal Respiratory Challenge with Andes Virus (2008). Journal of Virology 82:1332-1338.) Hitherto, attempts to produce vaccines that produce neutralizing antibodies against SNV have been unsuccessful. For instance, Hjelle et al. (U.S. Pat. No. 6,316,250) attempted to vaccinate with the entire SNV Gn or fragments of G1 to generated antibodies. However, their vaccine did not produce high titer neutralizing antibodies. There are currently no serious efforts to develop an HPS vaccine anywhere in the world, including SNV vaccine. (refs 17, 18 below) NIH is currently funding a handful of academic laboratories working on hantavirus basic research.

The inventors have produced DNA vaccines against other hantaviruses including Seoul virus (SEOV), Hantaan virus, (HTNV) Puumala virus (PUUV) and Andes virus (ANDV) (refs 1, 5 and 6 below). There are a number of issued and pending patents related to these vaccines (refs 23-26 below). SEOV, HTNV, and PUUV cause hemorrhagic fever with renal syndrome (HFRS). All of these DNA vaccines are based on the full-length M gene open reading frame that encodes the Gn and Gc proteins, and all of these vaccines elicit neutralizing antibodies in animal models. Neutralizing antibodies produced by DNA vaccination have been shown to protect against infection and disease in passive transfer studies (refs 3,4 below). In addition, the Hantaan and Puumala DNA vaccines have been tested in a phase 1 clinical trial (ongoing). The immunogenicity data generated in this phase 1 trial demonstrates that DNA vaccines against hantaviruses were capable of eliciting neutralizing antibodies in humans. This was the first time hantavirus neutralizing antibodies have been produced in humans using plasmid DNA. The overall seroconversion rate in this phase 1 trial was 43% (12 of 28). One of the most notable findings was that very high titers of neutralizing antibodies were achievable. Two of the peak anti-Hantaan virus titers were >1,000 and four of the peak anti-Puumala virus titers were >1,000. Neutralizing antibody titers as high as 10,240 were achieved for both Hantaan virus and Puumala virus.

The antibody response elicited by the hantavirus M gene-based DNA vaccines have been shown to cross-neutralize some, but not other hantaviruses. For example, the HTNV DNA vaccine was shown to elicit neutralizing antibodies against Seoul virus and Dobrava virus (a major cause of HFRS in the Balkans)(ref 1 below). In some cases the cross-neutralizing antibody response is produced in certain species using certain delivery technologies, but not others. This was the case with our ANDV DNA vaccine. When nonhuman primates were vaccinated with the ANDV DNA vaccine using a gene gun the sera contained antibodies that not only neutralized ANDV but also neutralized SNV and Black Creek Canal virus (ref. 3 below). Based on those results we concluded that the development of a SNV-specific DNA vaccine was unnecessary. However, recently we found that when rabbits were vaccinated with the ANDV DNA vaccine using muscle electroporation the sera was unable to neutralize SNV despite exhibiting very high titer ANDV-neutralizing activity (ref 4 below). It is speculated that this could be due to antibody specificity differences, antibody avidity differences, or antibody isotype differences.

This finding prompted us to reinitiate the development of a SNV M gene-based DNA vaccine rather than depend on the ANDV DNA vaccine to cross-protect against SNV.

The inventor is named as an inventor on other U.S. patents and publications, related to vaccines for hantaviruses and poxviruses, namely U.S. Pat. Nos. 6,451,309; 6,620,412; 6,562,376, 7,217,812, and U.S. Patent application publication US-2010-03203024 A1. The entire contents of these patents are incorporated herein by reference.

SUMMARY OF THE INVENTION

Key to the invention is a novel synthetic, codon-optimized Sin Nombre virus full-length M gene open reading frame (ORF). To date, there are no reports of a full-length M gene, or SNV M gene ORF, being successfully engineered into a DNA vaccine plasmid or other mammalian expression vector. This SNV M gene DNA sequence has been altered (or optimized) in such a way as to increase the stability of the mRNA and to, theoretically, eliminate sequences that destabilize the plasmid in E. coli. In addition, four amino acids that were unique to our full-length clone were changed to consensus amino acids based on alignments with five hantavirus M gene seuquences from GeneBank. The ORF nucleic acid sequence was changed without altering the coded amino acid sequence of the Sin Nombre M gene product, other than the four aforementioned amino acids. This was accomplished by codon optimizing the ORF. The process of codon optimization not only changed the nucleic sequence, but also it was intended to allow more efficient codon usage and increased stability of the mRNA produced by the plasmid. An algorithm called GeneOptimizer (patent pending), owned by GeneArt was used to allow more efficient codon usage and stabilization of the mRNA. It is noted that, while the ORF was codon optimized, the flanking sequence was unchanged.

This synthetic M gene has been engineered into a plasmid-based vaccine system, (i.e, pWRG/SN-M(opt)), and is believed could be subcloned into a virus-vectored vaccine. The preferred DNA plasmid containing this sequence is designated pWRG/SN-M(opt), and its DNA sequence is described in detail below. pWRG/SN-M(opt) is capable of eliciting good neutralizing antibody responses against Sin Nombre virus. In fact, pWRG/SN-M(opt), as a DNA vaccine delivered by gene gun, is the first vaccine of any kind that has elicited convincing levels of neutralizing antibodies against Sin Nombre virus in animals.

The development of this novel SNV full-length M segment and its use as a vaccine can be summarized as follows. As mentioned above, it had been hoped that an Andes virus M gene-based DNA vaccine would cross-neutralize with the other HPS virus, Sin Nombre virus. In fact, early results gave indication that this would be the case. When nonhuman primates were vaccinated with the ANDV DNA vaccine using a gene gun the sera contained antibodies that not only neutralized ANDV but also neutralized SNV and Black Creek Canal virus (6). Based on those results the inventor concluded that the development of a SNV-specific DNA vaccine was unnecessary. However, recently the inventor found that when rabbits were vaccinated with the ANDV DNA vaccine using muscle electroporation the sera was unable to neutralize SNV despite exhibiting very high titer ANDV-neutralizing activity (11). The data is published in Hooper J. W., A. M. Ferro, and V. Wahl-Jensen Immune Serum Produced by DNA Vaccination Protects Hamsters Against Lethal Respiratory Challenge with Andes Virus (2008). Journal of Virology 82:1332-1338. The inventor realized that the ANDV DNA vaccine would not be suitable as a vaccine to cross-protect against SNV, so sought a vaccine specifically for SNV.

The inventor cloned the full-length M gene from SNV, strain CC107 into a DNA vaccine vector, producing a plasmid with an intact open reading frame—pWRG/SN-M(2a). pWRG/SNV-M(2a) was tested for immunogenicity in rabbits, and it was discovered that high-titer neutralizing antibodies were produced after 4 vaccinations. This represented the first time high-titer SNV neutralizing antibodies were ever produced by any vaccine.

However, it required more vaccinations than the inventor would have preferred, so pWRG/SNV-M(2a) was re-designed for optimization. It was found that the M gene sequence in pWRG/SNV-M(2a) produced amino acids that were unique to our clone (i.e., not in published GeneBank SNV M sequences). This is shown in the Table 1 below, by identifying possible cloning errors in pWRG/SN-M(2a) M gene ORF and determining consensus amino acid sequence. In Table 1, SN-M(2a) is the amino acid sequence of the SNV M open reading frame (ORF) cloned into pWRG/SN-M(2a). This sequence as aligned with several SNV M gene ORFs from Genebank: AAA68036 (SNV strain CC107), AAA68036 (SNV strain CC107 isolate 74), NP_941974 (SNV strain NMH10), 083887 (New York virus), AAC54561 (NY-2 virus), and AC54559 (Rhode Island 1 virus). The four amino acids so identified were changed to the consensus amino acids in the synthetic gene cloned into pWRG/SN-N(opt), see below.

These consensus amino acids were identified at these positions and then an optimized version of this gene was synthesized. Next, we cloned the synthetic M gene (SN-M(2a)) into a DNA vaccine vector and named the plasmid pWRG/SN-M(opt). This plasmid pWRG/SN-M(opt) was deposited on Jan. 26, 2011 in the American Type Culture Collection, located at 10801 University Blvd. Manassas, Va. 20110. The deposit was made under the terms of the Budapest Treaty.

Table 2 shows the nucleic acid differences between the original cloned M gene (SN-M[2a]) and the optimized M gene (SN-M[opt]).

TABLE 1 The amino acid sequence encoded by the ORF cloned into pWRG/SN-M(2a) (SEQ ID NO: 15) was aligned with six SNV M sequences (SEQ ID NOS: 16-21, respectively, in order of appearance) from genebank (accession numbers are shown). There were four positions (the first “Q” in line 1; the first “A” in the line beginning with nucleic acid 241; the first “G” in the line beginning with nucleic acid 421; and the third “P” in the line beginning with nucleic acid 481) that were unique to the cloned ORF (highlighted in bold type and underlined). These amino acids were changed to the consensus amino acids when the new gene was synthesized to produce pWRG/SN-M(opt). SN-M(2a) 1 MVGWVCIFLVVLTTATAGLTRNLYEL Q IECPHTVGLGQGYVTGSVETTPILLTQVADLKI AAA6800 1 ..........................K................................. AAA68036 1 ..........................K................................. NP_941974 1 ..........................K...................I............. Q83887 1 .......S....A.T...........K............................T.... AAC54561 1 ...F........A.T...........K..................G.........T.... AAC54559 1 ............A.T...........K............................T.... consensus 1 ***.***.****.*.***********.******************..********.**** SN-M(2a) 61 ESSCNFDLHVPATTTQKYNQVDWTKKSSTTESTNAGATTFEAKTKEVNLKGTCNIPPTTF AAA6800 61 ............................................................ AAA68036 61 ............................................................ NP_941974 61 ..............................................I............. Q83887 61 ...........S.SI......E.A.........S.............S........V... AAC54561 61 .............S.SI....E.A.........S.............S........V... AAC54559 61 .............S.SI....E.A.........S.............S........V... consensus 61 ***********.*..******.*.*********.************..********.*** SN-M(2a) 121 EAAYKSRKTVICYDLACNQTHCLPTVHLIAPVQTCMSVRSCMIGLLSSRIQVIYEKTYCV AAA6800 121 ............................................................ AAA68036 121 ...F........................................................ NP_941974 121 ............................................................ Q83887 121 ............................................................ AAC54561 121 ............................................................ AAC54559 121 ....................Y....................................... consensus 121 ***.****************.*************************************** SN-M(2a) 181 TGQLIEGLCFIPTHTIALTQPGHTYDTMTLPVTCFLVAKKLGTQLKLAVELEKLITGVSC AAA6800 181 ............................................................ AAA68036 181 ............................................................ NP_941974 181 ............................................................ Q83887 181 ....V..........................I..............I.........ASG. AAC54561 181 ....V..........................I..............I.........ASG. AAC54559 181 ....V..........................I..............I.........ASG. consensus 181 ****.**************************.**************.*********...* SN-M(2a) 241 A ENSFQGYYICFIGKHSEPLFVPTMEDYRSAELFTRMVLNPRGEDHDPDQNGQGLMRIAG AAA6800 241 T........................................................... AAA68036 241 T........................................................... NP_941974 241 T........................................................... Q83887 241 T...........L..........M.D.................................. AAC54561 241 T...........L..........M.D.................................. AAC54559 241 T...........L.......S..M.D.................................. consensus 241 .***********.*******.**.*.********************************** SN-M(2a) 301 PVTAKVPSTETTETMQGIAFAGAPMYSSFSTLVRKADPEYVESPGIIAESNHSVCDKKTV AAA6800 301 ............................................................ AAA68036 301 ............................................................ NP_941974 301 ............................................................ Q83887 301 .I....................................D....................I AAC54561 301 .I...........A........................D....................I AAC54559 301 .I......................T.............D...................AI consensus 301 *.**********************.*************.*******************.. SN-M(2a) 361 PLTWTGFLAVSGEIERITGCTVECTLAGPGASCEAYSETGIFNISSPTCLVNKVQKFRGS AAA6800 361 ............................................................ AAA68036 361 ............................................................ NP_941974 361 ...............K............................................ Q83887 361 ...............K..........V................................. AAC54561 361 ...............K..........V................................. AAC54559 361 ...............K..........V......K.......................... consensus 361 ***************.**********.******.************************** SN-M(2a) 421 EQRINFMCQRVDQ G VVVYCNGQKKVILTKTLVIGQCIYTFTSLFSLIPGVAHSLAVELCV AAA6800 421 .............D.............................................. AAA68036 421 .............D.............................................. NP_941974 421 .............D.............................................. Q83887 421 .............D.I............................................ AAC54561 421 .............D.I............................................ AAC54559 421 .............D.I...............I............................ consensus 421 *************.*.***************.**************************** SN-M(2a) 481 PGLHGWATTALLITFCFGWLLIPTVTLIILKILRLLTF P CSHYSTESKEKVILERVKVEY AAA6800 481 ......................................S..................... AAA68036 481 ......................................S..................... NP_941974 481 .......................A..............S..................... Q83887 481 ........................I.M...........S...........A......... AAC54561 481 ........................I.M...........S...........A......... AAC54559 481 ........A...............I.M...........S...........A......... consensus 481 ********.**************..*.***********.***********.********* SN-M(2a) 541 QKTMGSMVCDICHHECETAKELETHKKSCPEGQCPYCMTITESTESALQAHFSICKLTNR AAA6800 541 ............................................................ AAA68036 541 ............................................................ NP_941974 541 ....................................................A....... Q83887 541 ..........V........................... M.................... AAC54561 541 ..........V........................... M.................... AAC54559 541 ..........A........................... M........L........... consensus 541 **********.****************************.********.***.******* SN-M(2a) 601 FQENLKKSLKRPEVRKGCYRTLGVFRYKSRCYVGLVWGILLTTELIIWAASADTPLMESG AAA6800 601 ...I........................................................ AAA68036 601 ...I........................................................ NP_941974 601 ............................................................ Q83887 601 ..............KQ......................V.......V............. AAC54561 601 ..............KQ......................V.......V............. AAC54559 601 ..............KQ.R....................V.......V............. consensus 601 ***.**********..*.********************.*******.************* SN-M(2a) 661 WSDTAHGVGIVPMKTDLELDFALASSSSYSYRRKLVNPANQEETLPFHFQLDKQVVHAEI AAA6800 661 ............................................................ AAA68036 661 ............................................................ NP_941974 661 ..........I................................................. Q83887 661 ........................................K................... AAC54561 661 ....................................D...K................... AAC54559 661 ........................................K................... consensus 661 **********.*************************.***.******************* SN-M(2a) 721 WSDTAHGVGIVPMKTDLELDFALASSSSYSYRRKLVNPANQEETLPFHFQLDKQVVHAEI AAA6800 721 ............................................................ AAA68036 721 ............................................................ NP_941974 721 ............................................................ Q83887 721 ............................................................ AAC54561 721 ............................................................ AAC54559 721 ............................................................ consensus 721 ************************************************************ SN-M(2a) 781 CTACGVYLDKLRSVGKAYKIVSLKYTRKVCIQLGTEQTCKHIDVNDCLVTPSVKVCMIGT AAA6800 781 ............................................................ AAA68036 781 ............................................................ NP_941974 781 ............................................................ Q83887 781 .............G..........F...............................L... AAC54561 781 .............G..........F...............................L... AAC54559 781 .............G..........F...............................L... consensus 781 *************.**********.*******************************.*** SN-M(2a) 841 ISKLQPGDTLLFLGPLEQGGIILKQWCTTSCVFGDPGDIMSTTSGMRCPEHTGSFRKICG AAA6800 841 ............................................................ AAA68036 841 ............................................................ NP_941974 841 ............................................................ Q83887 841 ...........................................T..K............. AAC54561 841 ...........................................T..K............. AAC54559 841 ...........................................T..K............. consensus 841 *******************************************.**.************* SN-M(2a) 901 FATTPTCEYQGNTVSGFQRMMATRDSFQSFNVTEPHITSNRLEWIDPDSSIKDH1NMVLN AAA6800 901 ............................................................ AAA68036 901 ............................................................ NP_941974 901 ............................................................ Q83887 901 .............I.............................................. AAC54561 901 .............I.............................................. AAC54559 901 .............I.............................................. consensus 901 *************.********************************************** SN-M(2a) 961 RDVSFQDLSDNPCKVDLHTQSIDGAWGSGVGFTLVCTVGLTECANFITSIKACDSAMCYG AAA6800 961 ............................................................ AAA68036 961 ............................................................ NP_941974 961 ............................................................ Q83887 961 ............................................................ AAC54561 961 ............................................................ AAC54559 961 ............................................................ consensus 961 ************************************************************ SN-M(2a) 1021 ATVINLLRGSNTVKVVGKGGHSGSLFKCCHDTDCTEEGLAASPPHLDRVTGYNQIDSDKV AAA6800 1021 ............................................................ AAA68036 1021 ............................................................ NP_941974 1021 ............................................................ Q83887 1021 ............................................................ AAC54561 1021 ............................................................ AAC54559 1021 ......................S..................................... consensus 1021 **********************.************************************* SN-M(2a) 1081 YDDGAPPCTIKCWFTKSGEWLLGILNGNWVVVAVLIVILILSILLFSFFCPVRNRKNKAN AAA6800 1081 ...............R............................................ AAA68036 1081 ............................................................ NP_941974 1081 .....................................................S...... Q83887 1081 ...................................................I.G....S. AAC54561 1081 ...................................................I.G....S. AAC54559 1081 ...................................................I.G....S. consensus 1081 ***************.***********************************.*.****.*

TABLE 2 The sequence starts at the Not 1 site and ends at the BstB1 or BglII  site depending on the construct (BstB1 for SN-M(2a) (SEQ ID NO: 22) and BglII for SN-M(opt) (SEQ ID NO: 2). SN-M(2a)    1 GCGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGCAAA SN-M(opt)    1 ............................................................ SN-M(2a)   61 CACTGAATAAAGGATATACAGAATGGTAGGGTGGGTTTGCATCTTCCTCGTGGTCCTTAC SN-M(opt)   61 ...........................G..C.....G...........G.....G..G.. SN-M(2a)  121 TACTGCAACTGCTGGATTGACACGGAATCTCTATGAATTACAGATAGAATGTCCACATAC SN-M(opt)  121 C..C..C..A..C..CC....C.....C..G..C..GC.GA....C..G..C..C..C.. SN-M(2a)  181 TGTGGGTCTAGGTCAAGGTTATGTGACAGGTTCTGTAGAAACTACACCTATTCTCTTAAC SN-M(opt)  181 C.....C..G..C..G..C..C.....C..CAGC..G..G..A..C..C..C..GC.G.. SN-M(2a)  241 ACAGGTAGCTGACCTCAAGATTGAGAGTTCTTGCAATTTTGACTTGCATGTCCCAGCCAC SN-M(opt)  241 C.....G..C.....G...........CAGC.....C..C...C....C..G..C..... SN-M(2a)  301 TACTACTCAGAAATACAATCAAGTTGACTGGACTAAAAAAAGTTCTACTACAGAAAGCAC SN-M(opt)  301 C..C..C...........C..G..G........C..G..G..CAGC..C..C..G..... SN-M(2a)  361 GAATGCAGGTGCAACTACATTTGAGGCTAAAACAAAAGAGGTAAATTTAAAAGGCACATG SN-M(opt)  361 C..C..C..A..C..C..C..C.....C..G..C.....A..G..CC.G..G.....C.. SN-M(2a)  421 TAATATTCCTCCAACTACGTTTGAGGCTGCATACAAGTCAAGGAAGACAGTGATTTGTTA SN-M(opt)  421 C..C..C..C..C..C..A........C..C......AGC..A.....C.....C..C.. SN-M(2a)  481 TGATTTGGCCTGTAATCAAACACATTGTCTTCCTACAGTCCATCTGATTGCTCCTGTTCA SN-M(opt)  481 C..CC.......C..C..G..C..C..C..G..C..C..G..C.....C..C..C..G.. SN-M(2a)  541 AACATGTATGTCTGTACGGAGCTGTATGATAGGTCTGTTATCTAGCAGGATCCAGGTTAT SN-M(opt)  541 G..C..C...AGC..G........C.....C..C...C.G..C...C..........G.. SN-M(2a)  601 CTACGAGAAGACATATTGTGTCACGGGTCAGTTAATAGAAGGGCTATGTTTCATTCCAAC SN-M(opt)  601 .........A..C..C..C..G..C..C...C.G..C..G..C..G..C.....C..C.. SN-M(2a)  661 ACATACAATTGCACTTACACAGCCTGGTCATACTTATGATACTATGACATTGCCTGTGAC SN-M(opt)  661 C..C.....C..C..G..C.....C..C..C..C..C..C..C.....CC....C..... SN-M(2a)  721 TTGTTTTTTAGTAGCCAAAAAGTTGGGGACGCAGCTTAAGCTGGCTGTTGAGTTAGAGAA SN-M(opt)  721 C..C...C.G..G.....G...C....C..C.....G........C..G...C.G..A.. SN-M(2a)  781 ATTGATTACTGGTGTGAGCTGCGCAGAGAATAGCTTCCAAGGTTATTACATCTGTTTTAT SN-M(opt)  781 GC....C..C..C.........A.C.....C........G..C..C........C..C.. SN-M(2a)  841 TGGAAAACATTCAGAGCCCTTATTTGTACCAACAATGGAAGATTATAGATCAGCTGAGTT SN-M(opt)  841 C..C..G..CAGC......C.G..C..G..C..C...........C...AGC..C...C. SN-M(2a)  901 ATTTACTCGTATGGTTTTAAATCCAAGAGGTGAAGATCATGACCCTGATCAAAATGGACA SN-M(opt)  901 G..C..C..G.....GC.G..C..C..G..C..G..C..C.....C..C..G..C..C.. SN-M(2a)  961 AGGGTTGATGAGAATAGCTGGACCTGTTACTGCCAAGGTACCATCTACAGAAACGACTGA SN-M(opt)  961 G..CC.....C.G..C..C.....C..G..C........G..CAGC..C..G..A..C.. SN-M(2a) 1021 AACAATGCAAGGAATTGCATTTGCTGGGGCACCAATGTATAGTTCATTCTCAACTCTTGT SN-M(opt) 1021 ...C.....G..C.....C..C..C..A..C..C.....C..CAGC...AGC..C..G.. SN-M(2a) 1081 GAGAAAAGCTGATCCTGAATATGTCTTTTCTCCAGGTATAATTGCAGAATCAAATCATAG SN-M(opt) 1081 .C.G..G..C..C..C..G..C..G..CAGC..C..C..C.....C..GAGC..C..C.. SN-M(2a) 1141 TGTTTGTGATAAAAAGACAGTGCCCCTAACATGGACTGGGTTTCTAGCAGTTTCAGGAGA SN-M(opt) 1141 C..G..C..C..G..A..C........G..C.....C..C..C..G..C..GAGC..C.. SN-M(2a) 1201 GATAGAAAGGATAACAGGCTGTACAGTTTTCTGTACATTGGCTGGACCTGGTGCCAGTTG SN-M(opt) 1201 ...C..GC....C..C.....C..C..G.....C..CC....C........C.....C.. SN-M(2a) 1261 TGAAGCATACTCAGAAACAGGAATCTTCAACATAAGCTCCCCAACTTGCTTGGTAAATAA SN-M(opt) 1261 C..G..C...AGC..G.....C...........C...AG...C..C...C....G..C.. SN-M(2a) 1321 AGTCCAAAAATTTAGAGGTTCAGAACAAAGAATTAATTTTATGTGTCAAAGGGTTGATCA SN-M(opt) 1321 G..G..G..G..CC.G..CAGC..G..GC.G..C..C..C.....C..GC....G..C.. SN-M(2a) 1381 AGGTGTTGTGGTTTACTGTAATGGACAGAAGAAAGTCATTCTTACCAAAACCCTAGTAAT SN-M(opt) 1381 G.AC..G.....G.....C..C..C.....A.....G..C..G.....G.....G..G.. SN-M(2a) 1441 AGGTCAATGTATCTACACATTTACTAGTCTGTTTTCACTGATCCCTGGAGTTGCTCATTC SN-M(opt) 1441 C..C..G..C........C..C..C..C.....CAGC...........C..G......AG SN-M(2a) 1501 CCTTGCTGTGGAGTTATGTGTTCCAGGTCTTCATGGCTGGGCTACAACAGCACTACTTAT SN-M(opt) 1501 ...G..A..C..AC.G..C..G..T..C..G..C..A.....C..C..C..C..G..G.. SN-M(2a) 1561 TACTTTCTGCTTTGGCTGGCTTCTCATACCAACAGTTACTTTAATTATACTAAAAATCTT SN-M(opt) 1561 C..C........C........G..G..C..C.....G..CC.G..C..C..G..G...C. SN-M(2a) 1621 AAGGCTATTGACCTTCCCATGCTCGCACTATTCTACAGAATCAAAATTCAAAGTCATTTT SN-M(opt) 1621 GC....GC........AGC...AGC.....CAGC..C..G..C..G........G...C. SN-M(2a) 1681 AGAAAGAGTCAAGGTGGAGTATCAAAAGACAATGGGTTCAATGGTGTGTGACATTTGTCA SN-M(opt) 1681 G...C.C..G...........C..G..A..C.....CAGC........C.....C..C.. SN-M(2a) 1741 CCATGAATGTGAGACGGCAAAAGAGCTCGAAACACATAAGAAAAGTTGCCCAGAAGGTCA SN-M(opt) 1741 ...C..G..C.....A..C........G.....C..C.....G..C.....C..G..C.. SN-M(2a) 1801 ATGCCCATACTGCATGACAATAACTGAGTCCACTGAGAGTGCATTACAAGCTCATTTTTC SN-M(opt) 1801 G.....C...........C..C..A...AG...C.....C..CC.G..G..C..C..CAG SN-M(2a) 1861 AATCTGTAAGCTAACGAACAGGTTCCAGGAAAATCTAAAAAAATCATTAAAACGTCCAGA SN-M(opt) 1861 C.....C.....G..C...C.............C..G..G..GAGCC.G..G..G..C.. SN-M(2a) 1921 AGTAAGGAAAGGTTGTTACAGGACATTAGGAGTATTCCGCTACAAGAGCAGGTGCTATGT SN-M(opt) 1921 ...GC....G..C..C...C....CC.G..C..G.....G.........C.......... SN-M(2a) 1981 TGGCTTAGTATGGGGGATCCTCTTGACGACAGAGCTGATTATATGGGCTGCTAGTGCAGA SN-M(opt) 1981 G...C.G..G.....C..T..GC....C...........C..C.....C..C..C..C.. SN-M(2a) 2041 TACCCCTCTAATGGAGTCTGGTTGGTCAGATACAGCACATGGTGTAGGTATAGTCCCTAT SN-M(opt) 2041 C.....C..G.....AAGC..G...AGC..C..C..T.....C..G..A..C..G..C.. SN-M(2a) 2101 GAAAACAGATTTAGAGCTTGACTTTGCCTTGGCCTCATCATCTTCTTATAGTTATAGAAG SN-M(opt) 2101 ......C..CC.G..A..G.....C...C.....AGCAGCAGCAGC..C..C..CC.GC. SN-M(2a) 2161 AAAGCTTGTAAACCCTGCCAATCAAGAGGAGACACTCCCTTTTCATTTCCAGTTAGATAA SN-M(opt) 2161 G.....G..G.....C.....C..G..A........G..C..C..C.....AC.G..C.. SN-M(2a) 2221 GCAAGTAGTGCATGCAGAAATACAGAACCTAGGGCATTGGATGGATGGCACATTCAACAT SN-M(opt) 2221 ...G..G.....C..C..G..C........G..C..C........C.....C.....T.. SN-M(2a) 2281 AAAGACTGCTTTCCATTGCTATGGAGAATGTAAAAAATATGCCTATCCTTGGCAGACAGC SN-M(opt) 2281 C.....C..C.....C.....C..C..G..C..G..G..C.....C..C........C.. SN-M(2a) 2341 CAAGTGTTTCTTTGAAAAAGATTATCAGTATGAAACAAGCTGGGGCTGTAACCCACCAGA SN-M(opt) 2341 ......C.....C..G..G..C..C.....C..G..............C.....C..C.. SN-M(2a) 2401 TTGCCCAGGAGTAGGGACAGGTTGTACAGCCTGTGGGGTATACTTAGACAAGCTCCGTTC SN-M(opt) 2401 C..T..T..C..G..C..C..C.....C.....C..C..G...C.G........G..GAG SN-M(2a) 2461 AGTTGGGAAAGCCTATAAAATTGTATCACTCAAATACACGCGAAAGGTGTGTATTCAATT SN-M(opt) 2461 C..G..C..G.....C..G..C..G..C..G..G.....C..G..A.....C..C..GC. SN-M(2a) 2521 GGGGACAGAACAAACCTGTAAACATATAGATGTTAATGATTGTTTGGTCACCCCGTCTGT SN-M(opt) 2521 ...C.....G..G..A..C..G..C..C..C..G..C.....CC....G.....CAGC.. SN-M(2a) 2581 TAAAGTTTGCATGATAGGTACCATCTCGAAGCTTCAGCCAGGTGACACCTTATTGTTTTT SN-M(opt) 2581 G.....C..T.....T..C......AGC.....G.....C..C..T...C.GC....CC. SN-M(2a) 2641 GGGCCCTTTAGAGCAAGGTGGGATTATTCTAAAACAATGGTGCACAACATCATGTGTGTT SN-M(opt) 2641 ......CC.G..A..G..C..C..C.....G..G..G.....T..C..C..C..C..... SN-M(2a) 2701 TGGAGACCCTGGTGATATCATGTCAACAACAAGTGGGATGAGATGCCCTGAGCACACAGG SN-M(opt) 2701 C..C.....C..C..C......AGC..C..CTCC..C...C.G.....C........C.. SN-M(2a) 2761 GTCTTTTAGAAAAATCTGTGGATTTGCTACAACACCTACATGTGAATATCAAGGTAATAC SN-M(opt) 2761 CAGC..CC.G..G..T.....C..C..C..C..C.....C..C..G..C..G..C..C.. SN-M(2a) 2821 AGTGTCTGGATTCCAACGCATGATGGCAACTCGAGATTCTTTTCAATCATTCAATGTGAC SN-M(opt) 2821 C.....C..C.....G..G........C..C..G...AGC..C..GAGC.....C..... SN-M(2a) 2881 AGAACCACATATTACCAGCAATCGACTGGAATGGATTGATCCAGATAGTAGTATTAAAGA SN-M(opt) 2881 C..G..C..C..C........C..G...........C..C..C..C..C..C..C..G.. SN-M(2a) 2941 CCATATCAACATGGTTTTGAATAGAGATGTTTCCTTCCAAGATCTAAGTGATAATCCATG SN-M(opt) 2941 ...C...........GC.C...C.G..C..GAG......G..C..G..C..C..C..C.. SN-M(2a) 3001 TAAGGTTGATTTGCATACACAATCTATTGATGGGGCTTGGGGATCAGGAGTGGGCTTTAC SN-M(opt) 3001 C.....G..CC....C..C..GAGC..C..C..C..C.....CAGC..C........C.. SN-M(2a) 3061 ATTAGTATGTACTGTAGGTCTTACAGAGTGTGCAAATTTCATAACTTCAATTAAGGCGTG SN-M(opt) 3061 .C.G..G..C..A..G..C..G..C.....C..C..C.....C..C..C..C.....C.. SN-M(2a) 3121 TGATTCTGCTATGTGTTATGGGGCCACAGTTACAAATCTACTCAGAGGGTCTAACACAGT SN-M(opt) 3121 C..CAGC..C.....C..C..C.....C..G..C..C..G..GC.G..C..C........ SN-M(2a) 3181 TAAAGTTGTCGGTAAAGGTGGGCATTCTGGGTCCTTGTTCAAGTGCTGCCATGATACTGA SN-M(opt) 3181 G..G..G..G..C..G..C..C..CAGC..CAG.C....T...........C..C..C.. SN-M(2a) 3241 CTGTACTGAAGAAGGTTTAGCAGCATCACCACCTCATTTAGATAGGGTTACTGGTTACAA SN-M(opt) 3241 ...C..C..G.....CC.G..C..CAGC..C.....CC.G..C..A..G..C..C..... SN-M(2a) 3301 TCAAATAGATTCTGATAAGGTTTATGATGACGGTGCACCGCCCTGTACAATTAAATGTTG SN-M(opt) 3301 C..G..C..CAGC..C.....G..C..C..T..C..C..T.....C..C..C..G..C.. SN-M(2a) 3361 GTTCACAAAGTCAGGTGAGTGGTTGCTAGGAATTCTTAATGGCAATTGGGTAGTAGTTGC SN-M(opt) 3361 ......C...AGC..C......C....G..C..C..G..C.....C.....C..C..G.. SN-M(2a) 3421 TGTTTTGATTGTAATTTTGATACTATCAATACTCCTGTTCAGCTTCTTTTGTCCTGTTAG SN-M(opt) 3421 C..GC....C..G..CC....C..G..T..C..G..............C..C..C..GC. SN-M(2a) 3481 AAATAGAAAAAATAAGGCCAATTAGCAAACATATATGTAAGTAAGGGTATGATCATATTA SN-M(opt) 3481 G..CC.G..G..C........C...................................... SN-M(2a) 3541 TATCATTATGCGTATACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATT SN-M(opt) 3541 ............................................................ SN-M(2a) 3601 TATATTAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTAAAAAAAACAA SN-M(opt) 3601 ............................................................ SN-M(2a) 3661 ACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGGCTTTTGTTCCTGCGGAGTCT SN-M(opt) 3661 ............................................................ SN-M(2a) 3721 ACTACTATTCGAA SN-M(opt) 3721 .......AGATCT

This new SNV vaccine was tested for a capacity to elicit neutralizing antibodies by vaccinating rabbits with the pWRG/SN-M(opt) using muscle electroporation. Very high titers of SNV neutralizing antibodies were produced after only a single vaccination.

The term “antibody” is art-recognized terminology and is intended to include molecules or active fragments of molecules that bind to known antigens. These active fragments can be derived from an antibody of the present invention by a number of techniques. For further description of general techniques for the isolation of active fragments of antibodies, see for example, Khaw, B. A. et al. J. Nucl. Med. 23:1011-1019 (1982). The term “antibody” also includes bispecific and chimeric antibodies and antibodies in nonmammalian species.

By neutralizing antibodies, or NAb, it is meant an antibody which defends a cell from an antigen or infectious body by inhibiting or neutralizing any effect it has biologically. For instance, a neutralizing antibody for SNV is an antibody which can inhibit or reduce the biological effects of SNV infection, that is, it binds to the virus and interferes with its ability to infect a cell.

By “high titer” it is meant neutralizing antibody titers similar to those produced in individuals that were infected with the virus and survived. As described in greater detail in the examples, the present inventors have found that serum from a vaccine immunized with a DNA vaccine comprising the M segment of Sin Nombre virus contains antibodies able to neutralize Sin Nombre virus.

As used herein the term “immunogenically active” designates the ability to stimulate an immune response, i.e., to stimulate the production of antibodies, particularly humoral antibodies, or to stimulate a cell-mediated response. For example, the ability to stimulate the production of circulating or secretory antibodies or the production of a cell-mediated response in local mucosal regions, (e.g., intestinal mucosa), peripheral blood, cerebral spinal fluid or the like. The effective immunizing amount of the immunogenically active component(s) of this invention may vary and may be any amount sufficient to evoke an immune response and provide immunological protection against Sin Nombre virus infection. Amounts where a dosage unit comprises at least about 5 micrograms to about 5 milligrams of plasmid DNA are contemplated. At least one dosage unit per patient is contemplated herein as a vaccination regimen. In some embodiments, two or more dosage units may be especially useful. The skilled artisan will quickly recognize that a particular quantity of vaccine composition per dosage unit, as well as the total number of dosage units per vaccination regimen, may be optimized, so long as an effective immunizing amount of the virus or a component thereof is ultimately delivered to the animal.

We next combined the SNV DNA vaccine with an Andes virus construct, pWRG/AND-M, and a mixture of the two plasmids was used to vaccinate rabbits using muscle electroporation. High titer neutralizing antibodies against both SNV and ANDV were produced after 1 or 2 vaccinations. The SNV neutralizing activity was especially potent (titers >10,000 after 1 vaccination). Thus, the combination of the pWRG/SN-M(opt) DNA vaccine and pWRG/AND-M DNA vaccine effectively elicited high-titer neutralizing antibodies against the most prevalent and lethal hantavirus in North and South America. The novelty and potency of this SNV DNA vaccine and its utility in alone or in combination with other hantavirus DNA vaccine plasmids is a main focus of this application.

The amino acid one letter code is defined as the following: A=Alanine (Ala), I=Isoleucine (Ile), L=Leucine (Leu), M=Methionine (Met), F=Phenylalanine (Phe), P=Proline (Pro), W=Tryptophan (Trp), V=Valine (Val), N=Asparagine (Asn), C=Cysteine (Cys), Q=Glutamine (Q), G=Glycine (Gly), S=Serine (Ser), T=Threonine (Thr), Y=Tyrosine (Tyr), R=Arginine (Arg), H=Histidine (His), K=Lysine (Lys), D=Aspartic acid (Asp), and E=Glutamic acid (Glu).

As would be understood by someone having skill in this art, this invention covers sequences that are not necessarily physically derived from the nucleotide sequence itself, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence bases in the region(s) from which the polynucleotide is derived. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use.

It is also understood in the art that certain changes to the nucleotide sequence employed in a genetic construct have little or no bearing on the proteins encoded by the construct, for example due to the degeneracy of the genetic code. Such changes result either from silent point mutations or point mutations that encode different amino acids that do not appreciably alter the behavior of the encoded protein. It is understood that portions of the coding region can be eliminated without affecting the ability of the construct to achieve the desired effect, namely induction of a protective immune response against Sin Nombre virus. It is further understood in the art that certain advantageous steps can be taken to increase the antigenicity of an encoded protein by modifying its amino acid composition. Such changes in amino acid composition can be introduced by modifying the genetic sequence encoding the protein. It is contemplated that all such modifications and variations of the M segment of Sin Nombre virus are equivalents within the scope of the present invention.

The DNA encoding the desired antigen can be introduced into the cell in any suitable form including, a linearized plasmid, a circular plasmid, a plasmid capable of replication, an episome, RNA, etc. Preferably, the gene is contained in a plasmid. In a particularly preferred embodiment, the plasmid is an expression vector, such as pWRG7077. In another embodiment, the DNA encoding the desired antigen can be introduced into virus-based vaccine vectors such as recombinant adenovirus, recombinant vesicular stomatitis virus, or alphavirus replicons. Individual expression vectors capable of expressing the genetic material can be produced using standard recombinant techniques.

This invention entails new recombinant SNV DNA sequences which are useful to elicit neutralizing antibodies against SNV. The DNA sequences include the codon-optimized full-length M segment [designated SN-M(opt)] (SEQ ID NO:1), the optimized ORF plus M gene flanking sequences (SEQ ID NO:2), and the optimized open reading frame (ORF) (SEQ ID NO:3).

Thus in one embodiment the invention entails an isolated nucleic acid sequence set forth in SEQ ID NO:1, which is as follows. The Sin Nombre virus M gene (optimized) open reading frame is underlined. The synthetic open reading frame and flanking sequence was cloned into the Not I, Bgl II site of pWRG7077 (published). The Not 1 cloning site (GCGGCCGCGG) (SEQ ID NO:7) and the Bgl II cloning site (GATCT) (SEQ ID NO:8) are in bold. An extraneous sequence having the sequence “ATCTGCAGGAATTCGGCACGAG” (SEQ ID NO:9) is in italics. The flanking sequences include 5′ and 3′ non-translated sequence from the SNV M genome segment, and a 24-base sequence (the extraneous sequence) between the Not I site and position +2 of the M gene (not +1 because the first nucleotide is missing). This sequence was found to be essential for expression of the Gn protein from the Hantaan virus and Seoul virus full-length M gene-based DNA vaccine plasmids, pWRG/HTN-M(x) and pWRG/SEO-M, respectably. (See U.S. Pat. No. 7,217,812) It is noted that experiments demonstrated that this 24-base sequence was not essential for expression of Gn from the Puumala M gene-based DNA vaccine plasmid or the Andes M gene-based DNA vaccine plasmid, but was retained in those constructs (See US Patent Application Publication No. 20100323024 and U.S. Pat. No. 7,217,812, respectively).

Two SNV M segment nontranslated regions are indicated by wavy underline, and are between the extraneous sequence and the beginning of the ORF, and between the end of the ORF and the Bgl II cloning site.

GGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGG TGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCAT CCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCT TTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTG  CTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCG TGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATT CAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTC TGCCAGTGTTACAACCAATTAACCAATTCTGATTAGAA AAACTCATCGAGCATCAAATGAAACTGCAATTTATTCA TATCAGGATTATCAATACCATATTTTTGAAAAAGCCGT TTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCA TAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGA CTCGTCCAACATCAATACAACCTATTAATTTCCCCTCG TCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGT GACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCA TTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGC TCGTCATCAAAATCACTCGCATCAACCAAACCGTTATT CATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGAT CGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGC AACCGGCGCAGGAACACTGCCAGCGCATCAACAATATT TTCACCTGAATCAGGATATTCTTCTAATACCTGGAATG CTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCA TCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAG AGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCT CATCTGTAACATCATTGGCAACGCTACCTTTGCCATGT TTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAA TCGATAGATTGTCGCACCTGATTGCCCGACATTATCGC GAGCCCATTTATACCCATATAAATCAGCATCCATGTTG GAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTG AATATGGCTCATAACACCCCTTGTATTACTGTTTATGT AAGCAGACAGTTTTATTGTTCATGATGATATATTTTTA TCTTGTGCAATGTAACATCAGAGATTTTGAGACACAAC GTGGCTTTCCCCCCCCCCCCGGCATGCCTGCAGGTCGA CAATATTGGCTATTGGCCATTGCATACGTTGTATCTAT ATCATAATATGTACATTTATATTGGCTCATGTCCAATA TGACCGCCATGTTGACATTGATTATTGACTAGTTATTA ATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCAT ATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGC CCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGAC GTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGG TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT GCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAAT GGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGG GACTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT CGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA  ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCA AGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTG GCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATA ACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTA CGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA CCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTG ACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGC GGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGC CAAGAGTGACGTAAGTACCGCCTATAGACTCTATAGGC ACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTG GCTTGGGGCCTATACACCCCCGCTTCCTTATGCTATAG GTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATTGA CCATTATTGACCACTCCCCTATTGGTGACGATACTTTC CATTACTAATCCATAACATGGCTCTTTGCCACAACTAT CTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGA CTGACACGGACTCTGTATTTTTACAGGATGGGGTCCCA TTTATTATTTACAAATTCACATATACAACAACGCCGTC CCCCGTGCCCGCAGTTTTTATTAAACATAGCGTGGGAT CTCCACGCGAATCTCGGGTACGTGTTCCGGACATGGGC TCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCC TGGTCCCATGCCTCCAGCGGCTCATGGTCGCTCGGCAG CTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACA GCACAATGCCCACCACCACCAGTGTGCCGCACAAGGCC  GTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGA TTGGGCTCGCACCGCTGACGCAGATGGAAGACTTAAGG CAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTA TTCTGATAAGAGTCAGAGGTAACTCCCGTTGCGGTGCT GTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCG TTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAG ACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAG TCACCGTCCAAGCTT GCGGCCGCGGATCTGCAGGAATTCGGCACGAG

ATGGTGGGCTGGGTGTGCA TCTTCCTGGTGGTGCTGACCACCGCCACAGCCGGCCTG ACCCGGAACCTGTACGAGCTGAAGATCGAGTGCCCCCA CACCGTGGGCCTGGGCCAGGGCTACGTGACCGGCAGCG TGGAGACAACCCCCATCCTGCTGACCCAGGTGGCCGAC CTGAAGATTGAGAGCAGCTGCAACTTCGACCTGCACGT GCCCGCCACCACCACCCAGAAATACAACCAGGTGGACT GGACCAAGAAGAGCAGCACCACCGAGAGCACCAACGCC GGAGCCACCACCTTCGAGGCCAAGACCAAAGAAGTGAA CCTGAAGGGCACCTGCAACATCCCCCCCACCACATTTG AGGCCGCCTACAAGAGCAGAAAGACCGTGATCTGCTAC GACCTGGCCTGCAACCAGACCCACTGCCTGCCCACCGT GCACCTGATCGCCCCCGTGCAGACCTGCATGAGCGTGC GGAGCTGCATGATCGGCCTGCTGTCCAGCCGGATCCAG GTGATCTACGAGAAAACCTACTGCGTGACCGGCCAGCT GATCGAGGGCCTGTGCTTCATCCCCACCCACACAATCG CCCTGACCCAGCCCGGCCACACCTACGACACCATGACC CTGCCCGTGACCTGCTTTCTGGTGGCCAAGAAGCTGGG CACCCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGCTGA TCACCGGCGTGAGCTGCACCGAGAACAGCTTCCAGGGC TACTACATCTGCTTCATCGGCAAGCACAGCGAGCCCCT GTTCGTGCCCACCATGGAAGATTACAGAAGCGCCGAGC TGTTCACCCGGATGGTGCTGAACCCCAGGGGCGAGGAC CACGACCCCGACCAGAACGGCCAGGGCCTGATGCGGAT CGCCGGACCCGTGACCGCCAAGGTGCCCAGCACCGAGA CAACCGAAACCATGCAGGGCATTGCCTTCGCCGGAGCC CCCATGTACAGCAGCTTCAGCACCCTGGTGCGGAAGGC CGACCCCGAGTACGTGTTCAGCCCCGGCATCATTGCCG AGAGCAACCACAGCGTGTGCGACAAGAAAACCGTGCCC CTGACCTGGACCGGCTTCCTGGCCGTGAGCGGCGAGAT CGAGCGGATCACCGGCTGCACCGTGTTCTGCACCCTGG CCGGACCTGGCGCCAGCTGCGAGGCCTACAGCGAGACA GGCATCTTCAACATCAGCAGCCCCACCTGCCTGGTGAA CAAGGTGCAGAAGTTCCGGGGCAGCGAGCAGCGGATCA ACTTCATGTGCCAGCGGGTGGACCAGGACGTGGTGGTG TACTGCAACGGCCAGAAAAAAGTGATCCTGACCAAGAC CCTGGTGATCGGCCAGTGCATCTACACCTTCACCAGCC TGTTCAGCCTGATCCCTGGCGTGGCTCATAGCCTGGCA GTCGAACTGTGCGTGCCTGGCCTGCACGGATGGGCCAC CACCGCCCTGCTGATCACCTTCTGCTTCGGCTGGCTGC TGATCCCCACAGTGACCCTGATCATCCTGAAGATCCTG CGGCTGCTGACCTTCAGCTGCAGCCACTACAGCACCGA GTCCAAGTTCAAAGTGATTCTGGAACGCGTGAAGGTGG AGTACCAGAAAACCATGGGCAGCATGGTGTGCGACATC TGCCACCACGAGTGCGAGACAGCCAAAGAGCTGGAAAC CCACAAGAAGAGCTGCCCCGAGGGCCAGTGCCCCTACT GCATGACCATCACAGAGAGCACCGAGAGCGCCCTGCAG GCCCACTTCAGCATCTGCAAGCTGACCAACCGGTTCCA GGAAAACCTGAAGAAGAGCCTGAAGCGGCCCGAAGTGC GGAAGGGCTGCTACCGGACCCTGGGCGTGTTCCGGTAC AAGAGCCGGTGCTATGTGGGCCTGGTGTGGGGCATTCT GCTGACCACAGAGCTGATCATCTGGGCCGCCAGCGCCG ACACCCCCCTGATGGAAAGCGGGTGGAGCGACACCGCT CATGGCGTGGGAATCGTGCCCATGAAAACCGACCTGGA ACTGGACTTCGCCCTGGCCAGCAGCAGCAGCTACAGCT ACCGGCGGAAGCTGGTGAACCCCGCCAACCAGGAAGAG ACACTGCCCTTCCACTTCCAACTGGACAAGCAGGTGGT GCACGCCGAGATCCAGAACCTGGGCCACTGGATGGACG GCACCTTCAATATCAAGACCGCCTTCCACTGCTACGGC GAGTGCAAGAAGTACGCCTACCCCTGGCAGACCGCCAA GTGCTTCTTCGAGAAGGACTACCAGTACGAGACAAGCT GGGGCTGCAACCCCCCCGACTGTCCTGGCGTGGGCACC GGCTGTACCGCCTGCGGCGTGTACCTGGACAAGCTGCG GAGCGTGGGCAAGGCCTACAAGATCGTGTCCCTGAAGT ACACCCGGAAAGTGTGCATCCAGCTGGGCACAGAGCAG ACATGCAAGCACATCGACGTGAACGATTGCCTGGTGAC CCCCAGCGTGAAAGTCTGTATGATTGGCACCATCAGCA AGCTGCAGCCCGGCGATACCCTGCTGTTCCTGGGCCCC CTGGAACAGGGCGGCATCATTCTGAAGCAGTGGTGTAC CACCTCCTGCGTGTTCGGCGACCCCGGCGACATCATGA GCACCACCTCCGGCATGCGGTGCCCCGAGCACACCGGC AGCTTCCGGAAGATTTGTGGCTTCGCCACCACCCCTAC CTGCGAGTACCAGGGCAACACCGTGTCCGGCTTCCAGC GGATGATGGCCACCCGGGATAGCTTCCAGAGCTTCAAC GTGACCGAGCCCCACATCACCAGCAACCGGCTGGAATG GATCGACCCCGACAGCAGCATCAAGGACCACATCAACA TGGTGCTCAATCGGGACGTGAGCTTCCAGGACCTGAGC GACAACCCCTGCAAGGTGGACCTGCACACCCAGAGCAT CGACGGCGCCTGGGGCAGCGGCGTGGGCTTCACACTGG TGTGCACAGTGGGCCTGACCGAGTGCGCCAACTTCATC ACCTCCATCAAGGCCTGCGACAGCGCCATGTGCTACGG CGCCACCGTGACCAACCTGCTGCGGGGCTCCAACACAG TGAAGGTGGTGGGCAAGGGCGGCCACAGCGGCAGCCTG TTTAAGTGCTGCCACGACACCGACTGCACCGAGGAAGG CCTGGCCGCCAGCCCCCCTCACCTGGACAGAGTGACCG GCTACAACCAGATCGACAGCGACAAGGTGTACGACGAT GGCGCCCCTCCCTGCACCATCAAGTGCTGGTTCACCAA GAGCGGCGAGTGGCTGCTGGGCATCCTGAACGGCAACT GGGTCGTCGTGGCCGTGCTGATCGTGATCCTGATCCTG TCTATCCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGAA CCGGAAGAACAAGGCCAACT

ACGTATGATCAGCCTCGACTGTGCCTTCTAGTTGCCAG CCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGAC CCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAA ATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCAT TCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGG GGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATG CGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGC TGGGGCTCGACAGCTCGACTCTAGAATTGCTTCCTCGC TCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATC CACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAG CAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCC GCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGA CGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGC GAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCC CCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT GCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGG GAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTAT CTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTG TGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCT TATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGA CACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAG GATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT TCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGA ACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTAC CTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAC AAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAG CAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGA ACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA TCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAA ATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAA CTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCA CCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGT TGCCTGACTC This is the full-length optimized SNV M gene of pWRG/SN-M(opt). The nucleic acids outside the Not 1 and Bgl II cloning sites are not considered significant to the use of the SNV M gene.

Another valuable sequence is the isolated nucleic acid sequence of the SNV M gene (optimized) open reading frame plus the flanking sequence, as shown in SEQ ID NO:2, as follows:

GCGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACG AAGAAGCAAACACTGAATAAAGGATATACAGAATGGTGGGCTGGGTGTGC ATCTTCCTGGTGGTGCTGACCACCGCCACAGCCGGCCTGACCCGGAACCT GTACGAGCTGAAGATCGAGTGCCCCCACACCGTGGGCCTGGGCCAGGGCT ACGTGACCGGCAGCGTGGAGACAACCCCCATCCTGCTGACCCAGGTGGCC GACCTGAAGATTGAGAGCAGCTGCAACTTCGACCTGCACGTGCCCGCCAC CACCACCCAGAAATACAACCAGGTGGACTGGACCAAGAAGAGCAGCACCA CCGAGAGCACCAACGCCGGAGCCACCACCTTCGAGGCCAAGACCAAAGAA GTGAACCTGAAGGGCACCTGCAACATCCCCCCCACCACATTTGAGGCCGC CTACAAGAGCAGAAAGACCGTGATCTGCTACGACCTGGCCTGCAACCAGA CCCACTGCCTGCCCACCGTGCACCTGATCGCCCCCGTGCAGACCTGCATG AGCGTGCGGAGCTGCATGATCGGCCTGCTGTCCAGCCGGATCCAGGTGAT CTACGAGAAAACCTACTGCGTGACCGGCCAGCTGATCGAGGGCCTGTGCT TCATCCCCACCCACACAATCGCCCTGACCCAGCCCGGCCACACCTACGAC ACCATGACCCTGCCCGTGACCTGCTTTCTGGTGGCCAAGAAGCTGGGCAC CCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGCTGATCACCGGCGTGAGCT GCACCGAGAACAGCTTCCAGGGCTACTACATCTGCTTCATCGGCAAGCAC AGCGAGCCCCTGTTCGTGCCCACCATGGAAGATTACAGAAGCGCCGAGCT GTTCACCCGGATGGTGCTGAACCCCAGGGGCGAGGACCACGACCCCGACC AGAACGGCCAGGGCCTGATGCGGATCGCCGGACCCGTGACCGCCAAGGTG CCCAGCACCGAGACAACCGAAACCATGCAGGGCATTGCCTTCGCCGGAGC CCCCATGTACAGCAGCTTCAGCACCCTGGTGCGGAAGGCCGACCCCGAGT ACGTGTTCAGCCCCGGCATCATTGCCGAGAGCAACCACAGCGTGTGCGAC AAGAAAACCGTGCCCCTGACCTGGACCGGCTTCCTGGCCGTGAGCGGCGA GATCGAGCGGATCACCGGCTGCACCGTGTTCTGCACCCTGGCCGGACCTG GCGCCAGCTGCGAGGCCTACAGCGAGACAGGCATCTTCAACATCAGCAGC CCCACCTGCCTGGTGAACAAGGTGCAGAAGTTCCGGGGCAGCGAGCAGCG GATCAACTTCATGTGCCAGCGGGTGGACCAGGACGTGGTGGTGTACTGCA ACGGCCAGAAAAAAGTGATCCTGACCAAGACCCTGGTGATCGGCCAGTGC ATCTACACCTTCACCAGCCTGTTCAGCCTGATCCCTGGCGTGGCTCATAG CCTGGCAGTCGAACTGTGCGTGCCTGGCCTGCACGGATGGGCCACCACCG CCCTGCTGATCACCTTCTGCTTCGGCTGGCTGCTGATCCCCACAGTGACC CTGATCATCCTGAAGATCCTGCGGCTGCTGACCTTCAGCTGCAGCCACTA CAGCACCGAGTCCAAGTTCAAAGTGATTCTGGAACGCGTGAAGGTGGAGT ACCAGAAAACCATGGGCAGCATGGTGTGCGACATCTGCCACCACGAGTGC GAGACAGCCAAAGAGCTGGAAACCCACAAGAAGAGCTGCCCCGAGGGCCA GTGCCCCTACTGCATGACCATCACAGAGAGCACCGAGAGCGCCCTGCAGG CCCACTTCAGCATCTGCAAGCTGACCAACCGGTTCCAGGAAAACCTGAAG AAGAGCCTGAAGCGGCCCGAAGTGCGGAAGGGCTGCTACCGGACCCTGGG CGTGTTCCGGTACAAGAGCCGGTGCTATGTGGGCCTGGTGTGGGGCATTC TGCTGACCACAGAGCTGATCATCTGGGCCGCCAGCGCCGACACCCCCCTG ATGGAAAGCGGGTGGAGCGACACCGCTCATGGCGTGGGAATCGTGCCCAT GAAAACCGACCTGGAACTGGACTTCGCCCTGGCCAGCAGCAGCAGCTACA GCTACCGGCGGAAGCTGGTGAACCCCGCCAACCAGGAAGAGACACTGCCC TTCCACTTCCAACTGGACAAGCAGGTGGTGCACGCCGAGATCCAGAACCT GGGCCACTGGATGGACGGCACCTTCAATATCAAGACCGCCTTCCACTGCT ACGGCGAGTGCAAGAAGTACGCCTACCCCTGGCAGACCGCCAAGTGCTTC TTCGAGAAGGACTACCAGTACGAGACAAGCTGGGGCTGCAACCCCCCCGA CTGTCCTGGCGTGGGCACCGGCTGTACCGCCTGCGGCGTGTACCTGGACA AGCTGCGGAGCGTGGGCAAGGCCTACAAGATCGTGTCCCTGAAGTACACC CGGAAAGTGTGCATCCAGCTGGGCACAGAGCAGACATGCAAGCACATCGA CGTGAACGATTGCCTGGTGACCCCCAGCGTGAAAGTCTGTATGATTGGCA CCATCAGCAAGCTGCAGCCCGGCGATACCCTGCTGTTCCTGGGCCCCCTG GAACAGGGCGGCATCATTCTGAAGCAGTGGTGTACCACCTCCTGCGTGTT CGGCGACCCCGGCGACATCATGAGCACCACCTCCGGCATGCGGTGCCCCG AGCACACCGGCAGCTTCCGGAAGATTTGTGGCTTCGCCACCACCCCTACC TGCGAGTACCAGGGCAACACCGTGTCCGGCTTCCAGCGGATGATGGCCAC CCGGGATAGCTTCCAGAGCTTCAACGTGACCGAGCCCCACATCACCAGCA ACCGGCTGGAATGGATCGACCCCGACAGCAGCATCAAGGACCACATCAAC ATGGTGCTCAATCGGGACGTGAGCTTCCAGGACCTGAGCGACAACCCCTG CAAGGTGGACCTGCACACCCAGAGCATCGACGGCGCCTGGGGCAGCGGCG TGGGCTTCACACTGGTGTGCACAGTGGGCCTGACCGAGTGCGCCAACTTC ATCACCTCCATCAAGGCCTGCGACAGCGCCATGTGCTACGGCGCCACCGT GACCAACCTGCTGCGGGGCTCCAACACAGTGAAGGTGGTGGGCAAGGGCG GCCACAGCGGCAGCCTGTTTAAGTGCTGCCACGACACCGACTGCACCGAG GAAGGCCTGGCCGCCAGCCCCCCTCACCTGGACAGAGTGACCGGCTACAA CCAGATCGACAGCGACAAGGTGTACGACGATGGCGCCCCTCCCTGCACCA TCAAGTGCTGGTTCACCAAGAGCGGCGAGTGGCTGCTGGGCATCCTGAAC GGCAACTGGGTCGTCGTGGCCGTGCTGATCGTGATCCTGATCCTGTCTAT CCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGAACCGGAAGAACAAGGCCA ACTAGCAAACATATATGTAAGTAAGGGTATGATCATATTATATCATTATG CGTATACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATT TATATTAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTA AAAAAAACAAACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGG CTTTTGTTCCTGCGGAGTCTACTACTAAGATCT The flanking sequences are the cloning sites plus the SNV M segment non-translated regions of SEQ ID NO:1, and also includes the “extraneous sequence” at the 5′ end. The first flanking sequence is:

(SEQ ID:NO 5) ATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGCAAA CACTGAATAAAGGATATACAGA; the second flanking sequence is (SEQ ID NO: 6) CAAACATATATGTAAGTAAGGGTATGATCATATTATATCATTATGCGTAT ACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATTTATAT TAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTAAAAAA AACAAACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGGCTTTT GTTCCTGCGGAGTCTACTACTAA

Another valuable sequence is the isolated nucleic acid sequence of the SNV M gene (optimized) open reading frame by itself, as shown in SEQ ID NO:3. As a point of reference, the ORF begins with the ATG start codon and ends with the TAG stop codon. SEQ ID NO:3 is as follows:

ATGGTGGGCTGGGTGTGCATCTTCCTGGTGGTGCTGACCACCGCCACAGC CGGCCTGACCCGGAACCTGTACGAGCTGAAGATCGAGTGCCCCCACACCG TGGGCCTGGGCCAGGGCTACGTGACCGGCAGCGTGGAGACAACCCCCATC CTGCTGACCCAGGTGGCCGACCTGAAGATTGAGAGCAGCTGCAACTTCGA CCTGCACGTGCCCGCCACCACCACCCAGAAATACAACCAGGTGGACTGGA CCAAGAAGAGCAGCACCACCGAGAGCACCAACGCCGGAGCCACCACCTTC GAGGCCAAGACCAAAGAAGTGAACCTGAAGGGCACCTGCAACATCCCCCC CACCACATTTGAGGCCGCCTACAAGAGCAGAAAGACCGTGATCTGCTACG ACCTGGCCTGCAACCAGACCCACTGCCTGCCCACCGTGCACCTGATCGCC CCCGTGCAGACCTGCATGAGCGTGCGGAGCTGCATGATCGGCCTGCTGTC CAGCCGGATCCAGGTGATCTACGAGAAAACCTACTGCGTGACCGGCCAGC TGATCGAGGGCCTGTGCTTCATCCCCACCCACACAATCGCCCTGACCCAG CCCGGCCACACCTACGACACCATGACCCTGCCCGTGACCTGCTTTCTGGT GGCCAAGAAGCTGGGCACCCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGC TGATCACCGGCGTGAGCTGCACCGAGAACAGCTTCCAGGGCTACTACATC TGCTTCATCGGCAAGCACAGCGAGCCCCTGTTCGTGCCCACCATGGAAGA TTACAGAAGCGCCGAGCTGTTCACCCGGATGGTGCTGAACCCCAGGGGCG AGGACCACGACCCCGACCAGAACGGCCAGGGCCTGATGCGGATCGCCGGA CCCGTGACCGCCAAGGTGCCCAGCACCGAGACAACCGAAACCATGCAGGG CATTGCCTTCGCCGGAGCCCCCATGTACAGCAGCTTCAGCACCCTGGTGC GGAAGGCCGACCCCGAGTACGTGTTCAGCCCCGGCATCATTGCCGAGAGC AACCACAGCGTGTGCGACAAGAAAACCGTGCCCCTGACCTGGACCGGCTT CCTGGCCGTGAGCGGCGAGATCGAGCGGATCACCGGCTGCACCGTGTTCT GCACCCTGGCCGGACCTGGCGCCAGCTGCGAGGCCTACAGCGAGACAGGC ATCTTCAACATCAGCAGCCCCACCTGCCTGGTGAACAAGGTGCAGAAGTT CCGGGGCAGCGAGCAGCGGATCAACTTCATGTGCCAGCGGGTGGACCAGG ACGTGGTGGTGTACTGCAACGGCCAGAAAAAAGTGATCCTGACCAAGACC CTGGTGATCGGCCAGTGCATCTACACCTTCACCAGCCTGTTCAGCCTGAT CCCTGGCGTGGCTCATAGCCTGGCAGTCGAACTGTGCGTGCCTGGCCTGC ACGGATGGGCCACCACCGCCCTGCTGATCACCTTCTGCTTCGGCTGGCTG CTGATCCCCACAGTGACCCTGATCATCCTGAAGATCCTGCGGCTGCTGAC CTTCAGCTGCAGCCACTACAGCACCGAGTCCAAGTTCAAAGTGATTCTGG AACGCGTGAAGGTGGAGTACCAGAAAACCATGGGCAGCATGGTGTGCGAC ATCTGCCACCACGAGTGCGAGACAGCCAAAGAGCTGGAAACCCACAAGAA GAGCTGCCCCGAGGGCCAGTGCCCCTACTGCATGACCATCACAGAGAGCA CCGAGAGCGCCCTGCAGGCCCACTTCAGCATCTGCAAGCTGACCAACCGG TTCCAGGAAAACCTGAAGAAGAGCCTGAAGCGGCCCGAAGTGCGGAAGGG CTGCTACCGGACCCTGGGCGTGTTCCGGTACAAGAGCCGGTGCTATGTGG GCCTGGTGTGGGGCATTCTGCTGACCACAGAGCTGATCATCTGGGCCGCC AGCGCCGACACCCCCCTGATGGAAAGCGGGTGGAGCGACACCGCTCATGG CGTGGGAATCGTGCCCATGAAAACCGACCTGGAACTGGACTTCGCCCTGG CCAGCAGCAGCAGCTACAGCTACCGGCGGAAGCTGGTGAACCCCGCCAAC CAGGAAGAGACACTGCCCTTCCACTTCCAACTGGACAAGCAGGTGGTGCA CGCCGAGATCCAGAACCTGGGCCACTGGATGGACGGCACCTTCAATATCA AGACCGCCTTCCACTGCTACGGCGAGTGCAAGAAGTACGCCTACCCCTGG CAGACCGCCAAGTGCTTCTTCGAGAAGGACTACCAGTACGAGACAAGCTG GGGCTGCAACCCCCCCGACTGTCCTGGCGTGGGCACCGGCTGTACCGCCT GCGGCGTGTACCTGGACAAGCTGCGGAGCGTGGGCAAGGCCTACAAGATC GTGTCCCTGAAGTACACCCGGAAAGTGTGCATCCAGCTGGGCACAGAGCA GACATGCAAGCACATCGACGTGAACGATTGCCTGGTGACCCCCAGCGTGA AAGTCTGTATGATTGGCACCATCAGCAAGCTGCAGCCCGGCGATACCCTG CTGTTCCTGGGCCCCCTGGAACAGGGCGGCATCATTCTGAAGCAGTGGTG TACCACCTCCTGCGTGTTCGGCGACCCCGGCGACATCATGAGCACCACCT CCGGCATGCGGTGCCCCGAGCACACCGGCAGCTTCCGGAAGATTTGTGGC TTCGCCACCACCCCTACCTGCGAGTACCAGGGCAACACCGTGTCCGGCTT CCAGCGGATGATGGCCACCCGGGATAGCTTCCAGAGCTTCAACGTGACCG AGCCCCACATCACCAGCAACCGGCTGGAATGGATCGACCCCGACAGCAGC ATCAAGGACCACATCAACATGGTGCTCAATCGGGACGTGAGCTTCCAGGA CCTGAGCGACAACCCCTGCAAGGTGGACCTGCACACCCAGAGCATCGACG GCGCCTGGGGCAGCGGCGTGGGCTTCACACTGGTGTGCACAGTGGGCCTG ACCGAGTGCGCCAACTTCATCACCTCCATCAAGGCCTGCGACAGCGCCAT GTGCTACGGCGCCACCGTGACCAACCTGCTGCGGGGCTCCAACACAGTGA AGGTGGTGGGCAAGGGCGGCCACAGCGGCAGCCTGTTTAAGTGCTGCCAC GACACCGACTGCACCGAGGAAGGCCTGGCCGCCAGCCCCCCTCACCTGGA CAGAGTGACCGGCTACAACCAGATCGACAGCGACAAGGTGTACGACGATG GCGCCCCTCCCTGCACCATCAAGTGCTGGTTCACCAAGAGCGGCGAGTGG CTGCTGGGCATCCTGAACGGCAACTGGGTCGTCGTGGCCGTGCTGATCGT GATCCTGATCCTGTCTATCCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGA ACCGGAAGAACAAGGCCAACTAG

SEQ ID NO:2 and SEQ ID NO:3 are especially useful as a DNA cassette. The preferred cassette is the SNV optimized M gene cassette in the SNV-M (opt) (preferably taken from the Not 1 site to the BglII site, or minimally the ORF (SEQ ID NO:3) operably linked to a promoter) which can be subcloned into any other vaccine/expression system available, and used to generate active or passive immunity against SN virus. The DNA cassette specifically includes at least SEQ ID NO:2 linked to a promoter operable in a eukaryotic expression system. Alternatively, the DNA cassette includes the sequence in SEQ ID NO:3 (within pWRG/SN-M(opt)) from the ATG start codon to the TAG stop codon.

The peptide encoded by DNA sequence SEQ ID NO:3 is as follows:

SN-M(opt) amino acid sequence (SEQ ID NO:4).

MVGWVCIFLVVLTTATAGLTRNLYELKIECPHTVGLGQGYVTGSVETTPI LLTQVADLKIESSCNFDLHVPATTTQKYNQVDWTKKSSTTESTNAGATTF EAKTKEVNLKGTCNIPPTTFEAAYKSRKTVICYDLACNQTHCLPTVHLIA PVQTCMSVRSCMIGLLSSRIQVIYEKTYCVTGQLIEGLCFIPTHTIALTQ PGHTYDTMTLPVTCFLVAKKLGTQLKLAVELEKLITGVSCTENSFQGYYI CFIGKHSEPLFVPTMEDYRSAELFTRMVLNPRGEDHDPDQNGQGLMRIAG PVTAKVPSTETTETMQGIAFAGAPMYSSFSTLVRKADPEYVFSPGIIAES NHSVCDKKTVPLTWTGFLAVSGEIERITGCTVFCTLAGPGASCEAYSETG IFNISSPTCLVNKVQKFRGSEQRINFMCQRVDQDVVVYCNGQKKVILTKT LVIGQCIYTFTSLFSLIPGVAHSLAVELCVPGLHGWATTALLITFCFGWL LIPTVTLIILKILRLLTFSCSHYSTESKFKVILERVKVEYQKTMGSMVCD ICHHECETAKELETHKKSCPEGQCPYCMTITESTESALQAHFSICKLTNR FQENLKKSLKRPEVRKGCYRTLGVFRYKSRCYVGLVWGILLTTELIIWAA SADTPLMESGWSDTAHGVGIVPMKTDLELDFALASSSSYSYRRKLVNPAN QEETLPFHFQLDKQVVHAEIQNLGHWMDGTFNIKTAFHCYGECKKYAYPW QTAKCFFEKDYQYETSWGCNPPDCPGVGTGCTACGVYLDKLRSVGKAYKI VSLKYTRKVCIQLGTEQTCKHIDVNDCLVTPSVKVCMIGTISKLQPGDTL LFLGPLEQGGIILKQWCTTSCVFGDPGDIMSTTSGMRCPEHTGSFRKICG FATTPTCEYQGNTVSGFQRMMATRDSFQSFNVTEPHITSNRLEWIDPDSS IKDHINMVLNRDVSFQDLSDNPCKVDLHTQSIDGAWGSGVGFTLVCTVGL TECANFITSIKACDSAMCYGATVTNLLRGSNTVKVVGKGGHSGSLFKCCH DTDCTEEGLAASPPHLDRVTGYNQIDSDKVYDDGAPPCTIKCWFTKSGEW LLGILNGNWVVVAVLIVILILSILLFSFFCPVRNRKNKAN

There are four residues that are altered in the M(opt) from the M(2a): K at position 27, T at position 241, D at position 434, and S at position 519. The enhanced immunogenicity of pWRG/SN-M(opt) vs pWRG/SN-M(2a) is speculated to be due to the nucleic acid changes, one or more of the four amino acid changes, or a combination thereof.

In another embodiment, the invention entails a recombinant DNA construct comprising:

(i) a vector, and

(ii) the DNA fragment comprising the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a DNA fragment comprising a nucleic acid sequence that encodes the amino acid sequence set forth in SEQ ID NO:4, operably linked to a promoter sequence.

As would be understood by someone having skill in this art, the DNA constructs of our invention will have all necessary structural components for expression of the DNA fragment of interest (e.g., promoters functional in mammals, and the like). The vector can take the form of a plasmid such as pCRII (Invitrogen) or pJW4303 (Konishi, E. et al., 1992, Virology 188:714), or any expression vector such as viral vectors e.g. adenovirus or Venezuelan equine encephalitis virus and others known in the art. Preferably the vector is a recombinant adenovirus or recombinant vesicular stomatitis virus, or alphavirus replicon. Preferably, a promoter sequence operable in the target cell is operably linked to the DNA sequence. Several such promoters are known for mammalian systems which may be joined 5′, or upstream, of the coding sequence for the encoded protein to be expressed. A suitable and preferred promoter is the human cytomegalovirus immediate early promoter, preferably operably linked to intron A. Another preferred promoter is the beta-actin promoter or the SV40 promoter. A downstream transcriptional terminator, or polyadenylation sequence, such as the polyA addition sequence of the bovine growth hormone gene, may also be added 3′ to the protein coding sequence.

Preferably, the construct is the pWRG/SN-M(opt) DNA vaccine plasmid, whose sequence is set forth above and referred to as SEQ ID NO:1.

In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs. The host cell can be prokaryotic such as Bacillus or E. coli, or eukaryotic such a Saccharomyces or Pichia, or mammalian cells or insect cells. The vector containing the Sin Nombre virus M gene sequence is expressed in the bacteria and the expressed product used for diagnostic procedures or as a vaccine. Please see e.g., Maniatis et al., 1985 Molecular Cloning: A Laboratory Manual or DNA Cloning, Vol. I and II (D. N. Glover, ed., 1985) for general cloning methods. The DNA sequence can be present in the vector operably linked to a highly purified IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of Sin Nombre virus proteins or peptides. The transformed or transfected host cells can be used as a source of DNA sequences described above. When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein or peptide encoded by the DNA. The DNA can be used as circular or linear, or linearized plasmid as long as the Sin Nombre virus sequences are operably linked to a promoter which can be expressed in the transfected cell.

In another embodiment, the invention entails vaccines against infection with Sin Nombre virus. In a method for eliciting in a subject an immune response against Sin Nombre virus, the method comprises administering to a subject a DNA fragment comprising a genome segment of hantavirus. In one preferred embodiment, the vaccine composition comprises an effective immunizing amount of SNV plasmid DNA, which plasmid DNA comprises one or more of the recombinant DNA constructs described above, and a pharmacologically acceptable carrier. That is, the recombinant DNA construct should minimally include (i) a vector, and (ii) the DNA fragment comprising the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a DNA fragment comprising a nucleic acid sequence that encodes the amino acid sequence set forth in SEQ ID NO:4. The DNA fragment is operably linked to a promoter sequence. The pharmacologically acceptable carrier may be any carrier that is known in the art, which is safe and effective for a SNV DNA vaccine. Examples of such carriers include PBS, water, saline, Tris-EDTA, and mixtures of these.

The vaccine composition may which further comprise an adjuvant. The adjuvant may be any one that is known in the art, which is safe and effective for a SNV DNA vaccine. As used herein the term “adjuvant” refers to any component which improves the body's response to a vaccine. The adjuvant will typically comprise about 0.1 to 50% vol/vol of the vaccine formulation of the invention, more preferably about 1 to 50% of the vaccine, and even more desirably about 1 to 20% thereof. Examples of such adjuvants include CpG (cystein-phosphate-guanine) oligodeoxynucleic acid, or plasmid DNA-encoded heat labile enterotoxins, or alum.

The immunizing amount of SNV plasmid DNA is preferably between about 5 micrograms (e.g., with gene gun administration) and about 5 milligrams (e.g., electroporation or other forms of administration). By “immunizing amount”, it is meant the amount of vaccine or immunogenic composition that is needed to raise high titers of neutralizing antibodies in response to the composition.

One unique aspect of our invention is that it can further comprise one or more additional vaccine components of other hantaviruses, to make a bi-valent, tri-valent, multivalent or pan-virus vaccine. In one embodiment, a DNA vaccine is contemplated that elicits an immune response against multiple HPS-associated hantaviruses and protects against more than one HPS virus. Such a DNA vaccine comprises one of the SNV sequences described above (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3), in combination with an HPS hantavirus M gene DNA vaccine (such as M gene DNA vaccine from one or more of Black Creek Canal virus, Bayou virus, New York virus, Andes virus and Laguna Negra virus) such that each M gene is expressed in the subject. The respective M gene DNA sequences may each be part of respective recombinant constructs that each include (i) a vector and (ii) the desired DNA fragment that is operably linked to a promoter sequence. A preferred HPS virus is Andes virus.

In another embodiment, a DNA vaccine elicits an immune response against both HFRS and HPS hantavirus and protects against all the hantaviruses causing severe disease by providing to a subject a DNA vaccine comprising one of the SNV sequences described above (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3), in combination with at least one HFRS hantavirus M gene DNA vaccine (such as Hantaan M gene DNA vaccine, Puumala M gene DNA vaccine, Seoul M gene DNA vaccine and Dobrava M gene DNA) such that each M gene is expressed in the subject. Furthermore, the M gene DNA vaccine from one or more of another HPS-associated virus (such as Black Creek Canal virus, Bayou virus, New York virus, Andes virus and Laguna Negra virus) may be included, to strengthen the HPS component. The respective M gene DNA sequences may each be part of respective recombinant constructs that each include (i) a vector and (ii) the desired DNA fragment that is operably linked to a promoter sequence. The SNV M gene or the other HPS or HFRS M gene may be administered separately, i.e. on separate vectors, or may be combined on the same vector as is described in one aspect of this invention. For instance, a pan-HPS virus vaccine can include any of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, and a suitable Andes M gene sequence (in whole, or an ORF with flanking sequences, or simply the ORF). A preferred Andes M gene sequence is SEQ ID NO:10, which is the full-length ANDV M gene described in U.S. Pat. No. 7,217,812 (and the sequence is referred to as SEQ ID NO:8 therein).

A preferred Puumala M gene sequence is SEQ ID NO:11, which is the full-length PUUV M gene described in U.S. patent publication number 20100323024 (and the sequence is referred to as SEQ ID NO: 1 therein). A preferred Hantaan M gene sequence is SEQ ID NO:12, which is the full-length HNTV M gene described in U.S. Pat. No. 7,217,812 (and the sequence is referred to as SEQ ID NO:7 therein). A preferred Seoul M gene sequence is SEQ ID NO:13, which is the full-length Seoul M gene described in U.S. Pat. No. 7,217,812 (and the sequence is referred to as SEQ ID NO:3 therein). The preferred HPS/HFRS vaccine combination includes Hantaan, Puumala, Andes, and Sin Nombre DNA vaccines, although Seoul DNA vaccine is also a good component for the combined vaccine. Any of these M genes can be used in full-length, or just the ORF with flanking sequences, or simply the ORF. As someone skilled in this art would understand, this invention entailing the combination of hantavirus M genes is not limited at all to these specific M genes—these are merely examples, and any M gene isolated or derived or improved or otherwise altered from the hantavirus (e.g., an altered Seoul M gene, or a non-optimized Puumala M gene).

The vaccine may involve the delivery of pWRG/SN-M(opt) DNA (SEQ ID NO:1), or the DNA of SEQ ID NO:2 or SEQ ID NO:3 (or, if a multivalent vaccine is employed, one or more of the above-described sequences of the other HPS- or HFRS-associated viruses) by any of several platforms used to deliver gene-based vaccines. For example, the vaccine could comprise a composition comprising inert particles and a nucleic acid coated onto the inert particles producing nucleic acid coated particles. The nucleic acid will comprise a promoter operative in the cells of a mammal and further comprise (or even consist essentially of or consist of) SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. As would be understood by someone having skill in this art, the ORF sequence (SEQ ID NO:3) is essential (and for the other HPS- or HFRS-associated viruses, the ORF of the respective M gene). The flanking region between the cloning sites and the ORF are preferably included, as they may be helpful for efficient expression. The inert particle may be gold particles, silver particles, platinum particles, tungsten particles, polystyrene particles, polypropylene particles, polycarbonate particles, and the like, as would be understood by someone having ordinary skill in this art. In particular, it is preferred that the inert particle is suitable for use in a gene gun.

The invention further encompasses a method for inducing a protective immune response against Sin Nombre virus infection in a mammal, comprising the step of accelerating into epidermal cells of the mammal in vivo a composition comprising inert particles and a nucleic acid coated onto the inert particles producing nucleic acid coated particles, such that said nucleic acid is expressed (e.g., gene gun administration). The nucleic acid will comprise a promoter effective and functional in the cells of a mammal and SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.

Electroporation is another method of administration. Electroporation involves injecting plasmid DNA into a tissue (e.g. muscle or skin) and then applying micropulses of an electric field causing transient permeability of the cells of the vaccine. This transient permeability allows for a more efficient take-up of the DNA vaccine plasmid.

In a more general method for inducing a protective immune response against Sin Nombre virus infection in a mammal, a composition is administered to a mammal comprising a nucleic acid comprising a promoter operative in the cells of a mammal and one of SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3. It is generally preferred that the chosen sequence be inserted into a plasmid, and the plasmid administered. To that end, preferably the nucleic acid is a component of one of the above-referenced DNA constructs. However, it is known that a linear piece of DNA consisting of only a promoter and the gene-of-interest can elicit an immune response. Thus, one option for the composition is that it comprises SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3 plus an appropriate promoter. One preferred method comprises the step of administering a composition comprising an effective immunizing amount of SNV plasmid DNA, which plasmid DNA comprises one of the recombinant DNA construct described above; and a pharmacologically acceptable carrier. Another preferred method comprises the step of administering a composition comprising an effective immunizing amount of SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3 operably linked to a promoter operative in the cells of a mammal plus an appropriate promoter; and a pharmacologically acceptable carrier. Appropriate pharmacologically acceptable carriers are discussed elsewhere in this document. Preferably, the immunizing amount of SNV plasmid DNA is between about 5 micrograms and about 5 milligrams.

In another embodiment, this invention provides a method for raising high titers of neutralizing antibodies against Sin Nombre virus in a mammal or a bird. The method comprises the step of administering a composition comprising a SNV plasmid DNA which comprises one or more of the recombinant DNA constructs described above (including SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3); and a pharmacologically acceptable carrier. Preferably, the titers are at least 100, and more preferably are at least 10,000. As someone having ordinary skill in this art would recognize, in the context of hantavirus infection, titers with a level of at least 100 are significant, and considered “high” because they are 10 times higher than the minimal titer of 10 that has been used to evaluate vaccines against HFRS (a titer of 10 indicates there was a 50% reduction in plaque forming units when virus was combined with serum for a final dilution of 1:10). Titers of >10,000 are similar to those produced in person who have developed HPS and survived.

High titers are obtained even with only one dose or administration of the composition, although additional doses or vaccinations can boost titers even higher. The pharmacologically acceptable carrier can be any such carrier known in the art which is safe and does not hamper effectiveness of the composition. Examples are mentioned above, and throughout this document. The amount of the composition required for raising high titers of neutralizing antibodies is between about 5 micrograms and about 5 milligrams. The inventors discovered that the composition was effective in both mammals and birds.

The invention also encompasses post-exposure prophylactics, or passive vaccines, for treating or preventing Sin Nombre virus infections, for someone who has already been exposed to Sin Nombre virus and may be infected. Polyclonal antibodies may be obtained using methods known in the art, from a population of vaccines (human or animal) vaccinated with a Sin Nombre virus DNA vaccine comprised of a plasmid expressing SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO;3, such as pWRG/SN-M(opt). Alternatively, polyclonal or monoclonal antibodies could be produced in animals using the pWRG/SN-M(opt) plasmid, or a plasmid containing SEQ ID NO:2 or SEQ ID NO:3, operably associated with a promoter and any other elements needed for expression of the sequence. The methods entail administration of a therapeutically or prophylactically effective amount of the antibodies which protect against Sin Nombre virus disease in combination with a pharmaceutically acceptable carrier or excipient. For instance, a therapeutic composition for ameliorating symptoms of Sin Nombre virus infection may comprise a composition comprising these polyclonal antibodies, and a pharmaceutically acceptable excipient. For instance, pWRG/SN-M(opt) may be used to vaccinate ducks, sheep, or transgenic cows or rabbits to produce polyclonal neutralizing antibodies for use in humans.

The invention also entails a method for diagnosis of Sin Nombre virus infection by assaying for the presence of Sin Nombre virus in a sample using the above-described antibodies. For instance, a method for the diagnosis of Sin Nombre virus infection may comprise the steps of:

(i) contacting a sample from an individual suspected of having Sin Nombre virus infection with a composition comprising the polyclonal antibodies (e.g., the pWRG/SN-M(opt) plasmid could be used to produce diagnostic antibodies in any of several species of animals—goats, rabbits, etc.); and

(ii) detecting the presence or absence of Sin Nombre virus infection by detecting the presence or absence of a complex formed between Sin Nombre virus antigens and antibodies specific therefor.

In addition, the invention encompasses novel immunoprobes and test kits for detection of Sin Nombre virus infection comprising antibodies according to the present invention. For immunoprobes, the antibodies are directly or indirectly attached to a suitable reporter molecule, e.g., and enzyme or a radionuclide. The test kit includes a container holding one or more antibodies according to the present invention and instructions for using the antibodies for the purpose of binding to Sin Nombre virus to form an immunological complex and detecting the formation of the immunological complex such that presence or absence of the immunological complex correlates with presence or absence of Sin Nombre virus. For instance, the kit may include kit may include a container holding one or more polyclonal antibodies of the present invention which binds a Sin Nombre virus antigen, and ancillary reagents suitable for use in detecting Sin Nombre virus antigens, and instructions for using any of the antibodies or polyclonal antibodies described herein for the purpose of binding to SNV antigen to form an immunological complex and detecting the formation of the immunological complex such that the presence or absence of the immunological complex correlates with presence or absence of Sin Nombre virus antigens in the sample. Examples of containers include multiwell plates which allow simultaneous detection of Sin Nombre virus in multiple samples.

Further, the invention contemplates a method for producing pseudotyped viruses for use in serologic assays or delivery of gene therapies to endothelial cells targeted by hantavirus glycoproteins. The invention as used for this purpose would comprise the following steps. The plasmid pWRG/SN-M(opt) or derivative thereof would be used to transfect cells or stably transform cells. Cells expressing the Sin Nombre glycoproteins could then be infected with viruses engineered to produce progeny that incorporate the Sin Nombre glycoproteins into progeny virus surface envelopes. Pseudotype virus systems include retrovirus systems and vesicular stomatitis virus systems. Pseudotypes have been produced using the hantavirus full-length M gene plasmids, including pWRG/SN-M(opt). The pseudotypes can be used for testing for neutralizing antibodies. They also may be used to deliver genes to endothelial cells in a clinical setting. For example, gene therapy viruses containing the Sin Nombre glycoproteins on their surface will target to certain endothelial cells.

The invention also entails a therapeutic composition for ameliorating symptoms of Sin Nombre virus infection. The composition includes polyclonal or monoclonal antibodies specifically raised against one of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. The composition may be combined with a pharmaceutically acceptable carrier and/or an adjuvant, such as the examples as described herein.

Other embodiments are discussed below. The invention is described in further detail by the non-limiting examples and text below.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A-1D. Hantavirus neutralizing antibodies produced in rabbits vaccinated with full-length hantavirus M gene-based DNA vaccines using muscle electroporation.

FIG. 1A) Hantaan, Puumala, and Andes DNA vaccines. Groups of 3 rabbits were vaccinated with either the Hantaan DNA vaccine, pWRG/HTN-M(x) (described in U.S. Pat. No. 7,217,812), or the Puumala DNA vaccine, pWRG/PUU-M(s2) (described in U.S. Patent Publication No. 20100323024) on days 0, 14, 28, and 32 by muscle electroporation (Invoio Elgen device, dose was 0.4 mg of DNA per injection. Sera were collected on weeks 0, 28, 56, and 116 and tested in homotypic PRNT. Symbols represent the mean of two separate PRNT±SE.

FIG. 1B) The same data from panel A were combined to show mean titers for the groups. In addition, published data from rabbits vaccinated with the Andes DNA vaccine, pWRG/AND-M, are included. Note the vaccination days were different for the Andes DNA vaccine (shown in grey arrows).

FIG. 1C) Sin Nombre DNA vaccines. The first generation SNV full-length M gene based DNA vaccine, pWRG/SNV-M(2a), was tested in three rabbits. The animals were vaccinated four times (arrows) and sera were tested for SNV neutralizing antibodies. High-titer neutralizing antibody could be produced after multiple vaccinations. The second generation plasmid, pWRG/SN-M(opt), was tested in rabbits. Rabbits were vaccinated on days 0, 28, 56 and 84. Sera collected on the indicated days were tested for SNV neutralizing antibodies. High-titers were achieved after 2, or fewer, vaccinations (sera from day 28 was not collected).

FIG. 1D) The same data from panel C were combined to show mean titers for the groups ±SE.

FIG. 2A-2B. Neutralizing antibody data from rabbits vaccinated with pWRG/SN-M(opt) (also designated as pWRG/SN-M(opt)). Rabbits were vaccinated on days 0, 28, 56 and 84. Sera collected on days 0, 56, and 70 where tested for Sin Nombre virus neutralizing antibodies by plaque reduction neutralization test (PRNT). The neutralizing antibody titers are shown. FIG. 2A. The titers are the reciprocal of the highest dilution reducing the number of plaques in the media alone wells by 80%. FIG. 2B. Raw plaque for one representative rabbit are shown before vaccination, after 2 (day 56) and after 3 (day 70). Note that there is 100% neutralization out to a 1:10,240 dilution for the day 70 serum. The numbers 6281, 6282, 6283, and 5284 are designations for the different rabbits vaccinated.

FIG. 3A-3B. HPS vaccine. Plasmid mixtures were tested in rabbits using muscle electroporation (EP). Three rabbits were vaccinated by muscle EP on day 0, 21, and 42 with a 1:1 mixture of the pWRG/SN-M(opt) and pWRG/AND-M DNA (described in U.S. Pat. No. 7,217,812) vaccine plasmids. Sera were collected at the indicated time points and plaque reduction neutralization tests (PRNT) were performed. Neutralizing antibodies were produced against both SNV and ANDV after a single vaccination. Overall, the neutralizing antibody titers were greater against SNV (FIG. 3A) than ANDV (FIG. 3B). Device=Ichor Tri-grid device; Dose=2.0 mg mixed DNA/injection, 1 injection per vaccination. (Unpublished) The numbers 6214, 6215, and 6216 are designations for the different rabbits vaccinated.

FIG. 4A-4C. Mixed hantavirus DNA vaccines are feasible. Three mixtures of hantavirus DNA vaccine plasmids delivered by muscle electroporation were tested in rabbits.

FIG. 4A) Experimental design. Groups of three rabbits were vaccinated three times by muscle electroporation using the Ichor Tri-grid at three-week intervals. The HFRS mixture was comprised of equal volumes of Hantaan and Puumala DNA vaccine plasmids, pWRG/HTN-M(x) and pWRG/PUU-M(52), respectively. The HPS mixture was comprised of equal volumes of Andes and Sin Nombre DNA vaccine plasmids, pWRG/AND-M and pWRG/SN-M(opt), respectively. The HFRS/HPS mixture was comprised of equal volumes of the Hantaan, Puumala, Andes, and Sin Nombre DNA vaccine plasmids. The mixtures contained 1 mg of each plasmid per dose.

FIG. 4B) Neutralizing antibody titers for individual rabbits are shown. The virus used in the neutralization test is shown on the y-axis. Sera from days 0, 21, 42, and 63 were tested.

FIG. 4C) Mean neutralizing titers for each group plus/minus standard error. The data demonstrate that it is possible to mix hantavirus DNA vaccines into a single-injection vaccine and produce neutralizing antibodies against multiple hantaviruses. The HFRS DNA vaccine was more effective at neutralizing Puumala virus and Hantaan virus and the HPS DNA vaccine was more effective at neutralizing Andes virus and Sin Nombre virus. The HFRS/HPS DNA vaccine elicited neutralizing antibodies against all four hantaviruses after a single vaccination for all but one rabbit.

FIG. 5. PRNT80 GMT against HTNV, PUUV, SNV, and ANDV for each DNA vaccine formulation after 1, 2, or 3 vaccinations are shown. These data are from the same experiment shown in FIG. 2A-2B; however PRNT80 GMT are shown here. PRNT80 titers are a more stringent measure of neutralizing antibodies that PRNT50. The HFRS mix (pWRG/HTN-M[x] and pWRG/PUU-M[s2]) produced GMTs >100 against HTNV and PUUV. The HPS mix (pWRG/SN-M[opt] and pWRG/AND-M) produced GMTs >100 against SNV and ANDV. And the HFRS/HPS mix “pan-hantavirus” produced GMTs >100 against all four hantaviruses. PUUV PRNT endpoints after 1 vaccination were not determined beyond 640 (indicated by ≥). <indicates GMT was below detection. These data demonstrate the utility of using the SN DNA vaccine as part of HPS vaccine or a pan-hantavirus DNA vaccine.

FIG. 6A-6B. pWRG/SN-M(opt) DNA vaccine is immunogenic and protective in hamsters. Groups of 7-8 hamsters received 2 vaccinations (week 0, 3), or three vaccinations (week 0, 3, 6) with pWRG/SN-M(opt), or 3 vaccinations with a negative control DNA vaccine, or no vaccine. Vaccinations were performed using a gene gun.

FIG. 6A) Sera collected on week 9 were tested for SNV neutralizing antibody by SNV PRNT. Each symbol represents the PRNT₅₀ titer of an individual hamster. The geometric mean titer and 95% confidence interval for each group are shown. The limit of detection was a titer of 20 (dashed line). Seroconversion rates after 2 or 3 vaccinations were 62.5% (5 of 8) and 71.4% (5 of 7), respectively. The immune response was lower than what we observed in rabbits using electroporation, but was nevertheless evidence that the pWRG/SN-M(opt) plasmid was immunogenic in hamsters.

FIG. 6B) The hamsters were challenged with 200 pfu of SNV by the intramuscular route on week 11. Sera were collected on week 16 and tested by ELISA for evidence of SNV infection (note that SNV infects hamsters but is not lethal). A positive ELISA indicates the hamsters were infected with SNV (i.e., not protected). 2 vaccinations with pWRG/SN-M(opt) protected 62.5% of the hamsters and 3 vaccinations protected 100% of the hamsters. All of the negative control hamsters were infected. <indicates titer was below level of detection.

FIG. 7. The pWRG/SN-M(opt) plasmid was used to make pseudovirions that were specifically neutralized by rabbit sera containing SNV neutralizing antibodies. 293T cells were transfected with pWRG/SN-M(opt) and then, after 24 hr, were “infected” with recombinant vesicular stomatitis virus (VSV) that had the G protein deleted and replaced with the Renilla luciferase gene (VSV deltaG luciferase reporter core virus system was provided by Robert Doms, University of Pennsylvania). After 48 hr at 37 C, the supernatant was harvested and pseudovirion particles were purified on a sucrose gradient. Two different preparations of pseudovirions (prep 1, top panel; prep 2, bottom panel) where then mixed with serial dilutions of naïve rabbit sera, anti-SNV rabbit sera, or anti-VSV-G antibody (as control) and incubated for 1 hr at 37 C. The mixtures were then used to infect BHK cells in a 96-well format for 24 hours. Cell lysates were harvested, combined with luciferase substrate, and the luciferase reporter activity in Relative Luminescent Units (RLU) was measured using a luminometer. Symbols represent the average value of duplicates. The data demonstrate that the anti-SNV rabbit sera, but not the other sera, reduced the RLU activity (neutralized the pseudovirions) in a dose dependent manor. This assay can be used to measure SNV neutralizing antibodies in any sera including humans vaccinated with candidate HPS vaccines, or naturally infected with hantaviruses

FIG. 8. The nonoptimized version of the Sin Nombre DNA vaccine, pWRG/SN-M(2a), was tested for the capacity to produce neutralizing antibodies in an avian species. Ducks were vaccinated with 0.4 mg of plasmid DNA using muscle electroporation on days 0, 14, and 42. Sera was collected on days 0, 28, and 56 and tested for SNV neutralizing antibodies by PRNT. Higher titers are expected using the optimized pWRG/SN-M(opt) plasmid. These data demonstrate that the Sin Nombre DNA vaccine can be used to produce high titer neutralizing antibodies in avian species. This antibody is reasonably expected to be purified from eggs and may be used in humans or other mammals as post-exposure prophylactics or therapeutics, or as diagnostic reagents. The duck IgY naturally loses the Fc fragment of the antibody and this, it is believed, will make the molecule less reactogenic when used in a human as a therapeutic or post-exposure prophylactic.

DETAILED DESCRIPTION OF THE INVENTION

Supplemental to the previous description of the invention, the following further details are provided.

The inventor has created a novel, synthetic codon optimized Sin Nombre virus full-length M gene, ORF plus flanking sequences, and ORF, that are each stably maintained in a DNA vaccine plasmid, and elicit good neutralizing antibodies in animal models. Heretofore, there was no full length Sin Nombre M gene clone stably inserted it on an expression plasmid, which could be successfully expressed. Likewise, this is the first time any vaccine, of any kind, has been shown to elicit high titer neutralizing antibodies and protect against SNV infection in an animal model.

The inventor cloned the full-length M gene from SNV, strain CC107 into a DNA vaccine vector (i.e., RNA was purified, reverse transcribed to cDNA, PCR amplified, and cloned into a DNA vaccine plasmid [pWRG7077]). Ultimately, the inventor was able to produce a unique plasmid with an intact open reading frame (designated pWRG/SN-M(2a) or “M(2a)”). It was confirmed that this plasmid could produce the Gn and Gc protein in cell culture. pWRG/SN-M(2a) was tested for immunogenicity in rabbits using muscle electroporation technology. Three rabbits were vaccinated on weeks 0, 2, 4, 6 with 0.4 mg of DNA per vaccination. Sera were collected on weeks 0, 4, and 8. PRNT were performed to detect SNV neutralizing antibodies. The data demonstrated that high-titer neutralizing antibody were produced after 4 vaccinations (FIG. 1A-1D). The titers reached were over 10,000, which is considered are similar to those produced in person who have developed HPS and survived. In the art of immunology, and especially regarding hantaviruses, any titer over 100 would be considered good, and useful for vaccine purposes. This was the first time high-titer SNV neutralizing antibodies were ever produced by any vaccine, confirming the uniqueness of the M(2a) plasmid. Nevertheless, one undesirable result was that the M(2a) required more vaccinations to raise high-titers than the inventor's previous hantavirus vaccines, namely the HTNV, PUUV, or ANDV M gene-based DNA vaccines.

In an attempt to improve immunogenicity and potency, the M(2a) plasmid was refined by (1) first determining any possible flaws in the open reading frame and (2) obtaining the synthesis of a codon-optimized version of the SNV M gene. The inventor analyzed the M gene sequence in pWRG/SN-M(2a) and discovered amino acids that were unique to the clone (i.e., not in published GeneBank SNV M sequences) (Table 1). He identified consensus amino acids at these positions and then had an optimized version of this gene synthesized (work contracted to GeneArt)(Table 2). Next, the synthetic M gene was cloned into a DNA vaccine vector and the resultant plasmid was named pWRG/SN-M(opt) (or “M(opt)”). The sequence of the pWRG/SN-M(opt) plasmid is given in SEQ ID NO:1. M(opt) was tested for a capacity to elicit neutralizing antibodies by vaccinating rabbits with the pWRG/SN-(opt) using muscle electroporation. Four rabbits were vaccinated on weeks 0, 4, and 8 with 1 mg of DNA per vaccination. Sera were collected on weeks 0, 8 and 10. PRNT were performed to detect SNV neutralizing antibodies. Very high titers of SNV neutralizing antibodies were produced after only 2 vaccinations (week 8 sera) with pWRG/SN-M(opt) (FIG. 2A) After 3 vaccinations (week 10 sera) there was 100% neutralization in all four rabbits even when the sera was diluted ≥1:5,000. This was a significant improvement over the M(2a) results—2 vaccinations is considered acceptable to be convenient enough for human or animal use.

Having found the pWRG/SN-M(opt) to be a potent DNA vaccine, the inventor next combined the SNV DNA vaccine with the pWRG/AND-M. A mixture of the two plasmids was used to vaccinate rabbits using muscle electroporation. High titer neutralizing antibodies against both SNV and ANDV were produced after 1 or 2 vaccinations (FIG. 3A-3B). The SNV neutralizing activity was especially potent (titers >10,000 after 1 vaccination). Thus, the combination of the pWRG/SN-M(opt) DNA vaccine and pWRG/AND-M DNA vaccine effectively elicited high-titer neutralizing antibodies against the most prevalent and lethal hantavirus in North and South America. The novelty and potency of this SNV DNA vaccine was surprising and unexpected.

In summary, the inventor produced two plasmids that elicited high titer neutralizing antibodies against SNV in animal models. Thus, one point of novelty of the invention is that it elicits Sin Nombre virus neutralizing antibodies, and with significantly high titers. To the best of the inventor's knowledge, there is no other SNV vaccine that elicits antibodies that directly neutralize Sin Nombre virus.

Vaccines and Immunogenic Compositions

To summarize, the vaccines and immunogenic compositions comtemplated by this invention include: (1) Sin Nombre virus vaccines and immunogenic compositions; (2) Sin Nombre virus+other HPS viruses (e.g., Andes virus) vaccines and immunogenic compositions; (3) Sin Nombre virus vaccines and immunogenic compositions+HFRS viruses (e.g., Puumula and Hantaan viruses) vaccines and immunogenic compositions; and (4) Sin Nombre virus+other HPS viruses (e.g., Andes virus) vaccines and immunogenic compositions+HFRS viruses (e.g., Puumula and Hantaan viruses) vaccines and immunogenic compositions. These vaccines and immunogenic compositions, when transfected into mammalian cells, result in the expression of proteins that mimic the Gn and Gc surface glycoproteins of SNV and the other hantaviruses targeted. When these DNA vaccines or immunogenic compositions are introduced into the cells of a vaccine, the vaccine produces a neutralizing antibody response against SNV, and, if relevant, the other hantavirus(es). Neutralizing antibody responses are sufficient to confer protection against SNV and the other hantaviruses. Thus, SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and derivatives thereof, represent a candidate vaccine for the prevention of HPS caused by SNV. Moreover, these novel sequences, and derivatives thereof, can be used to generate anti-SNV immunotherapeutics and diagnostic antibodies in animals. (The term transfected is used herein to refer to cells which have incorporated the delivered foreign DNA vaccine, whichever delivery technique is used.)

As noted above, there is no vaccine or drug to prevent or treat HPS. One of the embodiments of the invention described herein is a DNA vaccine based on the M-gene segment of Sin Nombre virus. The M genome segment encodes the two proteins found on the virus surface.

One embodiment of the invention encompasses DNA vaccines. DNA vaccination involves administering antigen-encoding polynucleotides in vivo to induce the production of a correctly folded antigen(s) within the target cells. The introduction of the DNA vaccine will cause to be expressed within those cells the structural protein determinants associated with the pathogen protein or proteins. The processed structural proteins will be displayed on the cellular surface of the transfected cells in conjunction with the Major Histocompatibility Complex (MHC) antigens of the normal cell. Even when cell-mediated immunity is not the primary means of preventing infection, it is likely important for resolving established infections. Furthermore, the structural proteins released by the expressing transfected cells can also be picked up by antigen-presenting cells to trigger systemic humoral antibody responses.

The DNA vaccine according to the present invention is inherently safe, is not painful to administer, and should not result in adverse side effects to the vaccinated individual. In addition, the invention does not require growth or use of Sin Nombre virus, which is a biosafety level 3 (BSL-3) virus, and is a BSL-4 virus if the virus is grown to high levels or used in animals.

In order to achieve the immune response sought, a DNA vaccine construct capable of causing transfected cells of the vaccinated individual to express one or more major viral antigenic determinant is necessary. This can be done by identifying regions of the viral genome which code for viral glycoproteins or capsid components, and joining such coding sequences to promoters capable of expressing the sequences in cells of the vaccine. Alternatively, the viral genome itself, or parts of the genome, can be used.

In a preferred embodiment, the vaccine is a plasmid based codon-optimized Sin Nombre virus (SNV) M gene open reading frame. The M gene encodes for two proteins that form a part of the viral capsid. In nature these are glycosylated during synthesis in mammalian cells which would occur after vaccination. SNV is one of several viruses that cause Hantavirus Pulmonary Syndrome, a disease with high mortality (20-50%). There have been several hundred cases in the Americas over the past several years. This vaccine has been shown to induce high neutralizing antibody titers in animals and therefore would be useful for a human vaccine. Two hantavirus DNA vaccines—Hantaan and Puumala—have been shown to induce neutralizing antibodies in human clinical trials. (Presentation given: “Preclinical and Phase 1 Clinical Studies of a DNA Vaccine for HFRS Caused by Hantaviruses” J. Hooper, to the American Society of Microbiology Biodefense Meeting, held in Baltimore, February, 2010)

As noted above, attempts to produce SNV vaccine that produce neutralizing antibodies against SNV have been unsuccessful. Here, for the first time, the inventor has synthesized a codon-optimized full-length M gene open reading frame and cloned it into a DNA vaccine expression vector (e.g., pWRG-SN-M(opt)). The nucleotide sequences are completely unique because the ORF has been optimized. Regarding the preferred embodiment pWRG/SN-M(opt), hamsters and rabbits vaccinated with pWRG/SN-M(opt) using a gene gun developed neutralizing antibodies as measured by plaque reduction neutralization test (PRNT) with PRNT₅₀ titers ranging from 10,240-over 81,920 in rabbits by electroporation; in hamsters, less than 20-1,280 by gene gun. This is believed to be the first candidate SNV vaccine that successfully elicits neutralizing antibodies against SNV.

In its preferred vaccine embodiment, the SNV virus M gene-based DNA vaccine is a plasmid that consists of a well-characterized backbone that enables expression of the above-described synthetic, codon-optimized, SNV virus full-length M gene, or the ORF with or without flanking sequences. Preferred examples are SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. It can be used in other vaccine systems and systems for generating SNV neutralizing antibodies.

In this application we describe the elicitation of protective immunity to SNV alone or with other hantaviruses by DNA vaccines. The gene(s) of interest, in our case, a synthetic Sin Nombre virus M gene having at least one of the sequences identified herein as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, is controlled by a mammalian or virus promoter (e.g., the cytomegalovirus immediate early promoter followed by intron A) that facilitates expression of the naked DNA gene product(s) within the vaccine's cells. Preferably, Intron A is included. It is preferred even to use pWRG/SN-M(opt) as the DNA vaccine plasmid. This intracellular expression can elicit both humoral and cell-mediated immune responses (Robinson and Torres, 1997, supra; and Gregoriadis, 1998, supra). Methods of DNA delivery include needle inoculation, needle-free jet injection, oral or pulmonary delivery, and inoculation by particle bombardment (i.e., gene gun) and electroporation—by well-known methods for each. Needle inoculation and needle-free jet injection may be made with or without electroporation. Delivery may be intramuscular or intradermal, as appropriate. A suitable construct for use in the method of the present invention is pWRG7077 (4326 bp)(PowderJect Vaccines, Inc., Madison, Wis.),. pWRG7077 includes a human cytomegalovirus (hCMV) immediate early promoter (IE) and a bovine growth hormone polyA addition site. Between the promoter and the polyA addition site is Intron A, a sequence that naturally occurs in conjunction with the hCMV IE promoter that has been demonstrated to increase transcription when present on an expression plasmid. Downstream from Intron A, and between Intron A and the polyA addition sequence, are unique cloning sites into which the hantavirus M DNA can be cloned. Also provided on pWRG7077 is a gene that confers bacterial host-cell resistance to kanamycin. Any of the fragments that encode hantavirus Gn and/or Gc or nucleocapsid peptides can be cloned into one of the cloning sites in pWRG7077, using methods known to the art.

The DNA can be delivered by injection into the tissue of the recipient, oral or pulmonary delivery and inoculation by particle bombardment (i.e., gene gun). Any of these methods can be used to deliver DNA as long as the DNA is expressed and the desired antigen is made in the cell. Two methods are exemplified in this application, both shown to be successful in eliciting a protective immune response in the vaccine.

In one aspect of the invention, the DNA vaccine is delivered by coating a small carrier particle with the DNA vaccine and delivering the DNA-coated particle into an animal's epidermal tissue via particle bombardment. This method may be adapted for delivery to either epidermal or mucosal tissue, or delivery into peripheral blood cells, and thus may be used to induce humoral, cell-mediated, and secretory immune responses in the vaccinated individual.

To deliver DNA vaccines by particle bombardment, we chose to use the PowderJect-XR™ gene gun device described in WO 95/19799, 27 Jul. 1995. Other instruments are available and known to people in the art. This instrument, which delivers DNA-coated gold beads directly into epidermal cells by high-velocity particle bombardment, was shown to more efficiently induce both humoral and cell-mediated immune responses, with smaller quantities of DNA, than inoculation of the same DNAs by other parenteral routes (Eisenbraun, M. et al., 1993, DNA Cell. Biol. 12: 791; Fynan, E. F. et al., 1993, Proc. Natl. Acad. Sci. USA 90: 11478; Haynes, J. R. et al., 1994, AIDS Res. Hum. Retroviruses 10: Suppl. 2:S43; Pertmer, T. M. et al., 1995, Vaccine 13: 1427). Epidermal inoculation of the DNA candidate vaccines also offers the advantages of gene expression in an immunologically active tissue that is generally exfoliated within 15 to 30 days, and which is an important natural focus of viral replication after tick-bite (Bos, J. D., 1997, Clin. Exp. Immunol. 107 Suppl. 1:3; Labuda, M. et al., 1996, Virology 219:357; Rambukkana, A. et al., 1995, Lab. Invest. 73:521; Stingl, G., 1993, Recent Results Cancer Res. 128:45; Evans et al., Vaccine, 2009, Vol. 27(18), pp. 2506-2512; Yager et al., Expert Rev. Vaccines, 2009, Vol. 8(9), pp. 1205-1220).

The technique of accelerated particles gene delivery or particle bombardment is based on the coating of DNA to be delivered into cells onto extremely small carrier particles, which are designed to be small in relation to the cells sought to be transformed by the process. The DNA sequence containing the desired gene can be simply dried onto a small inert particle. The particle may be made of any inert material such as an inert metal (gold, silver, platinum, tungsten, etc.) or inert plastic (polystyrene, polypropylene, polycarbonate, etc.). Preferably, the particle is made of gold, platinum or tungsten. Most preferably, the particle is made of gold. suitably, the particle is spherical and has a diameter of 0.5 to 5 microns, preferably 1 to 3 microns.

The DNA sequence containing the desired gene prepared in the form suitable for gene introduction can be simply dried onto naked gold or tungsten pellets. However, DNA molecules in such a form may have a relatively short period of stability and may tend to degrade rather rapidly due to chemical reactions with the metallic or oxide substrate of the particle itself. Thus, if the carrier particles are first coated with an encapsulating agent, the DNA strands have greatly improved stability and do not degrade significantly even over a time period of several weeks. A suitable encapsulating agent is polylysine (molecular weight 200,000) which can be applied to the carrier particles before the DNA molecules are applied. Other encapsulating agents, polymeric or otherwise, may also be useful as similar encapsulating agents, including spermidine. The polylysine is applied to the particles by rinsing the gold particles in a solution of 0.02% polylysine and then air drying or heat drying the particles thus coated. Once the metallic particles coated with polylysine were properly dried, DNA strands are then loaded onto the particles.

The DNA is loaded onto the particles at a rate of between 0.5 and 30 micrograms of DNA per milligram of gold bead spheres. A preferable ratio of DNA to gold is 0.5 5.0 ug of DNA per milligram of gold. A sample procedure begins with gamma irradiated (preferably about 30 kGy) tefzel tubing. The gold is weighed out into a microfuge tube, spermidine (free base) at about 0.05 M is added and mixed, and then the DNA is added. A 10% CaCl solution is incubated along with the DNA for about 10 minutes to provide a fine calcium precipitate. The precipitate carries the DNA with it onto the beads. The tubes are microfuged and the pellet resuspended and washed in 100% ethanol and the final product resuspended in 100% ethanol at 0.0025 mg/ml PVP. The gold with the DNA is then applied onto the tubing and dried.

The general approach of accelerated particle gene transfection technology is described in U.S. Pat. No. 4,945,050 to Sanford. An instrument based on an improved variant of that approach is available commercially from PowderJect Vaccines, Inc., Madison Wis., and is described in WO 95/19799. All documents cited herein supra and infra are hereby incorporated in their entirety by reference thereto. Briefly, the DNA-coated particles are deposited onto the interior surface of plastic tubing which is cut to a suitable length to form sample cartridges. A sample cartridge is placed in the path of a compressed gas (e.g., helium at a pressure sufficient to dislodge the particles from the cartridge e.g., 350 400 psi). The particles are entrained in the gas stream and are delivered with sufficient force toward the target tissue to enter the cells of the tissue. Further details are available in the published apparatus application.

The coated carrier particles are physically accelerated toward the cells to be transformed such that the carrier particles lodge in the interior of the target cells. This technique can be used either with cells in vitro or in vivo. At some frequency, the DNA which has been previously coated onto the carrier particles is expressed in the target cells. This gene expression technique has been demonstrated to work in prokaryotes and eukaryotes, from bacteria and yeasts to higher plants and animals. Thus, the accelerated particle method provides a convenient methodology for delivering genes into the cells of a wide variety of tissue types, and offers the capability of delivering those genes to cells in situ and in vivo without any adverse impact or effect on the treated individual. Therefore, the accelerated particle method is also preferred in that it allows a DNA vaccine capable of eliciting an immune response to be directed both to a particular tissue, and to a particular cell layer in a tissue, by varying the delivery site and the force with which the particles are accelerated, respectively. This technique is thus particularly suited for delivery of genes for antigenic proteins into the epidermis.

A DNA vaccine can be delivered in a non-invasive manner to a variety of susceptible tissue types in order to achieve the desired antigenic response in the individual. Most advantageously, the genetic vaccine can be introduced into the epidermis. Such delivery, it has been found, will produce a systemic humoral immune response.

To obtain additional effectiveness from this technique, it may also be desirable that the genes be delivered to a mucosal tissue surface, in order to ensure that mucosal, humoral and cellular immune responses are produced in the vaccinated individual. There are a variety of suitable delivery sites available including any number of sites on the epidermis, peripheral blood cells, i.e. lymphocytes, which could be treated in vitro and placed back into the individual, and a variety of oral, upper respiratory, and genital mucosal surfaces.

Gene gun-based DNA immunization achieves direct, intracellular delivery of DNA, elicits higher levels of protective immunity, and requires approximately three orders of magnitude less DNA than methods employing standard inoculation.

Moreover, gene gun delivery allows for precise control over the level and form of antigen production in a given epidermal site because intracellular DNA delivery can be controlled by systematically varying the number of particles delivered and the amount of DNA per particle. This precise control over the level and form of antigen production may allow for control over the nature of the resultant immune response.

The invention further covers passive vaccines for treating or preventing Sin Nombre virus infections comprising a therapeutically or prophylactically effective amount of the antibodies of the present invention which protect against Sin Nombre virus disease in combination with a pharmaceutically acceptable carrier or excipient. As described in greater detail herein, the present inventor has found that serum from a vaccine immunized with a DNA vaccine comprising the Sin Nombre virus M segment described above contains antibodies able to neutralize Sin Nombre virus and display in vitro and in vivo Sin Nombre virus neutralization properties.

The invention also contemplates a new recombinant DNA vaccine approach that involves vaccination with naked DNA expressing individual Sin Nombre virus genome segment cDNAs. Naked DNA vaccination involves delivery of plasmid DNA constructs with a gene(s) of interest into the tissue of the vaccine (reviewed in Robinson and Torres, 1997, Semin. Immunol. 9, 271-283; and Gregoriadis, 1998, Pharm. Res. 15, 661-670). DNA vaccination mimicks the de novo antigen production and MHC class I-restricted antigen presentation obtainable with live vaccines, without the risks of pathogenic infection. Also, this DNA vaccine approach allows delivery to mucosal tissues which may aid in conferring resistance to viral introduction since entry of the virus may be through mucosal tissues.

This vaccine was also tested for a capacity to elicit neutralizing antibodies in rabbits using muscle electroporation as the means of vaccine delivery. The electroporation device and dose of DNA delivered is compatible with human use (Ichor Tri-grid device). Well-known methods of electroporation are effective for this DNA vaccine. For instance, Hooper et al. (February 2008), describes methods useful for this. (Hooper et al, “Immune Serum Produced by DNA Vaccination Protects Hamsters against Lethal Respiratory Challenge with Andes Virus”, J. Virology, February 2008, Vol. 82, No. 3, pp. 1332-1338; also see, van Drunen, et al., Expert Rev. Vaccines, 2010, Vol. 9(5), pp. 503-517). In addition, mammals such as rabbits can be vaccinated by muscle electroporation with a DNA vaccine plasmid such as pWRG/SN-M(opt) to rapidly generate sera containing high-titer SNV neutralizing antibodies. Sera can be collected and tested for neutralizing antibodies by PRNT.

Vaccination with the SNV M gene-based DNA vaccine, called pWRG/SN-M(opt), elicits high-titer neutralizing antibodies. It is widely believed in the field that neutralizing antibodies are surrogate endpoints of protective immunity, so any vaccine that elicits high-titer neutralizing antibodies has utility as a vaccine. This vaccine could be used to immunize against North American HPS. In addition, it could be combined with other hantavirus DNA vaccines to create a pan-hantavirus vaccine. In short, the plasmid containing the synthetic codon-optimized SNV M gene is exceedingly effective at eliciting neutralizing antibodies.

For a HPS vaccine composition or immunogenic composition, the composition will have at least one of the above-described SNV sequences (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3), plus at least one other M-gene (e.g., whole full-length or ORF or ORF plus flanking sequences) from a different (non-SNV) HPS. Examples of other HPS viruses include Black Creek Canal virus, Bayou virus, New York virus, Andes virus, and Laguna Negra virus. A preferred HPS vaccine or immunogenic composition comprises at least one of the above-described SNV sequences, and the Andes M-gene—preferably plasmid pWRG/AND-M(x) (SEQ ID NO:10), below:

gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40 ttgctgactc ataccaggcc tgaatcgccc catcatccag   80 ccagaaagtg agggagccac ggttgatgag agctttgttg  120 taggtggacc agttggtgat tttgaacttt tgctttgcca  160 cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200 cttcaactca gcaaaagttc gatttattca acaaagccgc  240 cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280 ccaattaacc aattctgatt agaaaaactc atcgagcatc  320 aaatgaaact gcaatttatt catatcagga ttatcaatac  360 catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400 ctcaccgagg cagttccata ggatggcaag atcctggtat  440 cggtctgcga ttccgactcg tccaacatca atacaaccta  480 ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520 atcaccatga gtgacgactg aatccggtga gaatggcaaa  560 agcttatgca tttctttcca gacttgttca acaggccagc  600 cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640 gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680 cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720 gcaaccggcg caggaacact gccagcgcat caacaatatt  760 ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800 gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840 caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880 aaattccgtc agccagttta gtctgaccat ctcatctgta  920 acatcattgg caacgctacc tttgccatgt ttcagaaaca  960 actctggcgc atcgggcttc ccatacaatc gatagattgt 1000 cgcacctgat tgcccgacat tatcgcgagc ccatttatac 1040 ccatataaat cagcatccat gttggaattt aatcgcggcc 1080 tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120 ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160 catgatgata tatttttatc ttgtgcaatg taacatcaga 1200 gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240 tgcctgcagg tcgacaatat tggctattgg ccattgcata 1280 cgttgtatct atatcataat atgtacattt atattggctc 1320 atgtccaata tgaccgccat gttgacattg attattgact 1360 agttattaat agtaatcaat tacggggtca ttagttcata 1400 gcccatatat ggagttccgc gttacataac ttacggtaaa 1440 tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg 1480 acgtcaataa tgacgtatgt tcccatagta acgccaatag 1520 ggactttcca ttgacgtcaa tgggtggagt atttacggta 1560 aactgcccac ttggcagtac atcaagtgta tcatatgcca 1600 agtccgcccc ctattgacgt caatgacggt aaatggcccg 1640 cctggcatta tgcccagtac atgaccttac gggactttcc 1680 tacttggcag tacatctacg tattagtcat cgctattacc 1720 atggtgatgc ggttttggca gtacaccaat gggcgtggat 1760 agcggtttga ctcacgggga tttccaagtc tccaccccat 1800 tgacgtcaat gggagtttgt tttggcacca aaatcaacgg 1840 gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc 1880 aaatgggcgg taggcgtgta cggtgggagg tctatataag 1920 cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc 1960 catccacgct gttttgacct ccatagaaga caccgggacc 2000 gatccagcct ccgcggccgg gaacggtgca ttggaacgcg 2040 gattccccgt gccaagagtg acgtaagtac cgcctataga 2080 ctctataggc acaccccttt ggctcttatg catgctatac 2120 tgtttttggc ttggggccta tacacccccg cttccttatg 2160 ctataggtga tggtatagct tagcctatag gtgtgggtta 2200 ttgaccatta ttgaccactc ccctattggt gacgatactt 2240 tccattacta atccataaca tggctctttg ccacaactat 2280 ctctattggc tatatgccaa tactctgtcc ttcagagact 2320 gacacggact ctgtattttt acaggatggg gtcccattta 2360 ttatttacaa attcacatat acaacaacgc cgtcccccgt 2400 gcccgcagtt tttattaaac atagcgtggg atctccacgc 2440 gaatctcggg tacgtgttcc ggacatgggc tcttctccgg 2480 tagcggcgga gcttccacat ccgagccctg gtcccatgcc 2520 tccagcggct catggtcgct cggcagctcc ttgctcctaa 2560 cagtggaggc cagacttagg cacagcacaa tgcccaccac 2600 caccagtgtg ccgcacaagg ccgtggcggt agggtatgtg 2640 tctgaaaatg agctcggaga ttgggctcgc accgctgacg 2680 cagatggaag acttaaggca gcggcagaag aagatgcagg 2720 cagctgagtt gttgtattct gataagagtc agaggtaact 2760 cccgttgcgg tgctgttaac ggtggagggc agtgtagtct 2800 gagcagtact cgttgctgcc gcgcgcgcca ccagacataa 2840 tagctgacag actaacagac tgttcctttc catgggtctt 2880 ttctgcagtc agggtccaag cttgcggccg cggatctgca 2920 ggaattcggc acgagagtag tagactccgc acgaagaagc 2960 aaaaaattaa agaagtgagt ttaaaatgga agggtggtat 3000 ctggttgttc ttggagtctg ctatacgctg acactggcaa 3040 tgcccaagac catttatgag cttaaaatgg aatgcccgca 3080 cactgtgggt ctcggtcaag gttacatcat tggctcaaca 3120 gaactaggtt tgatctcaat tgaggctgca tctgatataa 3160 agctcgagag ctcttgcaat tttgatcttc atacaacatc 3200 tatggcccag aagagtttca cccaagttga atggagaaag 3240 aaaagtgaca caactgatac cacaaatgct gcgtccacta 3280 cctttgaagc acaaactaaa actgttaacc ttagagggac 3320 ttgtatactg gcacctgaac tctatgatac attgaagaaa 3360 gtaaaaaaga cagtcctgtg ctatgatcta acatgtaatc 3400 aaacacattg tcagccaact gtctatctga ttgcacctgt 3440 attgacatgc atgtcaataa gaagttgtat ggctagtgtg 3480 tttacaagca ggattcaggt gatttatgaa aagacacatt 3520 gtgtaacagg tcagctgatt gagggtcagt gtttcaaccc 3560 agcacacaca ttgacattat ctcagcctgc tcacacttat 3600 gatactgtca cccttcctat ctcttgtttt ttcacaccaa 3640 agaagtcgga gcaactaaaa gttataaaaa catttgaagg 3680 aattctgacg aagacaggtt gcacggagaa tgcattgcag 3720 ggttattatg tgtgtttttt agggagtcat tcagaacctt 3760 taattgttcc gagtttggag gacatacggt ctgctgaagt 3800 tgttagtagg atgcttgtac accctagggg agaagaccat 3840 gatgccatac agaattcaca aagtcactta agaatagtgg 3880 gacctatcac agcaaaagtg ccatcaacta gttccacaga 3920 taccctaaag gggacagcct ttgcaggcgt cccaatgtat 3960 agctctttat ctacactagt cagaaatgca gacccagaat 4000 ttgtattttc tccaggtata gtacctgaat ctaatcacag 4040 tacatgtgat aagaagacag tacctatcac atggacaggc 4080 tacctaccaa tatcaggtga gatggaaaaa gtgactggat 4120 gtacagtttt ttgtacacta gcaggacctg gtgctagttg 4160 tgaggcctat tctgaaaatg gtatatttaa catcagttct 4200 ccaacatgtc ttgtaaacaa agtccaaaga tttcgtggat 4240 ctgaacagaa aataaatttt atctgtcagc gggtagatca 4280 ggatgttgtt gtatactgca atgggcaaaa gaaagtcata 4320 ttaaccaaaa ctttggttat tgggcagtgt atttatacat 4360 tcacaagcct attttcattg atgcctgatg tagcccactc 4400 attggctgta gaattatgtg tcccgggatt acatgggtgg 4440 gccactgtca tgcttctatc aacattctgc tttgggtggg 4480 tcttgattcc tgcggtcaca ttaataatat taaagtgtct 4520 aagggttttg acgttttctt gttcccatta cactaatgag 4560 tcaaaattta aattcatcct ggaaaaagtt aaaattgaat 4600 accaaaagac tatgggatca atggtgtgcg atgtatgtca 4640 tcatgagtgt gaaacagcaa aagaacttga atcacataga 4680 cagagttgta tcaatggaca atgtccttat tgcatgacaa 4720 taactgaagc aactgaaagt gccttgcaag cccattattc 4760 catttgtaaa ttggcaggaa gatttcagga ggcactgaaa 4800 aagtcactta aaaagccaga ggtaaaaaaa ggttgttaca 4840 gaacactcgg ggtatttaga tataaaagta gatgttatgt 4880 gggtttggta tggtgcctat tgttgacatg tgaaattgtt 4920 atttgggccg caagtgcaga gactccacta atggagtcag 4960 gctggtcaga tacggctcat ggtgttggtg agattccaat 5000 gaagacagac ctcgagctgg acttttcact gccttcttca 5040 tcctcttaca gttataggag aaagctcaca aacccagcca 5080 ataaagaaga gtctattccc ttccacttcc agatggaaaa 5120 acaagtaatt catgctgaaa tccaacccct gggtcattgg 5160 atggatgcga catttaatat taagactgca tttcattgtt 5200 atggtgcatg ccagaaatac tcttatccat ggcagacatc 5240 taagtgcttc tttgaaaagg actaccagta tgaaacaggc 5280 tggggctgta atcctggtga ctgcccaggg gttgggactg 5320 gatgcactgc ttgtggtgtt tatctcgata aactaaaatc 5360 tgttgggaag gcctataaga taatttcttt aaaatatacc 5400 agaaaggttt gtattcagtt aggaacagaa caaacttgca 5440 agcatattga tgcaaatgat tgtttagtga caccatctgt 5480 gaaagtttgc atagtgggca cagtttcaaa acttcaacca 5520 tctgatactc ttttgttctt aggtccacta gaacaagggg 5560 gaatcattct taagcaatgg tgcacaacat catgtgcatt 5600 tggggaccct ggtgatatca tgtccactcc cagtggtatg 5640 aggtgtccag agcacactgg atcatttagg aaaatttgcg 5680 gttttgctac tacaccagtt tgtgaatatc aaggaaatac 5720 catttctgga tataaaagaa tgatggcaac aaaagattca 5760 ttccaatcat ttaacttaac agaacctcac atcacaacaa 5800 acaagcttga atggatcgac ccagatggga atacaagaga 5840 ccacgtaaac cttgtcttaa atagagatgt ctcatttcag 5880 gatttaagtg ataacccctg taaagtagac ctacacacac 5920 aagcaataga aggggcatgg ggttctggtg tagggtttac 5960 actcacatgt actgtcggat taacagagtg cccaagtttt 6000 atgacatcaa ttaaggcatg tgacctagct atgtgttatg 6040 gatcaacagt aacaaacctt gccaggggct ctaatacagt 6080 gaaagtagtt ggtaaaggag gccattcagg gtcctcattt 6120 aaatgctgtc atgatacaga ttgctcctct gaaggtttac 6160 ttgcatcagc ccctcatctt gagagggtaa caggattcaa 6200 tcaaattgat tcagataagg tttatgatga tggtgcacca 6240 ccttgcacat tcaaatgctg gttcactaag tcaggtgagt 6280 ggcttcttgg gatcttaaac gggaattgga ttgttgttgt 6320 agtgcttgtt gtgatactca ttctctctat cataatgttc 6360 agtgttttgt gtcccaggag agggcacaag aaaactgtct 6400 aagcattgac ctcaactcct acattagatc atatacattt 6440 atgcacttcc tcatatttag ctgcactaag atattaataa 6480 actctagtta ttgactttat aagattatta tggaactaac 6520 ctcacttaaa aaaaacaaat actttactca tatataactc 6560 catattctct taccgaggat tttgttcctg cggagcatac 6600 tactaggatc tacgtatgat cagcctcgac tgtgccttct 6640 agttgccagc catctgttgt ttgcccctcc cccgtgcctt 6680 ccttgaccct ggaaggtgcc actcccactg tcctttccta 6720 ataaaatgag gaaattgcat cgcattgtct gagtaggtgt 6760 cattctattc tggggggtgg ggtggggcag gacagcaagg 6800 gggaggattg ggaagacaat agcaggcatg ctggggatgc 6840 ggtgggctct atggcttctg aggcggaaag aaccagctgg 6880 ggctcgacag ctcgactcta gaattgcttc ctcgctcact 6920 gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat 6960 cagctcactc aaaggcggta atacggttat ccacagaatc 7000 aggggataac gcaggaaaga acatgtgagc aaaaggccag 7040 caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt 7080 ttttccatag gctccgcccc cctgacgagc atcacaaaaa 7120 tcgacgctca agtcagaggt ggcgaaaccc gacaggacta 7160 taaagatacc aggcgtttcc ccctggaagc tccctcgtgc 7200 gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 7240 cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc 7280 tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct 7320 ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 7360 ccgctgcgcc ttatccggta actatcgtct tgagtccaac 7400 ccggtaagac acgacttatc gccactggca gcagccactg 7440 gtaacaggat tagcagagcg aggtatgtag gcggtgctac 7480 agagttcttg aagtggtggc ctaactacgg ctacactaga 7520 agaacagtat ttggtatctg cgctctgctg aagccagtta 7560 ccttcgaaaa aagagttggt agctcttgat ccggcaaaca 7600 aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag 7640 cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 7680 tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 7720 ctcacgttaa gggattttgg tcatgagatt atcaaaaagg 7760 atcttcacct agatcctttt aaattaaaaa tgaagtttta 7800 aatcaatcta aagtatatat gagtaaactt ggtctgacag 7840 ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc 7880 tgtctatttc gttcatccat agttgcctga ctc 7913

For a HPS+HFRS, or pan-hantavirus, vaccine composition or immunogenic composition, the composition will have at least one of the above-described SNV sequences (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3), plus at least one other M-gene (e.g., whole full-length or ORF or ORF plus flanking sequences) from an HFRS virus. Examples of HFRS viruses include Seoul virus, Hantaan virus, Pumuula virus, and Dobrava virus. In addition, the vaccine composition or immunogenic composition may further include one or more of the above-described other HPS M-genes (e.g., whole full-length or ORF or ORF plus flanking sequences). A preferred HPS+HFRS vaccine or immunogenic composition comprises at least one of the above-described SNV sequences, and one or more of Puumala M-gene plasmid (preferably plasmid pWRG/PUU-M(s2) shown below as SEQ ID NO:11 or the ORF shown below as SEQ ID NO:14), Hantaan M-gene plasmid (preferably plasmid pWRG/HTN-M(x) shown below as SEQ ID NO:12), and Seoul (preferably plasmid pWRG-SEO-M which is Seoul hantavirus M segment, strain SR-11, subcloned into DNA vector pWRG7077, and shown below as SEQ ID NO:13).

pWRG/PUU-M(s2) DNA vaccine plasmid (the underlined section indicates the ORF)-- (SEQ ID NO: 11) GGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTC ATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCAC GGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTG CTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTC AACTCAGCAAAAGTTCGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCA GCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTCTGATTAGAAAA ACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAA TACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGA GGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTC GTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATC AAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAA GCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTC ATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGA GCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAAT CGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACC TGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCA GTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTC GGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTA ACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCAT CGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATC GCGAGCCCATTTATAC CCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGAC GTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAG CAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACA TCAGAGATTTTGAGACACAACGTGGCTTTCCCCCCCCCCCCGGCATGCCTGC AGGTCGACAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAA TATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGA TTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCC CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCT GACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCA TAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTAC GGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGC CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGT ACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT CGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATA GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGG GAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAA CCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTA TATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCC ACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGG CCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAA GTACCGCCTATAGA CTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTGGCTTG GGGCCTATACACCCCCGCTTCCTTATGCTATAGGTGATGGTATAGCTTAGCC TATAGGTGTGGGTTATTGACCATTATTGACCACTCCCCTATTGGTGACGATA CTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTATCTCTATTGG CTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGACTCTGTATTTTTA CAGGATGGGGTCCCATTTATTATTTACAAATTCACATATACAACAACGCCG TCCCCCGTGCCCGCAGTTTTTATTAAACATAGCGTGGGATCTCCACGCGAAT CTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTC CACATCCGAGCCCTGGTCCCATGCCTCCAGCGGCTCATGGTCGCTCGGCAG CTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCCAC CACCACCAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAA TGAGCTCGGAGATTGGGCTCGCACCGCTGACGCAGATGGAAGACTTAAGGC AGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTC AGAGGTAACTCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTG AGCAGTACTCGTTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAGAC TAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCCAAGCTTG CGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCAAGA AACAGCAAACACAGATAAATATGGGCGAGCTGTCCCCTGTGTGCCTGTACC TGCTGCTGCAGGGCCTGCTGCTGTGTAACACCGGAGCCGCCAGGAACCTGA ACGAGCTGAAGATGGAGTGCCCCCACACCATCAGACTGGGCCAGGGCCTG GTGGTGGGCAGCGT GGAGCTGCCCAGCCTGCCCATCCAGCAGGTGGAGACCCTGAAGCTGGAGA GCAGCTGTAACTTCGACCTGCACACCAGCACAGCCGGCCAGCAGAGCTTCA CCAAGTGGACCTGGGAGATCAAGGGCGACCTGGCCGAGAACACCCAGGCC AGCAGCACCAGCTTCCAGACCAAGAGCAGCGAGGTGAACCTGAGAGGCCT GTGCCTGATCCCCACACTGGTGGTGGAGACCGCCGCCAGAATGAGAAAGA CCATCGCCTGCTACGACCTGAGCTGTAACCAGACCGTGTGTCAGCCTACCG TGTACCTGATGGGCCCTATCCAGACCTGTATCACCACCAAGAGCTGCCTGC TGTCCCTGGGCGATCAGAGAATCCAGGTGAACTACGAGAAAACCTACTGTG TGAGCGGCCAGCTGGTGGAGGGCATCTGCTTCAACCCCATCCACACCATGG CCCTGAGCCAGCCTAGCCACACCTACGACATCATGACCATGATGGTGAGAT GCTTTCTGGTGATCAAGAAGGTGACCAGCGGCGACAGCATGAAGATCGAG AAGAACTTCGAGACCCTGGTGCAGAAGAATGGCTGTACCGCCAACAACTTC CAGGGCTACTACATCTGCCTGATCGGCAGCAGCAGCGAGCCCCTGTACGTG CCCGCCCTGGACGACTACAGAAGCGCCGAGGTGCTGTCCAGAATGGCCTTC GCCCCCCACGGCGAGGACCACGACATCGAGAAAAACGCCGTGTCCGCCAT GAGAATCGCCGGCAAGGTGACCGGCAAGGCCCCCAGCACCGAGTCCAGCG ACACCGTGCAGGGCATCGCCTTCAGCGGCAGCCCCCTGTACACCTCCACCG GCGTGCTGACCAGCAAGGACGACCCCGTGTACATCTGGGCCCCTGGCATCA TCATGGAGGGCAACCACAGCATCTGTGAGAAGAAAACCCTGCCCCTGACCT GGACCGGCTTCATCAGCCTGCCCGGCGAGATCGAGAAAACCACCCAGTGTA CCGTGTTCTGTACCCTGGCCGGACCTG GCGCCGACTGTGAGGCCTACAGCGAGACCGGCATCTTCAACATCAGCAGCC CCACCTGCCTGATCAACCGGGTGCAGAGGTTCAGAGGCAGCGAGCAGCAG ATCAAGTTTGTGTGCCAGCGGGTGGACATGGACATCACCGTGTACTGTAAC GGCATGAAGAAGGTGATCCTGACCAAGACACTGGTGATCGGCCAGTGTATC TACACCTTCACCAGCATCTTCTCCCTGATCCCCGGCGTGGCCCACAGCCTGG CCGTGGAGCTGTGTGTGCCCGGCCTGCACGGCTGGGCCACCATGCTGCTGC TGCTGACCTTCTGCTTCGGCTGGGTGCTGATCCCTACCATCACCATGATCCT GCTGAAGATCCTGATCGCCTTCGCCTACCTGTGCTCCAAGTACAACACCGA CAGCAAGTTCAGAATCCTGATCGAGAAAGTGAAGCGGGAGTACCAGAAAA CCATGGGCAGCATGGTGTGTGAAGTGTGCCAGTACGAGTGTGAGACCGCCA AGGAGCTGGAGTCCCACAGAAAGAGCTGCTCCATCGGCAGCTGCCCCTACT GCCTGAACCCCAGCGAGGCCACCACCTCCGCCCTGCAGGCCCACTTCAAAG TGTGTAAGCTGACCAGCCGGTTCCAGGAGAACCTGAGGAAGTCCCTGACCG TGTACGAGCCCATGCAGGGCTGCTACAGAACCCTGAGCCTGTTCCGGTACA GGAGCCGGTTCTTTGTGGGCCTGGTGTGGTGTGTGCTGCTGGTGCTGGAGCT GATTGTGTGGGCCGCCAGCGCCGAGACCCAGAACCTGAATGCCGGCTGGAC CGACACCGCCCACGGCAGCGGCATCATCCCCATGAAAACCGACCTGGAGCT GGACTTCAGCCTGCCTAGCAGCGCCTCCTACACCTACAGGCGGCAGCTGCA GAATCCTGCCAACGAGCAGGAGAAGATCCCCTTCCACCTGCAGCTGTCCAA GCAGGTGATCCACGCCGAGATTCAGCACCTGGGCCACTGGATGGACGCCAC CTTCAACCTGAAAACCGCC TTCCACTGCTACGGCAGCTGTGAGAAGTACGCCTACCCTTGGCAGACCGCC GGCTGCTTCATCGAGAAGGACTACGAGTACGAGACCGGCTGGGGCTGTAAT CCTCCTGATTGCCCCGGAGTGGGCACCGGCTGTACTGCATGTGGCGTGTAC CTGGACAAGCTGAAGTCTGTGGGCAAGGTGTTCAAGATCGTGTCCCTGAGG TACACCCGGAAAGTGTGTATCCAGCTGGGCACCGAGCAGACCTGTAAGACC GTGGACAGCAACGATTGCCTGATCACAACCAGCGTGAAAGTGTGTCTGATC GGCACCATCAGCAAGTTCCAGCCCAGCGATACCCTGCTGTTTCTGGGCCCC CTGCAGCAGGGCGGCCTGATCTTCAAGCAGTGGTGTACCACCACCTGCCAG TTCGGCGATCCCGGCGATATCATGAGCACCCCCACCGGCATGAAGTGCCCT GAGCTGAACGGCAGCTTCCGGAAGAAGTGTGCCTTCGCCACCACCCCTGTG TGTCAGTTCGACGGCAACACCATCAGCGGCTACAAGCGGATGATCGCCACC AAGGACAGCTTCCAGTCCTTCAACGTGACCGAGCCCCACATCAGCACCAGC GCCCTGGAGTGGATCGATCCCGACAGCAGCCTGAGGGACCACATCAACGTG ATCGTGTCCAGGGACCTGAGCTTCCAGGACCTGAGCGAGACCCCCTGCCAG ATCGACCTGGCCACCGCCAGCATCGATGGCGCCTGGGGCAGCGGAGTGGG CTTCAACCTGGTGTGTACAGTGAGCCTGACCGAGTGTAGCGCCTTCCTGAC CAGCATCAAAGCCTGTGACGCCGCCATGTGTTACGGCAGCACCACCGCCAA CCTGGTGAGAGGCCAGAACACCATCCACATTGTGGGCAAAGGCGGCCACA GCGGCAGCAAGTTTATGTGCTGCCACGACACCAAGTGTAGCAGCACCGGCC TGGTGGCCGCTGCCCCCCACCTGGACAGAGTGACCGGCTACAACCAGGCCG ACAGCGACAAGATTTTCGACGA CGGAGCCCCTGAGTGTGGCATGAGTTGCTGGTTCAAGAAGAGCGGCGAGTG GATTCTGGGCGTGCTGAACGGGAATTGGATGGTGGTGGCCGTGCTGGTCGT GCTGCTGATCCTGAGCATCCTGCTGTTCACCCTGTGCTGCCCTAGGAGACCC AGCTACCGGAAGGAGCACAAGCCCTGAGTTTTGCTTACTAACATAATTATT GTATTCTGTTTATTGACACAATTACCATATGATTAACTGTATTCCCCCATCTT ATATCTTATATAATATTCTTTATTTAATCACTATATAGAAAAAAAACTAGCA CTTTACTAATTAAATTACCCCATACCGATTATGCCTGGACTTTTGTTCCTGC GGAGCATACTACTAGGATCTACGTATGATCAGCCTCGACTGTGCCTTCTAG TTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAA GGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCA AGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGC TCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGACAGCTCGACTC TAGAATTGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGG CGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCA GGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCA GGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCG ACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGC TCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTC GGGAAGCGTGGCGC TTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTC CAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTT ATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCC ACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCG GTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAA CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAG TTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTT TGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATC CTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTA AGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTA AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGG TCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTC TATTTCGTTCATCCATAGTTGCCTGACTC Puumala synthetic full-length M-segment ORF-- SEQ ID NO: 14 ATGGGCGAGCTGTCCCCTGTGTGCCTGTACCTGCTGCTGCAGGGCCTGCTGC TGTGTAACACCGGAGCCGCCAGGAACCTGAACGAGCTGAAGATGGAGTGC CCCCACACCATCAGACTGGGCCAGGGCCTGGTGGTGGGCAGCGTGGAGCTG CCCAGCCTGCCCATCCAGCAGGTGGAGACCCTGAAGCTGGAGAGCAGCTGT AACTTCGACCTGCACACCAGCACAGCCGGCCAGCAGAGCTTCACCAAGTGG ACCTGGGAGATCAAGGGCGACCTGGCCGAGAACACCCAGGCCAGCAGCAC CAGCTTCCAGACCAAGAGCAGCGAGGTGAACCTGAGAGGCCTGTGCCTGAT CCCCACACTGGTGGTGGAGACCGCCGCCAGAATGAGAAAGACCATCGCCT GCTACGACCTGAGCTGTAACCAGACCGTGTGTCAGCCTACCGTGTACCTGA TGGGCCCTATCCAGACCTGTATCACCACCAAGAGCTGCCTGCTGTCCCTGG GCGATCAGAGAATCCAGGTGAACTACGAGAAAACCTACTGTGTGAGCGGC CAGCTGGTGGAGGGCATCTGCTTCAACCCCATCCACACCATGGCCCTGAGC CAGCCTAGCCACACCTACGACATCATGACCATGATGGTGAGATGCTTTCTG GTGATCAAGAAGGTGACCAGCGGCGACAGCATGAAGATCGAGAAGAACTT CGAGACCCTGGTGCAGAAGAATGGCTGTACCGCCAACAACTTCCAGGGCTA CTACATCTGCCTGATCGGCAGCAGCAGCGAGCCCCTGTACGTGCCCGCCCT GGACGACTACAGAAGCGCCGAGGTGCTGTCCAGAATGGCCTTCGCCCCCCA CGGCGAGGACCACGACATCGAGAAAAACGCCGTGTCCGCCATGAGAATCG CCGGCAAGGTGACCGGCAAGGCCCCCAGCACCGAGTCCAGCGACACCGTG CAGGGCATCGCCTTCAGCGGCAGCCCCCTGTACACCTCCACCGGCGTGCTG ACCAGCAAGGACGACCCCGTGTACATCTGGGCCCCTGGCATCATCATGGAG GGCAACCACAGCATCTGTGAGAAGAAAACCCTGCCCCTGACCTGGACCGGC TTCATCAGCCTGCCCGGCGAGATCGAGAAAACCACCCAGTGTACCGTGTTC TGTACCCTGGCCGGACCTGGCGCCGACTGTGAGGCCTACAGCGAGACCGGC ATCTTCAACATCAGCAGCCCCACCTGCCTGATCAACCGGGTGCAGAGGTTC AGAGGCAGCGAGCAGCAGATCAAGTTTGTGTGCCAGCGGGTGGACATGGA CATCACCGTGTACTGTAACGGCATGAAGAAGGTGATCCTGACCAAGACACT GGTGATCGGCCAGTGTATCTACACCTTCACCAGCATCTTCTCCCTGATCCCC GGCGTGGCCCACAGCCTGGCCGTGGAGCTGTGTGTGCCCGGCCTGCACGGC TGGGCCACCATGCTGCTGCTGCTGACCTTCTGCTTCGGCTGGGTGCTGATCC CTACCATCACCATGATCCTGCTGAAGATCCTGATCGCCTTCGCCTACCTGTG CTCCAAGTACAACACCGACAGCAAGTTCAGAATCCTGATCGAGAAAGTGA AGCGGGAGTACCAGAAAACCATGGGCAGCATGGTGTGTGAAGTGTGCCAG TACGAGTGTGAGACCGCCAAGGAGCTGGAGTCCCACAGAAAGAGCTGCTC CATCGGCAGCTGCCCCTACTGCCTGAACCCCAGCGAGGCCACCACCTCCGC CCTGCAGGCCCACTTCAAAGTGTGTAAGCTGACCAGCCGGTTCCAGGAGAA CCTGAGGAAGTCCCTGACCGTGTACGAGCCCATGCAGGGCTGCTACAGAAC CCTGAGCCTGTTCCGGTACAGGAGCCGGTTCTTTGTGGGCCTGGTGTGGTGT GTGCTGCTGGTGCTGGAGCTGATTGTGTGGGCCGCCAGCGCCGAGACCCAG AACCTGAATGCCGGCTGGACCGACACCGCCCACGGCAGCGGCATCATCCCC ATGAAAACCGACCTGGAGCTGGACTTCAGCCTGCCTAGCAGCGCCTCCTAC ACCTACAGGCGGCAGCTGCAGAATCCTGCCAACGAGCAGGAGAAGATCCC CTTCCACCTGCAGCTGTCCAAGCAGGTGATCCACGCCGAGATTCAGCACCT GGGCCACTGGATGGACGCCACCTTCAACCTGAAAACCGCCTTCCACTGCTA CGGCAGCTGTGAGAAGTACGCCTACCCTTGGCAGACCGCCGGCTGCTTCAT CGAGAAGGACTACGAGTACGAGACCGGCTGGGGCTGTAATCCTCCTGATTG CCCCGGAGTGGGCACCGGCTGTACTGCATGTGGCGTGTACCTGGACAAGCT GAAGTCTGTGGGCAAGGTGTTCAAGATCGTGTCCCTGAGGTACACCCGGAA AGTGTGTATCCAGCTGGGCACCGAGCAGACCTGTAAGACCGTGGACAGCA ACGATTGCCTGATCACAACCAGCGTGAAAGTGTGTCTGATCGGCACCATCA GCAAGTTCCAGCCCAGCGATACCCTGCTGTTTCTGGGCCCCCTGCAGCAGG GCGGCCTGATCTTCAAGCAGTGGTGTACCACCACCTGCCAGTTCGGCGATC CCGGCGATATCATGAGCACCCCCACCGGCATGAAGTGCCCTGAGCTGAACG GCAGCTTCCGGAAGAAGTGTGCCTTCGCCACCACCCCTGTGTGTCAGTTCG ACGGCAACACCATCAGCGGCTACAAGCGGATGATCGCCACCAAGGACAGC TTCCAGTCCTTCAACGTGACCGAGCCCCACATCAGCACCAGCGCCCTGGAG TGGATCGATCCCGACAGCAGCCTGAGGGACCACATCAACGTGATCGTGTCC AGGGACCTGAGCTTCCAGGACCTGAGCGAGACCCCCTGCCAGATCGACCTG GCCACCGCCAGCATCGATGGCGCCTGGGGCAGCGGAGTGGGCTTCAACCTG GTGTGTACAGTGAGCCTGACCGAGTGTAGCGCCTTCCTGACCAGCATCAAA GCCTGTGACGCCGCCATGTGTTACGGCAGCACCACCGCCAACCTGGTGAGA GGCCAGAACACCATCCACATTGTGGGCAAAGGCGGCCACAGCGGCAGCAA GTTTATGTGCTGCCACGACACCAAGTGTAGCAGCACCGGCCTGGTGGCCGC TGCCCCCCACCTGGACAGAGTGACCGGCTACAACCAGGCCGACAGCGACA AGATTTTCGACGACGGAGCCCCTGAGTGTGGCATGAGTTGCTGGTTCAAGA AGAGCGGCGAGTGGATTCTGGGCGTGCTGAACGGGAATTGGATGGTGGTG GCCGTGCTGGTCGTGCTGCTGATCCTGAGCATCCTGCTGTTCACCCTGTGCT GCCCTAGGAGACCCAGCTACCGGAAGGAGCACAAGCCCTGA Plasmid pWRG/HTN-M(x)-- SEQ ID NO: 12 gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40  ttgctgactc ataccaggcc tgaatcgccc catcatccag   80  ccagaaagtg agggagccac ggttgatgag agctttgttg  120  taggtggacc agttggtgat tttgaacttt tgctttgcca  160  cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200  cttcaactca gcaaaagttc gatttattca acaaagccgc  240  cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280  ccaattaacc aattctgatt agaaaaactc atcgagcatc  320  aaatgaaact gcaatttatt catatcagga ttatcaatac  360  catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400  ctcaccgagg cagttccata ggatggcaag atcctggtat  440  cggtctgcga ttccgactcg tccaacatca atacaaccta  480  ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520  atcaccatga gtgacgactg aatccggtga gaatggcaaa  560  agcttatgca tttctttcca gacttgttca acaggccagc  600  cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640  gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680  cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720  gcaaccggcg caggaacact gccagcgcat caacaatatt  760  ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800  gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840  caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880  aaattccgtc agccagttta gtctgaccat ctcatctgta  920  acatcattgg caacgctacc tttgccatgt ttcagaaaca  960  actctggcgc atcgggcttc ccatacaatc gatagattgt 1000  cgcacctgat tgcccgacat tatcgcgagc ccatttatac 1040  ccatataaat cagcatccat gttggaattt aatcgcggcc 1080  tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120  ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160  catgatgata tatttttatc ttgtgcaatg taacatcaga 1200  gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240  tgcctgcagg tcgacaatat tggctattgg ccattgcata 1280  cgttgtatct atatcataat atgtacattt atattggctc 1320  atgtccaata tgaccgccat gttgacattg attattgact 1360  agttattaat agtaatcaat tacggggtca ttagttcata 1400  gcccatatat ggagttccgc gttacataac ttacggtaaa 1440  tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg 1480  acgtcaataa tgacgtatgt tcccatagta acgccaatag 1520  ggactttcca ttgacgtcaa tgggtggagt atttacggta 1560  aactgcccac ttggcagtac atcaagtgta tcatatgcca 1600  agtccgcccc ctattgacgt caatgacggt aaatggcccg 1640  cctggcatta tgcccagtac atgaccttac gggactttcc 1680  tacttggcag tacatctacg tattagtcat cgctattacc 1720  atggtgatgc ggttttggca gtacaccaat gggcgtggat 1760  agcggtttga ctcacgggga tttccaagtc tccaccccat 1800  tgacgtcaat gggagtttgt tttggcacca aaatcaacgg 1840  gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc 1880  aaatgggcgg taggcgtgta cggtgggagg tctatataag 1920  cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc 1960  catccacgct gttttgacct gcatcgaaga caccgggacc 2000  gatccagcct ccgcggccgg gaacggtgca ttggaacgcg 2040  gattccccgt gccaagagtg acgtaagtac cgcctataga 2080  ctctataggc acaccccttt ggctcttatg catgctatac 2120  tgtttttggc ttggggccta tacacccccg cttccttatg 2160  ctataggtga tggtatagct tagcctatag gtgtgggtta 2200  ttgaccatta ttgaccactc ccctattggt gacgatactt 2240  tccattacta atccataaca tggctctttg ccacaactat 2280  ctctattggc tatatgccaa tactctgtcc ttcagagact 2320  gacacggact ctgtattttt acaggatggg gtcccattta 2360  ttatttacaa attcacatat acaacaacgc cgtcccccgt 2400  gcccgcagtt tttattaaac atagcgtggg atctccacgc 2440  gaatctcggg tacgtgttcc ggacatgggc tcttctccgg 2480  tagcggcgga gcttccacat ccgagccctg gtcccatgcc 2520  tccagcggct catggtcgct cggcagctcc ttgctcctaa 2560  cagtggaggc cagacttagg cacagcacaa tgcccaccac 2600  caccagtgtg ccgcacaagg ccgtggcggt agggtatgtg 2640  tctgaaaatg agctcggaga ttgggctcgc accgctgacg 2680  cagatggaag acttaaggca gcggcagaag aagatgcagg 2720  cagctgagtt gttgtattct gataagagtc agaggtaact 2760  cccgttgcgg tgctgttaac ggtggagggc agtgtagtct 2800  gagcagtact cgttgctgcc gcgcgcgcca ccagacataa 2840  tagctgacag actaacagac tgttcctttc catgggtctt 2880  ttctgcagtc accgtccaag cttgcggccg cggatctgca 2920  ggaattcggc acgagagtag tagactccgc aagaaacagc 2960  agtcaatcag caacatgggg atatggaagt ggctagtgat 3000  ggccagttta gtatggcctg ttttgacact gagaaatgtc 3040  tatgacatga aaattgagtg cccccataca gtaagttttg 3080  gggaaaacag tgtgataggt tatgtagaat taccccccgt 3120  gccattggcc gacacagcac agatggtgcc tgagagttct 3160  tgtagcatgg ataatcacca atcgttgaat acaataacaa 3200  aatataccca agtaagttgg agaggaaagg ctgatcagtc 3240  acagtctagt caaaattcat ttgagacagt gtccactgaa 3280  gttgacttga aaggaacatg tgctctaaaa cacaaaatgg 3320  tggaagaatc ataccgtagt aggaaatcag taacctgtta 3360  cgacctgtct tgcaatagca cttactgcaa gccaacacta 3400  tacatgattg taccaattca tgcatgcaat atgatgaaaa 3440  gctgtttgat tgcattggga ccatacagag tacaggtggt 3480  ttatgagaga tcttattgca tgacaggagt cctgattgaa 3520  gggaaatgct ttgtcccaga tcaaagtgtg gtcagtatta 3560  tcaagcatgg gatctttgat attgcaagtg ttcatattgt 3600  atgtttcttt gttgcagtta aagggaatac ttataaaatt 3640  tttgaacagg ttaagaaatc ctttgaatca acatgcaatg 3680  atacagagaa taaagtgcaa ggatattata tttgtattgt 3720  agggggaaac tctgcaccaa tatatgttcc aacacttgat 3760  gatttcagat ccatggaagc atttacagga atcttcagat 3800  caccacatgg ggaagatcat gatctggctg gagaagaaat 3840  tgcatcttat tctatagtcg gacctgccaa tgcaaaagtt 3880  cctcatagtg ctagctcaga tacattgagc ttgattgcct 3920  attcaggtat accatcttat tcttccctta gcatcctaac 3960  aagttcaaca gaagctaagc atgtattcag ccctgggttg 4000  ttcccaaaac ttaatcacac aaattgtgat aaaagtgcca 4040  taccactcat atggactggg atgattgatt tacctggata 4080  ctacgaagct gtccaccctt gtacagtttt ttgcgtatta 4120  tcaggtcctg gggcatcatg tgaagccttt tctgaaggcg 4160  ggattttcaa cataacctct cccatgtgct tagtgtcaaa 4200  acaaaatcga ttccggttaa cagaacagca agtgaatttt 4240  gtgtgtcagc gagtggacat ggacattgtt gtgtactgca 4280  acgggcagag gaaagtaata ttaacaaaaa ctctagttat 4320  tggacagtgt atatatacta taacaagctt attctcatta 4360  ctacctggag tagcacattc tattgctgtt gaattgtgtg 4400  tacctgggtt ccatggttgg gccacagctg ctctgcttgt 4440  tacattctgt ttcggatggg ttcttatacc agcaattaca 4480  tttatcatac taacagtcct aaagttcatt gctaatattt 4520  ttcacacaag taatcaagag aataggctaa aatcagtact 4560  tagaaagata aaggaagagt ttgaaaaaac aaaaggctca 4600  atggtatgtg atgtctgcaa gtatgagtgt gaaacctata 4640  aagaattaaa ggcacacggg gtatcatgcc cccaatctca 4680  atgtccttac tgttttactc attgtgaacc cacagaagca 4720  gcattccaag ctcattacaa ggtatgccaa gttactcaca 4760  gattcaggga tgatctaaag aaaactgtta ctcctcaaaa 4800  ttttacacca ggatgttacc ggacactaaa tttatttaga 4840  tacaaaagca ggtgctacat ctttacaatg tggatatttc 4880  ttcttgtctt agaatccata ctgtgggctg caagtgcatc 4920  agagacacca ttaactcctg tctggaatga caatgcccat 4960  ggggtaggtt ctgttcctat gcatacagat ttagagcttg 5000  atttctcttt aacatccagt tccaagtata cataccgtag 5040  gaggttaaca aacccacttg aggaagcaca atccattgac 5080  ctacatattg aaatagaaga acagacaatt ggtgttgatg 5120  tgcatgctct aggacactgg tttgatggtc gtcttaacct 5160  taaaacatcc tttcactgtt atggtgcttg tacaaagtat 5200  gaataccctt ggcatactgc aaagtgccac tatgaaagag 5240  attaccaata tgagacgagc tggggttgta atccatcaga 5280  ttgtcctggg gtgggcacag gctgtacagc atgtggttta 5320  tacctagatc aactgaaacc agttggtagt gcttataaaa 5360  ttatcacaat aaggtacagc aggagagtct gtgttcagtt 5400  tggggaggaa aacctttgta agataataga catgaatgat 5440  tgttttgtat ctaggcatgt taaggtctgc ataattggta 5480  cagtatctaa attctctcag ggtgatacct tattgttttt 5520  tggaccgctt gaaggtggtg gtctaatatt taaacactgg 5560  tgtacatcca catgtcaatt tggtgaccca ggagatatca 5600  tgagtccaag agacaaaggt tttttatgcc ctgagtttcc 5640  aggtagtttc aggaagaaat gcaactttgc tactacccct 5680  atttgtgagt atgatggaaa tatggtctca ggttacaaga 5720  aagtgatggc cacaattgat tccttccaat cttttaatac 5760  aagcactatg cacttcactg atgaaaggat agagtggaaa 5800  gaccctgatg gaatgctaag ggaccatata aacattttag 5840  taacgaagga cattgacttt gataaccttg gtgaaaatcc 5880  ttgcaaaatt ggcctacaaa catcttctat tgagggggcc 5920  tggggttctg gtgtggggtt cacattaaca tgtctggtat 5960  cactaacaga atgtcctacc tttttgacct caataaaggc 6000  ttgtgataag gctatctgtt atggtgcaga gagtgtaaca 6040  ttgacaagag gacaaaatac agtcaaggta tcagggaaag 6080  gtggccatag tggttcaaca tttaggtgtt gccatgggga 6120  ggactgttca caaattggac tccatgctgc tgcacctcac 6160  cttgacaagg taaatgggat ttctgagata gaaaatagta 6200  aagtatatga tgatggggca ccgcaatgtg ggataaaatg 6240  ttggtttgtt aaatcagggg aatggatttc agggatattc 6280  agtggtaatt ggattgtact cattgtcctc tgtgtatttc 6320  tattgttctc cttggtttta ctaagcattc tctgtcccgt 6360  aaggaagcat aaaaaatcat agctaaattc tgtgactatc 6400  ctgttcttat gtatagcttt aacatatata ctaattttta 6440  tattccagta tactctatct aacacactaa aaaaaatagt 6480  agctttctaa ccacaaaacg gatctacgta tgatcagcct 6520  cgactgtgcc ttctagttgc cagccatctg ttgtttgccc 6560  ctcccccgtg ccttccttga ccctggaagg tgccactccc 6600  actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 6640  gtctgagtag gtgtcattct attctggggg gtggggtggg 6680  gcaggacagc aagggggagg attgggaaga caatagcagg 6720  catgctgggg atgcggtggg ctctatggct tctgaggcgg 6760  aaagaaccag ctggggctcg acagctcgac tctagaattg 6800  cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 6840  gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 6880  ttatccacag aatcagggga taacgcagga aagaacatgt 6920  gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 6960  cgcgttgctg gcgtttttcc ataggctccg cccccctgac 7000  gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 7040  acccgacagg actataaaga taccaggcgt ttccccctgg 7080  aagctccctc gtgcgctctc ctgttccgac cctgccgctt 7120  accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 7160  cgctttctca tagctcacgc tgtaggtatc tcagttcggt 7200  gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 7240  cccgttcagc ccgaccgctg cgccttatcc ggtaactatc 7280  gtcttgagtc caacccggta agacacgact tatcgccact 7320  ggcagcagcc actggtaaca ggattagcag agcgaggtat 7360  gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 7400  acggctacac tagaagaaca gtatttggta tctgcgctct 7440  gctgaagcca gttaccttcg gaaaaagagt tggtagctct 7480  tgatccggca aacaaaccac cgctggtagc ggtggttttt 7520  ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 7560  tcaagaagat cctttgatct tttctacggg gtctgacgct 7600  cagtggaacg aaaactcacg ttaagggatt ttggtcatga 7640  gattatcaaa aaggatcttc acctagatcc ttttaaatta 7680  aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 7720  acttggtctg acagttacca atgcttaatc agtgaggcac 7760  ctatctcagc gatctgtcta tttcgttcat ccatagttgc 7800  pWRG-SEO-M (Seoul hantavirus M segment, strain SR-11, subcloned into DNA vector pWRG7077)- SEQ ID NO: 13 gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40  ttgctgactc ataccaggcc tgaatcgccc catcatccag   80  ccagaaagtg agggagccac ggttgatgag agctttgttg  120  taggtggacc agttggtgat tttgaacttt tgctttgcca  160  cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200  cttcaactca gcaaaagttc gatttattca acaaagccga  240  cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280  ccaattaacc aattctgatt agaaaaactc atcgagcatc  320  aaatgaaact gcaatttatt catatcagga ttatcaatac  360  catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400  ctcaccgagg cagttccata ggatggcaag atcctggtat  440  cggtctgcga ttccgactcg tccaacatca atacaaccta  480  ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520  atcaccatga gtgacgactg aatccggtga gaatggcaaa  560  agcttatgca tttctttcca gacttgttca acaggccagc  600  cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640  gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680  cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720  gcaaccggcg caggaacact gccagcgcat caacaatatt  760  ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800  gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840  caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880  aaattccgtc agccagttta gtctgaccat ctcatctgta  920  acatcattgg caacgctacc tttgccatgt ttcagaaaca  960  actctggcgc atcgggcttc ccatacaatc gatagattgt 1000  cgcacctgat tgccccacat tatcgcgagc ccatttatac 1040  ccatataaat cagcatccat gttggaattt aatcgcggcc 1080  tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120  ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160  catgatgata tatttttatc ttgtgcaatg taacatcaga 1200  gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240  tgcctgcagg tcgacataaa tcaatattgg ctattggcca 1280  ttgcatacgt tgtatctata tcataatatg tacatttata 1320  ttggctcatg tccaatatga ccgccatgtt gacattgatt 1360  attgactagt tattaatagt aatcaattac ggggtcatta 1400  gttcatagcc catatatgga gttccgcgtt acataactta 1440  cggtaaatgg cccgcctcgt gaccgcccaa cgacccccgc 1480  ccattgacgt caataatgac gtatgttccc atagtaacgc 1520  caatagggac tttccattga cgtcaatggg tggagtattt 1560  acggtaaact gcccacttgg cagtacatca agtgtatcat 1600  atgccaagtc cggcccccta ttgacgtcaa tgacggtaaa 1640  tggcccgcct ggcattatgc ccagtacatg accttacggg 1680  actttcctac ttggcagtac atctacgtat tagtcatcgc 1720  tattaccatg gtgatgcggt tttggcagta caccaatggg 1760  cgtggatagc ggtttgactc acggggattt ccaagtctcc 1800  accccattga cgtcaatggg agtttgtttt ggcaccaaaa 1840  tcaacgggac tttccaaaat gtcgtaataa ccccgccccg 1880  ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct 1920  atataagcag agctcgttta gtgaaccgtc agatcgcctg 1960  gagacgccat ccacgctgtt ttgacctcca tagaagacac 2000  cgggaccgat ccagcctccg cggccgggaa cggtgcattg 2040  gaacgcggat tccccgtgcc aagagtgacg taagtaccgc 2080  ctatagactc tataggcaca cccctttggc tcttatgcat 2120  gctatactgt ttttggcttg gggcctatac acccccgctc 2160  cttatgctat aggtgatggt atagcttagc ctataggtgt 2200  gggttattga ccattattga ccactcccct attggtgacg 2240  atactttcca ttactaatcc ataacatggc tctttgccac 2280  aactatctct attggctata tgccaatact ctgtccttca 2320  gagactgaca cggactctgt atttttacag gatggggtcc 2360  catttattat ttacaaattc acatatacaa caacgccgtc 2400  ccccgtgccc gcagttttta ttaaacatag cgtgggatct 2440  ccacgcgaat ctcgggtacg tgttccggac atgggctctt 2480  ctccggtagc ggcggagctt ccacatccga gccctggtcc 2520  catgcctcca gcggctcatg gtcgctcggc agctccttgc 2560  tcctaacagt ggaggccaga cttaggcaca gcacaatgcc 2600  caccaccacc agtgtgccgc acaaggccgt ggcggtaggg 2640  tatgtgtctg aaaatgagct cggagattgg gctcgcaccg 2680  tgacgcagat ggaagactta aggcagcggc agaagaagat 2720  gcaggcagct gagttgttgt attctgataa gagtcagagg 2760  taactcccgt tgcggtgctg ttaacggtgg agggcagtgt 2800  agtctgagca gtactcgttg ctgccgcgcg cgccaccaga 2840  cataatagct gacagactaa cagactgttc ctttccatgg 2880  gtcttttctg cagtcaccgt ccaagcttgc ggccgcggat 2920  ctgcaggaat tcggcacgag agtagtagac tccgcaagaa 2960  acagcagtta aagaacaata ggatcatgtg gagtttgcta 3000  ttactggccg ctttagttgg ccaaggcttt gcattaaaaa 3040  atgtatttga catgagaatt cagttgcccc actcagtcaa 3080  ctttggggaa acaagtgtgt caggctatac agaatttccc 3120  ccactctcat tacaggaggc agaacagcta gtgccagaga 3160  gctcatgcaa catggacaac caccagtcac tctcaacaat 3200  aaataaatta accaaggtca tatggcggaa aaaagcaaat 3240  caggaatcag caaaccagaa ttcatttgaa gttgtggaaa 3280  gtgaagtcag ctttaaaggg ttgtgtatgt taaagcatag 3320  aatggttgaa gaatcatata gaaataggag atcagtaatc 3360  tgttatgatc tagcctgtaa tagtacattc tgtaaaccaa 3400  ctgtttatat gattgttcct atacatgctt gcaacatgat 3440  gaaaagctgt ttgattggcc ttggccccta cagaatccag 3480  gttgtctatg aaaggacata ctgcactacg ggtatattga 3520  cagaaggaaa atgctttgtc cctgacaagg ctgttgtcag 3560  tgcattgaaa agaggcatgt atgctatagc aagcatagag 3600  acaatctgct tttttattca tcagaaaggg aatacatata 3640  agatagtgac tgccattaca tcagcaatgg gctccaaatg 3680  taataataca gatactaaag ttcaaggata ttatatctgt 3720  attattggtg gaaactccgc ccctgtatat gcccctgctg 3760  gtgaagactt cagagcaatg gaggtttttt ctgggattat 3800  tacatcacca catggagaag accatgacct acccggcgaa 3840  gaaatcgcaa cgtaccagat ttcagggcag atagaggcaa 3880  aaatccctca tacagtgagc tccaaaaact taaaattgac 3920  tgcttttgca ggtattccat catactcatc aactagtata 3960  ttggctgctt cagaagatgg tcgtttcata tttagtcctg 4000  gtttatttcc taacctaaat cagtcagtct gtgacaacaa 4040  tgcactccct ttaatctgga ggggcctaat tgatttaacg 4080  ggatactatg aggcagtcca cccttgcaat gtgttctgtg 4120  tcttatcagg accaggtgct tcatgtgagg ccttttcaga 4160  aggaggtatt ttcaatatta cttctccaat gtgtctggtg 4200  tctaagcaaa atagatttag agcagctgag cagcagatta 4240  gctttgtctg ccaaagagtt gatatggata ttatagtgta 4280  ctgtaatggt cagaaaaaaa caatcctaac aaaaacatta 4320  gttataggcc aatgtattta tactattaca agtctctttt 4360  cactgttacc aggggttgcc cattctattg ctattgagtt 4400  gtgtgttcca gggtttcatg gctgggccac agctgcactt 4440  ttgattacat tctgcttcgg ctgggtattg attcctgcat 4480  gtacattagc tattctttta gtccttaagt tctttgcaaa 4520  tatccttcat acaagcaatc aagagaaccg attcaaagcc 4560  attctacgga aaataaagga ggagtttgaa aaaacaaagg 4600  gttccatggt ttgtgagatc tgtaagtatg agtgtgaaac 4640  attaaaggaa ttgaaggcac ataacctatc atgtgttcaa 4680  ggagagtgcc catattgctt tacccactgt gaaccgacag 4720  aaactgcaat tcaggcacat tacaaagttt gtcaagccac 4760  ccaccgattc agagaagatt taaaaaagac tgtaactcct 4800  caaaatattg ggccaggctg ttaccgaaca ctaaatcttt 4840  ttaggtataa aagtaggtgt tatattctga caatgtggac 4880  tcttcttctc attattgaat ccatcctctg ggcagcaagt 4920  gcagcagaaa tcccccttgt ccctctctgg acagataatg 4960  ctcatggcgt tgggagtgtt cctatgcata cggatcttga 5000  attagacttc tctttgccat ccagttctaa gtacacatac 5040  aaaagacatc tcacaaaccc agttaatgac caacagagtg 5080  tctcattgca tatagaaatt gaaagtcaag gcattggtgc 5120  tgctgttcat catcttggac attggtatga tgcaagattg 5160  aatctaaaaa cctcatttca ttgttatggt gcctgcacaa 5200  aatatcaata cccatggcac actgcaaaat gccattttga 5240  gaaagattat gagtatgaaa atagctgggc ttgcaacccc 5280  ccagattgcc caggggttgg tacaggttgt actgcttgtg 5320  gattatatct agatcaattg aagccggtag gaacagcctt 5360  taaaattata agtgtaagat acagtagaaa agtgtgcgtg 5400  cagtttggtg aagaacacct ttgtaaaaca attgatatga 5440  atgattgctt tgtgactagg catgccaaaa tatgtataat 5480  tgggactgta tctaagtttt ctcaaggtga cactctacta 5520  tttctggggc ccatggaagg aggtggtata atctttaaac 5560  actggtgtac atctacctgt cactttggag accctggtga 5600  tgtcatgggt ccaaaagata aaccatttat ttgccctgaa 5640  ttcccagggc aatttaggaa aaaatgtaac tttgccacaa 5680  ctccagtttg tgaatatgat ggaaacatta tatcaggcta 5720  taagaaagta cttgcaacaa ttgattcttt ccaatcattt 5760  aacacaagca atatacactt cactgatgag agaattgaat 5800  ggagagaccc tgatggcatg cttcgggatc atattaatat 5840  tgttatttct aaagatattg attttgaaaa tttggctgag 5880  aatccttgta aagtagggct ccaggcagca aacatagaag 5920  gtgcctgggg ttcaggtgtc gggtttacac tcacatgcaa 5960  ggtgtctctc acagaatgcc caacatttct tacatcaata 6000  aaggcctgtg acatggcaat ttgttatggt gcagaaagtg 6040  tgacactctc acgaggacaa aatactgtca aaattaccgg 6080  gaaaggtggc catagtggtt cttcattcaa atgctgtcat 6120  gggaaagaat gttcatcaac tggcctccaa gccagtgcac 6160  cacatctgga taaggtaaat ggtatctctg agttagaaaa 6200  cgagaaagtt tatgatgacg gtgcacctga atgtggcatt 6240  acttgttggt ttaaaaaatc aggtgaatgg gttatgggta 6280  taatcaatgg gaactgggtt gtcctaattg tcttgtgtgt 6320  actgctgctc ttttctctta tcctgttgag catcttgtgt 6360  cctgttagaa agcataaaaa atcataaatc ccacctaaca 6400  atcttcacat catgtatcga ttttcaaaca ctttatcatt 6440  tagaacttaa cttggcacta ctatctgata actgactttc 6480  atttttattt ttatatggat taattactaa aaaaaatact 6520  ctctcgtgcc gaattcgata tcaagcttat cgataccgtc 6560  gacctcgagg gggggcccgg tacccgggat cctcgcaatc 6600  cctaggagga ttaggcaagg gcttgagctc acgctcttgt 6640  gagggacaga aatacaatca ggggcagtat atgaatactc 6680  catggagaaa cccagatcta cgtatgatca gcctcgactg 6720  tgccttctag ttgccagcca tctgttgttt gcccctcccc 6760  cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc 6800  ctttcctaat aaaatgagga aattgcatcg cattgtctga 6840  gtaggtgtca ttctattctg gggggtgggg tggggcagga 6880  cagcaagggg gaggattggg aagacaatag caggcatgct 6920  ggggatgcgg tgggctctat ggcttctgag gcggaaagaa 6960  ccagctgggg ctcgacagct cgactctaga attgcttcct 7000  cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 7040  agcggtatca gctcactcaa aggcggtaat acggttatcc 7080  acagaatcag gggataacgc aggaaagaac atgtgagcaa 7120  aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 7160  gctggcgttt ttccataggc tccgcccccc tgacgagcat 7200  cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga 7240  caggactata aagataccag gcgtttcccc ctggaagctc 7280  cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga 7320  tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 7360  ctcaatgctc acgctgtagg tatctcagtt cggtgtaggt 7400  cgttcgctcc aagctgggct gtgtgcacga accccccgtt 7440  cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 7480  agtccaaccc ggtaagacac gacttatcgc cactggcagc 7520  agccactggt aacaggatta gcagagcgag gtatgtaggc 7560  ggtgctacag agttcttgaa gtggtggcct aactacggct 7600  acactagaag gacagtattt ggtatctgcg ctctgctgaa 7640  gccagttacc ttcggaaaaa gagttggtag ctcttgatcc 7680  ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt 7720  gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 7760  agatcctttg atcttttcta cggggtctga cgctcagtgg 7800  aacgaaaact cacgttaagg gattttggtc atcagattat 7840  caaaaaggat cttcacctag atccttttaa attaaaaatg 7880  aagttttaaa tcaatctaaa gtatatatga gtaaacttgg 7920  tctgacagtt accaatgctt aatcagtgag gcacctatct 7960  cagcgatctg tctatttcgt tcatccatag ttgcctgact 8000  c 8001  More preferably, it further includes the Andes M-gene construct pWRG/AND-M(x) (SEQ ID NO:10), which strengthens the HPS component.

Where gene-gun delivery is contemplated, the DNA segments from different viruses can be on different particles or on the same particle, whichever results in the desired immune response. The vaccine is designed to protect against pathologies resulting from exposure to one or several hantaviruses. The vaccine can also be combined with reagents which increase the antigenicity of the vaccine, or reduce its side effects. As shown above, the delivery of a combination of vaccines by electroporation involves mixtures of DNA. This demonstrates that plasmids can be mixed and any interference from the respective DNA with each other can be overcome—another advantage of this invention.

For DNA vaccinations described here, as appropriate, when inducing cellular, humoral, and protective immune responses after DNA vaccination the preferred target cells are epidermal cells, rather than cells of deeper skin layers such as the dermis. Epidermal cells are preferred recipients of DNA vaccines because they are the most accessible cells of the body and may, therefore, be immunized non-invasively. Secondly, in addition to eliciting a humoral immune response, DNA immunized epidermal cells also elicit a cytotoxic immune response that is stronger than that generated in sub-epidermal cells. Delivery to epidermis also has the advantages of being less invasive and delivering to cells which are ultimately sloughed by the body.

Although it can be desirable to induce an immune response by delivering genetic material to a target animal, merely demonstrating an immune response is not necessarily sufficient to confer protective advantage on the animal. What is important is to achieve a protective immune response that manifests itself in a clinical difference. That is, a method is effective only if it prevents infection or reduces the severity of the disease symptoms. It is preferred that the immunization method be at least 20% effective in preventing death in an immunized population after challenge with SNV or, if a multivalent vaccine is used, at least one of the other targeted hantaviruses. More preferably, the vaccination method is 50% or more effective, and most preferably 70 100% effective, in preventing death in an immunized population. The vaccination method is shown herein to be 100% effective in the hamster models for hantavirus. Hamsters have been used extensively as the laboratory models of choice for assessment of protective immune responses to hantaviruses. In contrast, unimmunized animals are uniformly infected by challenge with hantavirus. The inventor's results indicate that vaccination with our SNV vaccines protects against infection with SNV. As is well known, high titer antibody such as achieved by the inventor is predictive of protection.

Generally, the DNA vaccine administered may be in an amount of about 5 ug-5 mg of DNA per dose and will depend on the delivery technology, subject to be treated, capacity of the subject's immune system to develop the desired immune response, and the degree of protection desired. Precise amounts of the vaccine to be administered may depend on the judgement of the practitioner and may be peculiar to each subject and antigen. Delivery technology plays an important role in determining dosage—e.g., an adjuvant may change the dosage or number of vaccinations needed.

The vaccine for eliciting an immune response against one or more viruses, may be given in a single dose schedule, or if deemed necessary or desirable, a multiple dose schedule in which a primary course of vaccination may be with 1-8 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1 4 months for a second dose, and if needed, a subsequent dose(s) after several months. Examples of suitable immunization schedules include: (i) 0, 1 months and 6 months, (ii) 0, 7 days and 1 month, (iii) 0 and 1 month, (iv) 0 and 6 months, or other schedules sufficient to elicit the desired immune responses expected to confer protective immunity, or reduce disease symptoms, or reduce severity of disease.

In a related embodiment, this invention provides a method for raising high titers of neutralizing antibodies against Sin Nombre virus in a mammal or a bird. The method comprises the step of administering a composition comprising a SNV plasmid DNA which comprises one or more of the recombinant DNA constructs described above (including SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3); and a pharmacologically acceptable carrier. The step of administering may need to be repeated as desired in order to achieve the level of titer targeted. Preferably the titer is measured to be between 100 and 10,000.

Therapeutic Use of Polyclonal and Monoclonal Antibodies

In another embodiment, the present invention relates to polyclonal antibodies from vaccinees receiving the DNA vaccines described above. A composition comprising the polyclonal antibodies can be used as a prophylactic or therapeutic effective in preventing onset of Sin Nombre virus infection after exposure to it, and/or in treating Sin Nombre virus disease. For example, the composition of the present invention is composed of polyclonal antiserum from a population of animals or humans vaccinated with a DNA vaccine comprised of a plasmid expressing the above-described synthetic Sin Nombre virus M gene. The polyclonal serum would contain neutralizing antibodies against Sin Nombre virus. Unlike conventional polyclonal immune serum products, the process used to make this invention (DNA vaccination to produce antibody in vaccinees) does not involve live virus and does not require the identification of patients who have survived Sin Nombre virus disease.

Similarly, animals or humans vaccinated with one of the above-described DNA vaccines can produce SNV-neutralizing monoclonal antibodies (Mab), which Mab can then be engineered into expression systems.

In one embodiment of this method, the invention contemplates a method to treat or prevent or ameliorate symptoms after onset of Sin Nombre virus infection by administering a therapeutically or prophylactically effective amount of serum of the present invention or a mixture of antibodies of the present invention to a subject in need of such treatment. The antibodies are specific for peptides encoded by the nucleic acids described herein—e.g., where the Gn and Gc are encoded by the nucleic acid of one of SEQ ID NO:1, SEQ ID NO:2 and/or SEQ ID NO:3.

The polyclonal antibodies described herein are characterized in that the antibody binds to the appropriate immunogen, i.e. Gn and Gc, as measured by assays such as ELISA, immunoprecipitation, or immunofluorescence. Also, the antibodies must neutralize Sin Nombre virus as measured by plaque reduction neutralization test (PRNT). Any antibody retaining these characteristics is related to the present invention. The polyclonal antibody may be concentrated, irradiated, and tested for a capacity to neutralize Sin Nombre virus. Serum lots with sufficiently high neutralizing antibody titers, i.e., high enough to give a detectable response in the recipient after transfer, can be pooled. The product can then be lyophilized for storage and reconstituted for use.

As described in greater detail in the examples, the present inventor has found that serum from a vaccinee immunized with a DNA vaccine comprising one of the above-described SNV sequences, contains antibodies able to neutralize hantavirus.

Given these results, polyclonal antibodies according to the present invention are suitable both as therapeutic and prophylactic agents for treating or preventing SNV infection or disease in susceptible SNV-exposed subjects. Subjects include rodents such as mice or guinea pigs, avian, and mammals (including transgenic animals), including humans.

Any active form of the antibodies can be administered. Antibodies of the present invention can be produced in any system, including insect cells, baculovirus expression systems, chickens, rabbits, goats, cows, or plants such as tomato, potato, banana or strawberry. Methods for the production of antibodies in these systems are known to a person with ordinary skill in the art. Preferably, the antibodies used are compatible with the recipient species such that the immune response to the antibodies does not result in clearance of the antibodies before virus can be controlled, and the induced immune response to the antibodies in the subject does not induce “serum sickness” in the subject.

Treatment of individuals having SNV infection may comprise the administration of a therapeutically effective amount of anti-SNV antibodies of the present invention. The antibodies can be provided in a kit as described below. In providing a patient with antibodies, or fragments thereof, capable of binding to SNV, or an antibody capable of protecting against SNV in a recipient patient, the dosage of administered agent will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition, previous medical history, etc.

In general, it is desirable to provide the recipient with a dosage of antibody which is in the range of from about 1 pg/kg 100 pg/kg, 100 pg/kg 500 pg/kg, 500 pg/kg 1 ng/kg, 1 ng/kg 100 ng/kg, 100 ng/kg 500 ng/kg, 500 ng/kg 1 ug/kg, 1 ug/kg 100 ug/kg, 100 ug/kg 500 ug/kg, 500 ug/kg 1 mg/kg, 1 mg/kg 50 mg/kg, 50 mg/kg 100 mg/kg, 100 mg/kg 500 mg/kg, 500 mg/kg 1 g/kg, 1 g/kg 5 g/kg, 5 g/kg 10 g/kg (body weight of recipient), although a lower or higher dosage may be administered.

The antibodies capable of protecting against hantavirus are intended to be provided to recipient subjects in an amount sufficient to effect a reduction in the SNV infection symptoms. An amount is said to be sufficient to “effect” the reduction of infection symptoms if the dosage, route of administration, etc. of the agent are sufficient to influence such a response. Responses to antibody administration can be measured by analysis of subject's vital signs.

A composition is said to be “pharmacologically acceptable” if its administration can be tolerated by a recipient patient. Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.

The compounds of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences (16th ed., Osol, A. ed., Mack Easton Pa. (1980)). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the above-described compounds together with a suitable amount of carrier vehicle.

Additional pharmaceutical methods may be employed to control the duration of action. Control release preparations may be achieved through the use of polymers to complex or absorb the compounds. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the method of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate the compounds of the present invention into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacylate)-microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).

Administration of the antibodies disclosed herein may be carried out by any suitable means, including parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection), in ovo injection of birds, orally, or by topical application of the antibodies (typically carried in a pharmaceutical formulation) to an airway surface. Topical application of the antibodies to an airway surface can be carried out by intranasal administration (e.g., by use of dropper, swab, or inhaler which deposits a pharmaceutical formulation intranasally). Topical application of the antibodies to an airway surface can also be carried out by inhalation administration, such as by creating respirable particles of a pharmaceutical formulation (including both solid particles and liquid particles) containing the antibodies as an aerosol suspension, and then causing the subject to inhale the respirable particles. Methods and apparatus for administering respirable particles of pharmaceutical formulations are well known, and any conventional technique can be employed. Oral administration may be in the form of an ingestible liquid or solid formulation.

The treatment may be given in a single dose schedule, or preferably a multiple dose schedule in which a primary course of treatment may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. Examples of suitable treatment schedules include: (i) 0, 1 month and 6 months, (ii) 0, 7 days and 1 month, (iii) 0 and 1 month, (iv) 0 and 6 months, or other schedules sufficient to elicit the desired responses expected to reduce disease symptoms, or reduce severity of disease.

Diagnostic Methods

The present invention still further pertains to a method for detecting SNV in a sample suspected of containing SNV. The method includes contacting the sample with polyclonal antibodies of the present invention which bind SNV antigens, allowing the antibody to bind to the SNV antigen(s) to form an immunological complex, detecting the formation of the immunological complex and correlating the presence or absence of the immunological complex with the presence or absence of SNV antigen in the sample. The sample can be biological, environmental or a food sample.

The language “detecting the formation of the immunological complex” is intended to include discovery of the presence or absence of SNV antigen in a sample. The presence or absence of SNV antigen can be detected using an immunoassay. A number of immunoassays used to detect and/or quantitate antigens are well known to those of ordinary skill in the art. See Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, New York 1988 555 612). Such immunoassays include antibody capture assays, antigen capture assays, and two-antibody sandwich assays. These assays are commonly used by those of ordinary skill in the art.

In an antibody capture assay, the antigen is attached to solid support, and labeled antibody is allowed to bind. After washing, the assay is quantitated by measuring the amount of antibody retained on the solid support. A variation of this assay is a competitive ELISA wherein the antigen is bound to the solid support and two solutions containing antibodies which bind the antigen, for example, serum from a SNV virus vaccinee and the polyclonal antibodies of the present invention, are allowed to compete for binding of the antigen. The amount of polyclonal antibody bound is then measured, and a determination is made as to whether the serum contains anti SNV antigen antibodies. This competitive ELISA can be used to indicate immunity to known protective epitopes in a vaccinee following vaccination.

In an antigen capture assay, the antibody is attached to a solid support, and labeled antigen is allowed to bind. The unbound proteins are removed by washing, and the assay is quantitated by measuring the amount of antigen that is bound. In a two-antibody sandwich assay, one antibody is bound to a solid support, and the antigen is allowed to bind to this first antibody. The assay is quantitated by measuring the amount of a labeled second antibody that can bind to the antigen.

These immunoassays typically rely on labeled antigens, antibodies, or secondary reagents for detection. These proteins can be labeled with radioactive compounds, enzymes, biotin, or fluorochromes of these, radioactive labeling can be used for almost all types of assays and with most variations. Enzyme-conjugated labels are particularly useful when radioactivity must be avoided or when quick results are needed. Biotin-coupled reagents usually are detected with labeled streptavidin. Streptavidin binds tightly and quickly to biotin and can be labeled with radioisotopes or enzymes. Fluorochromes, although requiring expensive equipment for their use, provide a very sensitive method of detection. Antibodies useful in these assays include monoclonal antibodies, polyclonal antibodies, and affinity purified polyclonal antibodies. Those of ordinary skill in the art will know of other suitable labels which may be employed in accordance with the present invention. The binding of these labels to antibodies or fragments thereof can be accomplished using standard techniques commonly known to those of ordinary skill in the art. Typical techniques are described by Kennedy, J. H., et al., 1976 (Clin. Chim Acta 70:1 31), and Schurs, A. H. W. M., et al. 1977 (Clin. Chim Acta 81:1 40). Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, and others, all of which are incorporated by reference herein.

The language “biological sample” is intended to include biological material, e.g. cells, tissues, or biological fluid. By “environmental sample” is meant a sample such as soil and water. Food samples include canned goods, meats, and others.

Yet another aspect of the present invention is a kit for detecting hantavirus in a biological sample. The kit includes a container holding one or more polyclonal antibodies of the present invention which binds a SNV antigen and instructions for using the antibody for the purpose of binding to SNV antigen to form an immunological complex and detecting the formation of the immunological complex such that the presence or absence of the immunological complex correlates with presence or absence of SNV in the sample. Examples of containers include multiwell plates which allow simultaneous detection of SNV in multiple samples.

Production of Pseudotyped Virions

Another use of the invention is a method for producing pseudotyped virions. One of the above-described DNA constructs is used to transfect cells, under conditions that pseudotyped virions or SNV glycoprotein is produced. The pseudotyped viruses are useful in serologic assays or delivery of gene therapies to endothelial cells targeted by hantavirus glycoproteins.

REFERENCES

-   1. Hooper J W, Custer D M, Thompson E, Schmaljohn C S. DNA     vaccination with the hantaan virus m gene protects hamsters against     three of four HFRS hantaviruses and elicits a high-titer     neutralizing antibody response in rhesus monkeys. J Virol 2001;     75(18): 8469-8477. -   2. Fuller D H, Loudon P, Schmaljohn C. Preclinical and clinical     progress of particle-mediated DNA vaccines for infectious diseases.     Methods 2006:40:86-97. -   3. Custer D M, Thompson E, Schmaljohn C S, et al. Active and passive     vaccination against hantavirus pulmonary syndrome with Andes virus M     genome segment-based DNA vaccine. J Virol 2003; 77(18):9894-9905. -   4. Hooper J W, Ferro A M, and Wahl-Jensen V Immune Serum Produced by     DNA Vaccination Protects Hamsters Against Lethal Respiratory     Challenge with Andes Virus. Journal of Virology 2008 82:1332-1338. -   5. Hooper J W, Kamrud K I, Elgh F, et al. DNA vaccination with     hantavirus M segment elicits neutralizing antibodies and protects     against Seoul virus infection. Virology 1999; 255:269-278. -   6. Hooper J W, Custer D M, Smith J., and Wahl-Jensen W.     Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive     neutralizing antibody response in nonhuman primates. Virology 2006;     347:208-216. -   7. Condon C, Watkins S C, Celluzzi C M, et al. DNA-based     immunization by in vivo transfection of dendritic cells. Nat Med     1996; 10:1122-1128. -   8. Barry M A, Johnston S A. Biological features of genetic     immunization. Vaccine 1997; 15:788-791. -   9. Yoshida A, Nagata T, Uchijima M, et al. Advantage of gene     gun-mediated over intramuscular inoculation of plasmid DNA vaccine     in reproducible induction of specific immune responses. Vaccine     2000; 18:1725-1729. -   10. Steele K E, Stabler K, VanderZanden L. Cutaneous DNA vaccination     against Ebola virus by particle bombardment: histopathology and     alteration of CD3-positive dendritic epidermal cells. Vet Path 2001;     38:203-215. -   11. Monteiro-Riviere N A, Riviere J. The pig as a model for     cutaneous pharmacology and toxicology research. In: Tumbleson M E,     Schook L B (eds). Advances in Swine in Biomedical Research, Vol. 2,     New York, Plenum Press, 1996, pp. 425-458. -   12. Draize J H, Woodward G, Calvery H O. Methods for the study of     irritation and toxicity of substances applied topically to the skin     and mucous membranes. J Pharmacol Exp Ther 1944; 82, 377-390. -   13. Klinman D M, Sechler J M G, Conover J, et al. Contribution of     cells at the site of DNA vaccination to the generation of     antigen-specific immunity and memory. J Immunol 1998; 160:     2388-2392. -   14. Gurunathan S, Klinman D, Seder R. DNA vaccines. 2000 Ann Rev     Immunol 2000; 7-74. -   15. McElroy A K, Smith J M, Hooper J W, Schmaljohn C S. Andes virus     M genome segment is not sufficient to confer the virulence     associated with Andes virus in Syrian hamsters. Virology 2004;     326(1):130-139. -   16. Charles River Laboratories—Arkansas Division. Assessment of the     Local Skin Reactivity and Systemic Toxicity of Hantaan Virus DNA     Vaccine pWRG/HTN-M(x) following PowderJect® Delivery to Syrian     Hamster Skin. Final Study Report for Protocol Number JTA00001. 2005. -   17. Hammerbeck, C. D., Wahl-Jensen, V., Hooper, J. W. Hantavirus.     In: Vaccines for Biodefense and Emerging and Neglected Diseases     (A. D. T. Barrett and L. R. Stanberry, Eds.), pp. 379-411. London:     Academic Press, 2009. -   18. Jonsson C. B, J. Hooper, and G. Mertz (2008). Treatment of     hantavirus pulmonary syndrome. Antiviral Res. Antiviral Res.     78:162-169. -   23. Schmaljohn, C. S., and J. W. Hooper (Jan. 27, 2000). U.S. patent     application Ser. No. 09/491,974; publication number 2002/0114818,     published Aug. 22, 2002, entitled “DNA vaccines against hantavirus     infections” -   24. Hooper, J. W., C. S. Schmaljohn and M. Custer. “Extraneous DNA     sequence that facilitates hantavirus gene expression. U.S. Pat. No.     7,217,812. Issued May 15, 2007. -   25. Hooper, J. W., C. S. Schmaljohn. DNA Vaccines Against     Hantavirus. Korean Patent 660040. Issued December 2006, and European     Patent EPO 00908388.2, issued January 2007 -   26. Hooper, J. W. Puumala virus full-length M segment-based DNA     vaccines. U.S. application Ser. No. 12/449,504, filed Aug. 11, 2009;     PCT/US2008/001847, published Jan. 15, 2009

The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference. 

1. A therapeutic composition for ameliorating symptoms after onset of Sin Nombre virus infection comprising antibodies specific for peptides encoded by the nucleic acid having the sequence set forth in SEQ ID NO:3. 